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Abstract 
The asymmetric reduction of imino bonds is a well known and utilised 
method of chiral amine synthesis. Chapter 1 gives an insight into the published 
methods for a range of substrates via hydrogenation and transfer hydrogention 
systems. 
This thesis presents a range of novel iridicycles, all of which contain chiral 
oxazoline and imidazoline ligands. The synthesised complexes demonstrate a 
variety of electronic and steric properties. Their activities are presented in the latter 
chapters for the asymmetric reduction of C=N bonds. 
 Chapter 3 demonstrates the activity of the 4,5,6-trimethoxyimidazoline 
iridium complex for direct asymmetric reductive amination. High activity, yielding 
up to quantitative product is reported, under unusually mild conditions, in both 
aqueous and organic solvent systems.  The enantioselectivites achieved were 
moderate to high for the substrates screened. 
 The use of a bulky 2,4,6-tri-iso-propyloxazoline iridium complex is reported 
for the asymmetric reduction of quinolones, via transfer hydrogenation conditions. 
The tetrahydroquinolines were produced in high yields and moderate 
enantioselectivities. The addition of co-solvents to the aqueous system yielded 
improved enantioselectivies and conversions. 
 For the reduction of pyridinium salts a bromo-dioxole imidazoline iridium 
complex presented high activity. This presents unprecedentedly mild conditions via 
a transfer hydrogenation system, producing high yields of N-benzyl piperidines. The 
enantioselectivites determined were high, although some could not be measured by 
the available means. 
 The 2,4,6-tri-iso-propyloxazoline iridium complex further demonstrates high 
activity and enantioselectivity for the asymmetric hydrogenation of acyclic imines. 
An NMR and mechanistic study revealed the in-situ formation of a new iridium 
species present only in TFE. 
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Chapter 1: Introduction   
2 
 
1.1 Introduction to Chiral Amines 
 -Chiral amines are prevalent motifs in natural products and therapeutic 
agents, and are used as key building blocks in synthetic chemistry. They are utilised 
in multiple industries, including pharmaceuticals, fragrances and agrochemicals, and 
additionally show activity as chiral ligands and catalysts. 
 A range of important commercial chiral amines are shown in Figure 1.1. For 
example (S)-Metolachlor is widely used as a herbicide.1–3 Many drugs also contain a 
chiral amine moiety, for example ephedrine,4,5 commonly used as a decongestant. 
Other pharmaceutically important cyclic amines appear in a number of natural 
products, such as tubulosine which shows activity as an antitumor drug.6,7  
 
Figure 1.1 Examples of commercial chiral amines. 
 (L)-Proline is a naturally occurring amino acid (Figure 1.2) which has found 
extensive use as a chiral organocatalyst,8 with high selectivity for asymmetric aldol 
reactions, proceeding via an enamine intermediate. Chiral amines can readily 
coordinate to metal centres and therefore have been utilised as chiral ligands. One 
of the most well known examples is diphenylethylenediamine (DPEN), which can be 
used for a wide range of reactions, including reductions.9,10 They have also been 
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used as chiral auxiliaries, for example [1,1’-binaphthalene]-2,2’-diamine (Figure 1.2), 
which contains axial chirality.11,12 
 
Figure 1.2 Examples of chiral amine catalysts/ligands. 
 The preparation and isolation of these important enantiomerically enriched 
amines has been widely investigated. One of the oldest systems is resolution, which 
is the separation of the two enantiomers from a racemic mixture. This can be 
achieved by reaction with a chiral agent, such as tartaric acid13,14 or mandelic 
acid,15,16  to form diastereomeric salts that can be crystallised for separation 
(Scheme 1.1). Although a relatively cheap procedure, there is significant amount of 
waste as the maximum isolated yield can be only 50%. 
 
Scheme 1.1 Tartaric acid (top) and mandelic acid (bottom) for chiral resolution. 
 Asymmetric synthesis of chiral amines has long been explored; the most 
successful method is via reduction reactions. Whilst significant work has been 
performed on the reduction of unsaturated C=C and C=O bonds,17–19 the reduction 
of imines has proved one of the most difficult to achieve, compared to carbonyls17,18 
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or olefins19. This has partially been attributed to: the difficulty in isolating the imine; 
the weak binding of the imine to a metal catalyst; and the strong coordination of 
the product amine to the metal centre, poisoning the catalysts. As a research group 
we are interested in the synthesis of amines via the reduction of imines using novel 
metal complexes.20–22 In this project, the focus will be on the development of an 
asymmetric version, confined to two reaction pathways: hydrogenation and 
transfer hydrogenation. 
1.2 Asymmetric Reduction of Acyclic Imines 
The reduction of acyclic imines is the most widely explored area in C=N bond 
reduction, with many reported systems using either H2 gas or an organic hydride 
source, such as iso-propanol (IPA) and Hantzsch esters (HEH). Many issues still 
require attention including; the limited substrate scope, the use of harsh reaction 
conditions and additives. 
1.2.1 Asymetric Hydrogenation of acyclic imines 
1.2.1.1 Rhodium catalysed AH 
Scorrano and co-workers reported the asymmetric hydrogenation (AH) of 
imines in 1975, demonstrating the use of rhodium in the presence of the 
diphosphine ligand (-)-diop (Scheme 1.2), as well as olefin and ketone reduction.23 
Although this system yielded a low ee for the reported amine of just 22%, it set a 
precedent that this transformation was possible. 
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Scheme 1.2 First reported AH of an imine. 
 A significant amount of research has since been dedicated to the 
development of rhodium diphosphine systems. Kutney and co-workers were the 
first to report a high ee for these systems using (R)-cycphos to yield up to 91% ee 
for N-benzyl imines (Eq 1, Scheme 1.3).24  This improvement in selectivity may be 
attributed to the low temperature of -25 oC. N-aryl imines under the same 
conditions were only able to produce up to 69% ee (Eq 2, Scheme 1.3),25,26 with 
both substrates requiring several days for high conversions and the addition KI to 
activate the imine towards reduction. 
 
Scheme 1.3 Early AH systems with high ee. 
A range of chiral diphosphine ligands active in the presence of rhodium are 
shown in Figure 1.3.27–30 Notably Borner et al. conducted a study on a range of 
phosphines and phosphonites to directly compare the conversion and ee (Figure 
1.3).31 Many of those tested showed low to moderate ee, with the highest 
enantioselectivity achieved with the electron poor ligand (R,R)-bdpch at 71% ee. 
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Figure 1.3 Some diphosphine ligands tested for benzyl imine AH. 
1.2.1.2 Iridium catalysed AH 
 In the 1990’s diphosphine ligands were first reported in the presence of 
iridium. Osborn et al. showed that up to 80% ee could be obtained under mild 
conditions, using (-)-bdpp on cyclic imines, whilst N-aryl imines reached just 40% ee 
with the same ligand (Scheme 1.4).32 
 
Scheme 1.4 First AH using iridium diphosphine complex. 
 Several groups have since reported iridium (I) diphosphine systems for N-
aryl imine AH (Figure 1.4). Dervisi and co-workers showed that ddppm was a 
suitable ligand for this transformation, requiring a chlorinated solvent to yield high 
conversions and ee’s up to 94%.33 Imamoto et al. utilised (S,S)-tBu-BisP as ligand  
and achieved up to 99% ee.34 Ligands containing the phosphine-phosphite 
combination (P-OP) were also highly active. Pizzano and co-workers developed a 
range of these complexes and were able to provide ee’s up to 85%.35 More recently 
Hu et al. developed a similar phosphine-phosphoramidite ligand, containing a H8-
BINOL moiety. The complex formed in situ achieved up to 99% ee, including for alkyl 
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imines.36 The phenyl-ferrocenylethyl scaffold has also been reported in the 
presence of iridium although only one substrate is reported with an ee of 43% 
(Figure 1.4).37,38 
 
Figure 1.4 Iridium (I) complexes used for AH of imines. 
 Another common class of highly active ligands used with iridium for AH are 
phosphine oxazolines (PHOX) (Figure 1.5). An early example of their activity was 
shown with an N-benzyl imine by James et al. although active the enantioselectivity 
was moderate, with 63% ee being the highest.39 Zhou and co-workers later 
developed a SIPHOX ligand, which completed the AH with a much greater ee of 90-
97% for all substrates reported under mild conditions (Figure 1.5).40 Andersson et 
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al. have also developed modified PHOX ligands containing an N-P bond (Figure 
1.5).41 These complexes achieved up to 90% ee for N-aryl imines, however, they 
proved inactive for cyclic imines.42 
 
Figure 1.5 Iridium PHOX complexes employed for AH of imines. 
 Ikariya and co-workers demonstrated that diamine ligands were highly 
active for imine AH.43 Silver salts were required to improve both the conversion and 
ee (up to 78%) with a Ts-cydn ligand (Scheme 1.5). The addition of phosphoric acids 
as a counter ion was able to produce high ee’s up to 98%, as reported by Xiao and 
co-workers.44–46 Both chiral and achiral diamine ligands could be employed in the 
presence of (R)-TRIP (Scheme 1.5). 
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Scheme 1.5 Diamine ligands utilised with iridium for AH. 
1.2.1.3 Other metal catalysed AH 
Fan et al. showed that ruthenium cymene in the presence of the Ms-DPEN 
ligand can provide the desired AH in up to 99% ee, for a wide range of N-benzyl 
imines (left, Figure 1.6).47,48 Ohkuma and co-workers have also shown that the use 
of (S,S)-DPEN and (S,S)-xyl-Skewphos with a ruthenium precursor was able to 
achieve up to 99% ee’s (centre, Figure 1.6).49 Beller et al. has also demonstrated 
that (S)-TRIP is highly selective in the presence of Knolkers iron complex, achieving 
up to 98% ee (right, Figure 1.6).50 
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Figure 1.6 Ruthenium and Iron complexes used for AH of imines. 
1.2.2 Asymetric Transfer Hydrogenation of acyclic imines 
1.2.2.1 Metal catalysed ATH 
 Transfer hydrogenation for imine reduction, using an organic hydride source 
is less well explored. First reported by Noyori in 1996, a formic acid triethylamine 
5/2 complex (FT) was employed as the hydride source.51 The ATH system was 
catalysed by a ruthenium Ts-DPEN complex and produced ee’s as high as 89%, 
although it proved more selective for cyclic imines (Scheme 1.6).52–54 A study 
conducted into the N-benzyl imine indicated that the lower selectivity is caused by 
isomerisation of the imine, with reduction of the E isomer leading to enantiopure 
(S)-amine, whilst the Z imine produces a lower purity of the (R)-amine.55 
 
Scheme 1.6 Noyori's ATH of imines utilising Ru-TsDPEN. 
Switching to a rhodium metal centre showed a detrimental effect on the 
selectivity, although high activity was maintained (Scheme 1.7).56 Cyclic examples 
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maintained a high selectivity (< 99% ee), whilst acyclic imines resulted in a drop of 
enantioselectivity to 8.4%. Reduction of sulfonated imines under this system 
yielded up to 99% ee. 57 
 
Scheme 1.7 ATH of imines utilising a rhodium TsDPEN complex. 
Chiral amino alcohols also show high activity for the reduction of sulfonated 
imines. Yus et al. utilised (1S,2R)-1-amino-2-indanol in the presence of ruthenium, 
which produced ee’s as high as 99% (Scheme 1.8).58,59 A racemic ligand, namely 2-
amino-2-methyl-1-propanol, could also be used if a chiral sulfonate was placed on 
the imine, achieving similarly high conversions and ee’s.60–63  
 
Scheme 1.8 Use of amino alcohol ligands with rhodium for sulfonated imines. 
 Morris et al. has demonstrated the use of iron PNNP pincer complexes on a 
range of protected imines (Scheme 1.9).64–66 N-diphenylphosphenoyl imines, as well 
as N-tosyl imines and ketones, can be reduced effectively to yield high conversion 
and selectivity under these conditions. 
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Scheme 1.9 Iron catalysed ATH of imines. 
1.2.2.2 Organocatalytic ATH 
Chiral phosphoric acids also demonstrate catalytic activity for ATH in their 
own right, providing alternative metal-free systems; however, these systems are 
generally slower than their metalated counter-parts. The Brønsted acid protonates 
the imine, therefore activating it for reduction and forming a chiral ion pair. 
This was first reported in 2005 by the groups of Rueping and List. Both 
groups showed the activity of chiral phosphoric acids for the ATH of N-aryl imines 
(Eq 1, Scheme 1.10) to afford amines in high ee’s of 70 to 93%,  utilising a Hantszch 
ester (HEH) as the hydride source.67,68  -Imino-esters could also undergo ATH in 
the presence of chiral phosphoric acids, leaving the ester group intact (Eq 2, Scheme 
1.10).69,70 However, the alkenyl functionality proved susceptible to reduction 
forming an olefin (Eq 3, Scheme 1.10).71 
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Scheme 1.10 Brønsted acid catalysed reduction of imines. 
  Benzothiazolines have also shown activity as a hydride source in the 
presence of Brønsted acid catalysts (Scheme 1.11). Akiyama et al. reported in 2009 
complete conversion with 98% ee being achieved in 24 hours, with the 
benzothiazoline premade or formed in situ. 
 
Scheme 1.11 Use of benzothiazoline for ATH of imine. 
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1.3 Direct Asymmetric Reductive Amination (DARA) 
 Direct asymmetric reductive amination (DARA) is a more economical route 
for the synthesis of chiral amines. This is the one-pot reaction of a pro-chiral ketone 
with an amine to form the imine in situ, before a reduction reaction occurs, 
eliminating the challenging isolation of the imine intermediate (Figure 1.7). Despite 
its appeal this transformation is less well documented, due to the competition 
between ketone and imine reductions, as well as potential poisoning of the catalyst 
by the amine substrate and products. 
 
Figure 1.7 Reductive amination vs. ketone reduction. 
1.3.1 Asymetric Hydrogenation for DARA 
1.3.1.1 Ruthenium catalysed DARA 
 An early report of DARA was in 2009 by Saito and co-workers employing 
ruthenium diacetate with (R)-DM-segphos to synthesise sitagliptin and several 
derivatives (Scheme 1.12).72 The DARA could be performed between -keto amides 
or -keto esters73  with ammonium salicylate, to directly produce primary amines 
with up to 99% ee. Utilising (S)-MeO-BiPhep, in the presence of ruthenium, 
tetralones could undergo DARA with benzylamine to produce secondary amines 
with up to 47% ee.74   
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Scheme 1.12 DARA utilising ruthenium diphosphine compelxes. 
1.3.1.2 Iridium catalysed DARA 
A more versatile system was reported by Xiao et al. (Scheme 1.13), under 
similar conditions to those reported above for AH of imines (Scheme 1.5).75,76 
Utilising an iridium Ts-DPEN complex in the presence of (R)-TRIP, a wide range of 
substrates could undergo DARA, producing ee’s up to 96%. Slight variation of the 
sulfonate group allowed for both alkyl and aryl ketones to be utilised. 
 
Scheme 1.13 DARA with iridium Ts-DPEN and a chiral phosphoric acid. 
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  (S,S)-f-binaphane in the presence of iridium has also proved an active 
catalyst utilising phenyl hydrazine as the amine source (Scheme 1.14).77  In the 
presence of several additives (4Å MS, PTSA and iodine) it was able to achieve high 
conversions, with ee’s up to 97%.  
 
Scheme 1.14 DARA with phenyl hydrazine using iridium. 
1.3.1.3 Iron catalysed DARA  
Beller and co-workers reported a unique system for DARA employing the 
achiral Knölker’s iron complex in the presence of (S)-TRIP (Scheme 1.15).78 This 
system proved highly effective, with a large substrate scope, capable of DARA with 
both alkyl and aryl ketones in the presence of anilines, producing ee’s up to 99%. 
 
Scheme 1.15 DARA using an iron complex with a chiral phosphoric acid. 
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1.3.2 Asymetric Transfer Hydrogenation for DARA 
1.3.2.1 Enzymatic routes for DARA 
 Natural enzymes are capable of DARA, utilising chiral amino acids to create a 
pocket in which the reaction may occur. Several enzymes have undergone directed 
evolution to render them more stable and reusable. Kroutil et al. reported the use 
of both aryl and alkyl ketones to yield primary amines, one of the few successful 
systems capable of producing 99% ee (Scheme 1.16).53 However, this system 
required a complicated setup; using three separate enzymes, along with both L-
alanine and NADH as hydrogen sources. 
 
Scheme 1.16 Three enzyme system for DARA. 
 Hughes and co-workers have also reported the directed evolution of an 
enzyme, via 27 mutations, to develop an enzyme capable of producing up to 100% 
ee on an industrial scale.54 Pyridoxal-5'-phosphate (PLP) promotes this reaction by 
forming a Schiff base and transferring a hydride from a lysine residue on the catalyst 
to the substrate (Scheme 1.17). 
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Scheme 1.17 Modified transaminase for DARA. 
1.3.2.2 Organocatalytic DARA 
MacMillan et al. reported the use of a chiral BINOL phosphoric acid catalyst 
and a HEH, although a slow reaction (1-4 days) high ee’s of up to 97% could be 
obtained (Scheme 1.18).81 A limited substrate scope was also observed; 
functionalities larger than a methyl were not tolerated and only a few alkyl 
substrates were reported. List and co-workers have reported similar conditions 
utilising (R)-TRIP as the phosphoric acid (Scheme 1.18).82 A range of cyclic -
substituted ketones were reported, with ee’s up to 98% and diastereoselectivities 
ranging from 5:1 to 99:1, with a preference for the cis amine product. 
 
Scheme 1.18 Phosphoric acid catalysed DARA in the presence of HEH. 
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  An imidazole based catalyst was also shown to be active for this 
transformation by Martin and co-workers. Utilising trichlorosilane as a hydride 
source with up to 70% conversion and 84% ee being obtained (Scheme 1.19).83  
However, alkyl amines proved difficult, requiring tandem reaction conditions and 
microwave irradiation to promote imine formation. 
 Scheme 1.19 Organocatalytic system using trichlorosilane. 
1.3.2.3 Metal-Catalysed DARA 
 Whilst enzymatic and organocatalytic DARA has proved successful for ATH, 
they still have many drawbacks, predominantly the high catalyst loading, long 
reaction time and substrate specificity.  
 The first metal catalysed system was published by Wills et al. utilising a 
ruthenium Ts-DPEN complex in the presence of FT (Scheme 1.20).84 A single chiral 
cyclic amine was produced in 86% ee. 
 
Scheme 1.20 First ATH transition metal catalysed DARA. 
The most successful system published to date by Riermeier et al.85 has 
shown to be active for a wide range of ketones, producing a mix of primary amines 
and acetylated amines. A ruthenium tol-BINAP catalyst was employed, in the 
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presence of a large excess of ammonium formate with ammonia in methanol, as the 
hydride source and solvent, to yield complete conversion and up to 98% ee (Scheme 
1.21).  
 
Scheme 1.21 Most successful metal catalysed DARA reported to date. 
1.4 Asymmetric Reduction of Quinolines 
The asymmetric reduction of heterocycles is less well developed. Nearly all 
reported systems have the same major drawback whereby chirality can only be 
installed in the 2-position, with very limited reports for the 2,3-position and just one 
report for chirality in the 4-position. 
1.4.1 Asymetric Hydrogenation of quinolines 
1.4.1.1 Iridium catalysed AH 
 The first reported AH was by Zhou et al. which detailed the use of 
[Ir(COD)Cl]2, with a chiral diphosphine ligand ((R)-MeO-BiPhep) (Figure 1.8).
86 This 
system yielded tetrahydroquinolines in up to 96% ee and high conversions, carried 
out in the presence of iodine, this system was also active on exocyclic enamines.87 
C3-TunePhos also proved an active ligand under similar conditions, producing up to 
92% ee and giving complete conversion, for a limited range of substrates (Figure 
1.8).88 
Benzyl chloroformate89 and piperidinium triflate90 have both been used as 
alternatives for iodine, activating the quinoline towards reduction (Figure 1.8). In 
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the presence of [Ir(COD)Cl]2 and SegPhos these additives enable the synthesis of 
tetrahydroquinolines in up to 92% ee. Switching to a (S)-H8-BINAPO ligand in either 
THF or DMPEG/hexane as solvent was able to yield up to 96% ee (Figure 1.8).91  
Similarly (R)-P-Phos (Figure 1.8) proved active in these reaction solvents, with up to 
92% ee. In the latter solvent system the complex was immobilised allowing for easy 
recyclability.92 
Further work by Zhou et al. on quinoline reduction led to the development 
of modified BiPhep diphosphine ligand to produce an immobilised complex (Figure 
1.8)93 forming a more stable catalyst that was able to hydrogenate the quinoline. 
The use of this immobilised complex is advantageous for being recyclable with 
activity proven for 5 runs with only a small drop in conversion and enantioselectivity 
(< 10% drop). 
The use of electron withdrawing ligands were able to improve conversion. 
Commercially available (R)-difluoroPhos (Figure 1.8) was able to offer much higher 
conversions,94 allowing for a reduction in catalysts loading, although this system 
once more required the addition of iodine for activation of the quinoline. Zhou 
developed (R)-CF3O-BiPhep
95 which led to a greater increase in activity with this 
complex (Figure 1.8),  producing similar ee’s and yields, whilst using a much lower 
catalyst loading of 0.0005 mol %. 
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Figure 1.8 A range of diphosphine ligands active with iridium COD chloride for quinoline 
AH. 
 Noyori’s Ts-DPEN ligand, in the presence of iridium is also active for the AH 
of quinolines. Xu and co-workers showed that the [IrCp*(CF3TsDPEN)OTf] complex 
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in the presence of a catalytic amount of trifluoroacetic acid yielded up to 99% ee 
(Scheme 1.22).96  
 
Scheme 1.22 Iridium TsDPEN complex for AH of quinolines. 
1.4.1.2 Ruthenium catalysed AH 
Chan et al. continued their work utilising ruthenium with Ts-DPEN ligands 
(Eq 1, Scheme 1.23), reporting the transformation in neat ionic liquids.97 The 
catalytic system afforded excellent selectivity for all substrates published with up to 
99% ee, whilst allowing the catalyst to be recycled for 8 runs. The same complex 
was also active in alcoholic solvents, allowing for 2,3-disubstituted quinolines to be 
reduced in moderate to high enantioselectivities (Eq 2, Scheme 1.23).98 An in-depth 
mechanistic study was reported, indicating that the reaction proceeds via a 1,4-
hydride addition to the quinoline salt, followed by isomerisation of this product, 
setting up a 1,2-hydride addition to yield the final tetrahydroquinoline (Figure 1.9). 
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Scheme 1.23 Ruthenium DPEN complexes for AH of quinolines. 
 
Figure 1.9 Proposed mechanism for AH of 2-substitued quinoline. 
1.4.2 Asymetric Transfer Hydrogenation of quinolines 
1.4.2.1 Metal catalysed ATH 
  Zhou et al.  reported a metal catalysed ATH, similar to their hydrogenation 
system, utilising [Ir(COD)Cl]2, mixed with (S)-SegPhos to obtain up to 88% ee over 
two days (Scheme 1.24).99 As in the AH system iodine was required to activate the 
substrate, but a HEH was used in place of the hydrogen gas.  
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Scheme 1.24 First metal catalysed ATH of quinolines. 
 Xiao et al. developed a system using rhodium in aqueous reaction 
conditions, utilising a buffered sodium formate solution as hydride source and 
solvent (Eq 1, Scheme 1.25).100 This system also allowed for the reduction of a 
couple of 2,3-disubstituted quinolines with high ee and dr (Eq 2, Scheme 1.25).  
 
Scheme 1.25 Best metal catalysed ATH of quinolines. 
 A combination of TRIP with a racemic NHC gold complex was reported by 
Gong and co-workers (Scheme 1.26).101 The system worked well in the presence of 
HEH, at low temperatures and reasonable times, achieving up to 98% ee with 
quantitative conversion. 
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Scheme 1.26 ATH system using an achiral gold and chiral phosphoric acid. 
1.4.2.2 Organocatalytic ATH of quinolines 
The first of these metal free systems was reported by Theissrmann et al. 
using a bulky 9-phenanthryl substituted phosphoric acid (left, Scheme 1.27), 
achieving up to 99% ee, although up to 60 hours were required for high 
conversions.102  Xu and co-workers  were able to reduce the reaction temperature 
and time whilst still maintaining excellent ee’s (up to 98%), using a modified bulky 
phosphoric acid containing cyclohexyloxy group (right, Scheme 1.27).103  
 
Scheme 1.27 First chiral acid catalysed ATH of quinolines. 
  A recent system published by Zhou et al. in 2014 has proven successful at 
producing 2,3-disubstituted tetrahydroquinolines, using TRIP as the catalyst 
(Scheme 1.28).104  Only quinoline-3-tosylamines are suitable substrates for ATH 
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producing up to 97% ee, indicating that the tosyl group is crucial for chiral induction 
with the acid. 
 
Scheme 1.28 Quinoline-3-amine ATH using chiral phosphoric acid. 
Novel P-chiral thiophosphoric acids bearing a sugar backbone are also 
capable of catalysing the reduction of 2-phenylquinolines in the presence of a HEH 
in moderate ee’s of up to 67% (Scheme 1.29).  
 
Scheme 1.29 ATH of 2-phenylquinoline by a chiral thiophosphoric acid. 
 Only one successful system for the asymmetric reduction of 4-substituted 
quinolines has been reported (Scheme 1.30). This system requires the use of an 
octahydro-BINOL-phosphate bearing triphenylsilyl residues, in the presence of a 
bulky HEH to give a range of 4-substituted products of up to 92% ee.105 
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Scheme 1.30 ATH of 4-substituted quinolines. 
1.5 Asymmetric Reduction of Pyridines 
Pyridine reduction is one of the most difficult C=N bond reductions to 
perform, with few chiral examples reported. The majority of those prove to be very 
substrate specific or require harsh conditions, such as high pressure. 
1.5.1 Asymetric Hydrogenation of pyridines 
The first report came in 2000 by Blaser et al. in which only four pyridine 
substrates were reported, all of which were carboxyl substituted (Scheme 1.31).106 
The AH was performed using a rhodium complex in the presence of various 
diphosphine ligands, but was only able to produce a maximum of 26% ee.  
 
Scheme 1.31 First AH of pyridine. 
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Lehmann and co-workers greatly improved the ee to 96%, for 
polysubstituted pyridine rings (Scheme 1.32) by utilising a chiral auxiliary in the 2-
position, which was removed under the acidic workup conditions.107  A high 
pressure was required in the presence of palladium hydroxide on carbon.  
 
Scheme 1.32 AH of pyridines with a chiral auxiliary. 
The pressure required for the hydrogenation was eventually reduced by 
Charette et al. however, these conditions were specific for N-
benzyoyliminopyrdinium ylides, utilising [Ir(COD)Cl]2 combined with a PHOX ligand 
to yield up to 90% ee (Eq 1, Scheme 1.33).108 Zhou utilised (S)-MeO-BiPhep in the 
presence of iridium, to partially reduce 7,8-dihydro-quinolin-5-(6H)-ones producing 
ee’s up to 97%.109 (Eq 2, Scheme 1.33).  
 
Scheme 1.33 AH of pyridines using iridium COD. 
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Building on their quinoline reduction work, Zhou et al. produced 2-
substituted piperidines in high yield and enantioselectivities (up to 93% ee), once 
more utilising [Ir(COD)Cl]2 with (R)-SymPhos (Scheme 1.34).
110  Though this system 
utilised a wider scope than previous systems it was not without limits, with only one 
example of a 2-alkyl substituted pyridine being presented with just a 65% ee and 
60% yield. Zhang et al. reported an improved version of this system, changing the 
ligand to a more bulky (R)-MP2-SegPhos (Scheme 1.34).111 Although again only few 
2-alkyl substituted pyridinium substrates were reported with moderate ee’s, the 
range of protecting groups was extended from just benzyls to include alkyl 
protecting groups, producing high ee’s.  
 
 
Scheme 1.34 AH of pyridinium salts. 
1.5.2 Asymetric Transfer Hydrogenation of pyridines 
 The ATH of pyridines has proved most difficult with just one system having 
been reported in 2007 by Antonchick et al. which required a bulky chiral phosphoric 
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acid in the presence of a HEH (Scheme 1.35).112 This system was active only on 7,8-
dihydro-quinolin-5(6H)-ones and 2-methyl-3-cyano-6-substituted-pyridines and only 
capable of partial hydrogenation, in up to 92% ee. Although racemic TH systems 
have been reported, ATH systems remain unexplored.  
 
Scheme 1.35 Partial ATH of pyridine using chiral phosphoric acid catalysis. 
1.6 Aims of this thesis 
 Previous work within the Xiao group has focused on the development of 
cyclometalated complexes and their uses. These iridicycles possess an iridium-
nitrogen bond, which is able to stabilise the metal-carbon bond. These have proved 
to be extremely stable complexes, tolerant of being stored in air for extended 
periods of time with no signs of decomposition. They are also simple to synthesise 
by sodium acetate activation as previously reported (Scheme 1.39).113 
 
Scheme 1.36 Cyclometallation to form iridicycle complex. 
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 This class of iridicycles has proved active for a wide range of reductive and 
oxidative reactions. They was initially reported for direct reductive amination (DRA) 
via transfer hydrogenation20–22 (Eq 3, Figure 1.10), but have since been shown to be 
active for hydrogenation114 (Eq 2 and 4, Figure 1.10) as well as transfer 
hydrogenation of N-heterocycles115 (Eq 4, Figure 1.10) and carbonyls116 (Eq 1, Figure 
1.10). By varying the conditions these iridicycles were also shown to be active for 
the dehydrogenation of N-heterocycles117 (Eq 4, Figure 1.10) and formic acid118 (Eq 
6, Figure 1.10), as well as the dehydrogenative coupling of N-heterocycles119 (Eq 5, 
Figure 1.10). They have also been used for alkylation reactions, utilising a hydrogen 
borrowing mechanism under similar conditions (Eq 7, Figure 1.10).120 
 
Figure 1.10 Reactions performed using the Xiao group’s iridicycles. 
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 Whilst these iridicycles have shown great activity, there has been very 
limited work on chiral derivatives of these species, towards the AH of a few simple 
imines. This shall be the aim of this thesis: to expand upon and develop a range of 
chiral iridicycles and to determine the extent to which they are active for a number 
of asymmetric reduction reactions. 
  
34 
 
1.7 References 
1 H. Blaser, Adv. Synth. Catal., 2002, 344, 17–31. 
2 C. J. Peter and J. B. Weber, Weed Sci., 1985, 33, 874–881. 
3 D. Sloan M, E. Camper N, Environ. Exp. Bot., 1986, 26, 1–7. 
4 S. Toubro, A. V Astrup, L. Breum and F. Quaade, Int. J. Obes. Relat. Metab. 
Disord., 1993, 17 Suppl 1, S69—72. 
5 A. Lee, W. D. Ngan Kee and T. Gin, Anesth. Analg., 2002, 94, 920–926. 
6 L. Carrasco, A. Jimenez and D. Vazquez, Eur. J. Biochem., 1976, 64, 1–5. 
7 W. Ma, J. E. Anderson, A. T. McKenzie, S. R. Byrn and J. L. McLaughlin, J. Nat. 
Prod., 1990, 53, 1009–1014. 
8 Z. An, W. Zhang, H. Shi and J. He, J. Catal., 2006, 241, 319–327. 
9 T. Ohkuma, H. Doucet, T. Pham, K. Mikami, T. Korenaga, M. Terada and R. 
Noyori, J. Am. Chem. Soc., 1998, 120, 1086–1087. 
10 C. J. Cobley and J. P. Henschke, Adv. Synth. Catal., 2003, 345, 195–201. 
11 S. Telfer, Coord. Chem. Rev., 2003, 242, 33–46. 
12 J. Y. Kim and T. Livinghouse, Org. Lett., 2005, 7, 1737–9. 
13 K. Kodama, N. Hayashi, M. Fujita and T. Hirose, RSC Adv., 2014, 4, 25609. 
14 Z. Ren, Y. Zeng, Y. Hua, Y. Cheng and Z. Guo, J. Chem. Eng. Data, 2014, 59, 
2517–2522. 
15 T. Vries, H. Wynberg, E. Van Echten, J. Koek, W. Hoeve, R. M. Kellogg, Q. B. 
Broxterman, A. Minnaard, S. Van Der Sluis, L. Hulshof and J. Kooistra, Angew. 
Chem. Int. Ed., 1998, 37, 2349–2354. 
35 
 
16 J. K. Whitesell and D. Reynolds, J. Org. Chem., 1983, 48, 3548–3551. 
17 T. Ohkuma, Proc. Japan Acad. Ser. B, 2010, 86, 202–219. 
18 S. Gladiali and E. Alberico, Chem. Soc. Rev., 2006, 35, 226–36. 
19 J. J. Verendel, O. Pa, M. Dieguez and P. G. Andersson, Chem. Rev., 2014, 114, 
2130–2169. 
20 C. Wang, A. Pettman, J. Basca and J. Xiao, Angew. Chem. Int. Ed., 2010, 49, 
7548–52. 
21 Q. Lei, Y. Wei, D. Talwar, C. Wang, D. Xue and J. Xiao, Chem. Eur. J., 2013, 19, 
4021–4029. 
22 D. Talwar, N. P. Salguero, C. M. Robertson and J. Xiao, Chem. Eur. J., 2014, 20, 
245–252. 
23 A. Levi, G. Modena and G. Scorrano, J. Chem. Soc. Chem. Commun., 1975, 
1975, 6. 
24 G. Kang, W. R. Cullen, M. D. Fryzuk, B. R. James and J. P. Kutney, J. Chem. Soc. 
Chem. Commun., 1988, 1466–1467. 
25 W. R. Cullen, M. D. Fryzuk, B. B. James, J. P. Kutney, G.-J. Kang, G. Herb, I. S. 
Thorburn and R. Spogliarich, J. Mol. Catal., 1990, 62, 243–253. 
26 A. G. Becalski, W. R. Cullen, M. D. Fryzuk, B. R. James, G. Kang and S. J. Rettig, 
Inorg. Chem., 1991, 30, 5002–5008. 
27 J. Bakos, A. Orosz, B. Heil, M. Laghmari, P. Lhoste and D. Sinou, J. Chem. Soc. 
Chem. Commun., 1991, 4, 1684. 
28 Q. Zhao, J. Wen, R. Tan, K. Huang, P. Metola, R. Wang, E. V. Anslyn and X. 
Zhang, Angew. Chemie . Int. Ed., 2014, 53, 8467–8470. 
36 
 
29 C. Lensink and J. G. De Vries, Tet. Asym., 1992, 3, 235–238. 
30 J. M. Buriak and J. a. Osborn, Organometallics, 1996, 15, 3161–3169. 
31 V. I. Tararov, R. Kadyrov, T. H. Riermeier, J. Holz and A. Börner, Tet. Asym., 
1999, 10, 4009–4015. 
32 Y. Ng Cheong Chan and J. A. Osborn, J. Am. Chem. Soc., 1990, 112, 9400–
9401. 
33 A. Dervisi, C. Carcedo and L. L. Ooi, Adv. Synth. Catal., 2006, 348, 175–183. 
34 T. Imamoto, N. Iwadate and K. Yoshida, Org. Lett., 2006, 8, 2289–2292. 
35 S. Vargas, M. Rubio, A. Suárez, D. Del Río, E. Àlvarez and A. Pizzano, 
Organometallics, 2006, 25, 961–973. 
36 C. J. Hou, Y. H. Wang, Z. Zheng, J. Xu and X. P. Hu, Org. Lett., 2012, 14, 3554–
3557. 
37 G. Espino, L. Xiao, M. Puchberger, K. Mereiter, F. Spindler, B. R. Manzano, F. a 
Jalón and W. Weissensteiner, Dalt. Trans., 2009, 2751–2763. 
38 Y. Wang, T. Sturm, M. Steurer, V. B. Arion, K. Mereiter, F. Spindler and W. 
Weissensteiner, Organometallics, 2008, 27, 1119–1127. 
39 M. B. Ezhova, B. O. Patrick, B. R. James, F. J. Waller and M. E. Ford, J. Mol. 
Catal., 2004, 224, 71–79. 
40 S. Zhu, J. Xie, Y. Zhang, S. Li and Q. Zhou, J. Am. Chem. Soc., 2006, 128, 
12886–12891. 
41 A. Triforiova, J. S. Diesen, C. J. Chapman and P. G. Andersson, Org. Lett., 2004, 
6, 3825–3827. 
37 
 
42 A. Trifonova, J. S. Diesen and P. G. Andersson, Chem. Eur. J., 2006, 12, 2318–
2328. 
43 S. Y. Shirai, H. Nara, Y. Kayaki and T. Ikariya, Organometallics, 2009, 28, 802–
809. 
44 C. Li, C. Wang, B. Villa-Marcos and J. Xiao, J. Am. Chem. Soc., 2008, 130, 
14450–1. 
45 W. Tang and J. Xiao, Synth., 2014, 46, 1297–1302. 
46 W. Tang, S. Johnston, C. Li, J. a. Iggo, J. Bacsa and J. Xiao, Chem. Eur. J., 2013, 
19, 14187–14193. 
47 F. Chen, T. Wang, Y. He, Z. Ding, Z. Li, L. Xu and Q. H. Fan, Chem. Eur. J., 2011, 
17, 1109–1113. 
48 F. Chen, Z. Ding, Y. He, J. Qin, T. Wang and Q. H. Fan, Tetrahedron, 2012, 68, 
5248–5257. 
49 N. Arai, N. Utsumi, Y. Matsumoto, K. Murata, K. Tsutsumi and T. Ohkuma, 
Adv. Synth. Catal., 2012, 354, 2089–2095. 
50 S. Zhou, S. Fleischer, K. Junge and M. Beller, Angew. Chemie . Int. Ed., 2011, 
50, 5120–5124. 
51 N. Uematsu, A. Fujii, S. Hashiguchi, T. Ikariya and R. Noyori, J. Am. Chem. Soc., 
1996, 118, 4916–4917. 
52 R. Noyori and S. Hashiguchi, Acc. Chem. Res., 1997, 30, 97–102. 
53 J. Václavík, M. Kuzma, J. Přech and P. Kačer, Organometallics, 2011, 30, 
4822–4829. 
38 
 
54 M. Kuzma, J. Václavík, P. Novák, J. Přech, J. Januščák, J. Červený, J. Pecháček, 
P. Šot, B. Vilhanová, V. Matoušek, I. I. Goncharova, M. Urbanová and P. Kačer, 
Dalt. Trans., 2013, 42, 5174–82. 
55 P. Šot, M. Kuzma and J. Václavík, Organometallics, 2012, 31, 6496–6499. 
56 J. Mao, D. C. Baker, R. Rhcl, C. H. C. H. C. H. Nh, S. Rhcltsdpen and C. Rhcl, 
Org. Lett., 1999, 1, 814–843. 
57 S. H. Kwak, S. A. Lee and K. I. Lee, Tet. Asym., 2010, 21, 800–804. 
58 D. Guijarro, Ó. Pablo and M. Yus, Tet. Lett., 2009, 50, 5386–5388. 
59 D. Guijarro, O. Pablo and M. Yus, J. Org. Chem., 2010, 75, 5265–5270. 
60 D. Guijarro, Ó. Pablo and M. Yus, Tet. Lett., 2011, 52, 789–791. 
61 Ó. Pablo, D. Guijarro, G. Kovács, A. Lledós, G. Ujaque and M. Yus, Chem. Eur. 
J., 2012, 18, 1969–1983. 
62 Ó. Pablo, D. Guijarro and M. Yus, J. Org. Chem., 2013, 78, 9181–9189. 
63 Ó. Pablo, D. Guijarro and M. Yus, European J. Org. Chem., 2014, 2014, 7034–
7038. 
64 A. a. Mikhailine, M. I. Maishan and R. H. Morris, Org. Lett., 2012, 14, 4638–
4641. 
65 W. Zuo, A. J. Lough, Y. F. Li and R. H. Morris, Science., 2013, 342, 1080–1083. 
66 W. Zuo and R. H. Morris, Nat. Protoc., 2015, 10, 241–257. 
67 M. Rueping, E. Sugiono, C. Azap, T. Theissmann and M. Bolte, Org. Lett., 
2005, 7, 3781–3. 
68 S. Hoffmann, A. M. Seayad and B. List, Angew. Chem. Int. Ed., 2005, 44, 7424–
7. 
39 
 
69 G. Li, Y. Liang and J. C. Antilla, J. Am. Chem. Soc., 2007, 129, 5830–1. 
70 Q. Kang, Z.-A. Zhao and S.-L. You, Adv. Synth. Catal., 2007, 349, 1657–1660. 
71 Q. Kang, Z. Zhao and S. You, Org. Lett., 2008, 10, 2031–2034. 
72 D. Steinhuebel, Y. Sun, K. Matsumura, N. Sayo and T. Saito, J. Am. Chem. Soc., 
2009, 131, 11316–7. 
73 K. Matsumura, X. Zhang, K. Hori, T. Murayama, T. Ohmiya, H. Shimizu, T. Saito 
and N. Sayo, Org. Process Res. Dev., 2011, 15, 1130–1137. 
74 O. Bondarev and C. Bruneau, Tet. Asym., 2010, 21, 1350–1354. 
75 C. Li, B. Villa-Marcos and J. Xiao, J. Am. Chem. Soc., 2009, 131, 6967–9. 
76 B. Villa-Marcos, C. Li, K. R. Mulholland, P. J. Hogan and J. Xiao, Molecules, 
2010, 15, 2453–2472. 
77 M. Chang, S. Liu, K. Huang and X. Zhang, Org. Lett., 2013, 15, 4354–4357. 
78 S. Zhou, S. Fleischer, H. Jiao, K. Junge and M. Beller, Adv. Synth. Catal., 2014, 
365, 3451–3455. 
79 D. Koszelewski, I. Lavandera, D. Clay, G. M. Guebitz, D. Rozzell and W. Kroutil, 
Angew. Chem. Int. Ed., 2008, 47, 9337–40. 
80 C. K. Savile, J. M. Janey, E. C. Mundorff, J. C. Moore, S. Tam, W. R. Jarvis, J. C. 
Colbeck, A. Krebber, F. J. Fleitz, J. Brands, P. N. Devine, G. W. Huisman and G. 
J. Hughes, Science., 2010, 329, 305–9. 
81 R. I. Storer, D. E. Carrera, Y. Ni and D. W. C. MacMillan, J. Am. Chem. Soc., 
2006, 128, 84–6. 
82 V. N. Wakchaure, J. Zhou, S. Hoffmann and B. List, Angew. Chem. Int. Ed., 
2010, 49, 4612–4. 
40 
 
83 F.-M. Gautier, S. Jones, X. Li and S. J. Martin, Org. Biomol. Chem., 2011, 9, 
7860–8. 
84 G. D. Williams, R. a Pike, C. E. Wade and M. Wills, Org. Lett., 2003, 5, 4227–
30. 
85 R. Kadyrov and T. H. Riermeier, Angew. Chem. Int. Ed., 2003, 42, 5472–4. 
86 W. Wang, S. Lu, P. Yang, X. Han and Y. Zhou, J. Am. Chem. Soc., 2003, 125, 
10536–10537. 
87 X.-B. Wang, D.-W. Wang, S.-M. Lu, C.-B. Yu and Y.-G. Zhou, Tet. Asym., 2009, 
20, 1040–1045. 
88 F. R. Gou, W. Li, X. Zhang and Y. M. Liang, Adv. Synth. Catal., 2010, 352, 
2441–2444. 
89 S.-M. Lu, Y.-Q. Wang, X.-W. Han and Y.-G. Zhou, Angew. Chem. Int. Ed., 2006, 
45, 2260–3. 
90 D.-S. Wang and Y.-G. Zhou, Tet. Lett., 2010, 51, 3014–3017. 
91 K. H. Lam, L. Xu, L. Feng, Q.-H. Fan, F. L. Lam, W. Lo and A. S. C. Chan, Adv. 
Synth. Catal., 2005, 347, 1755–1758. 
92 L. Xu, K. H. Lam, J. Ji, J. Wu, Q.-H. Fan, W.-H. Lo and A. S. C. Chan, Chem. 
Commun., 2005, 1390–2. 
93 X. Wang and Y. Zhou, J. Org. Chem., 2008, 73, 5640–5642. 
94 W. Tang, Y. Sun, Lijin Xu, T. Wang, Qinghua Fan, K.-H. Lam and A. S. C. Chan, 
Org. Biomol. Chem., 2010, 8, 3464–71. 
95 D.-Y. Zhang, C.-B. Yu, M.-C. Wang, K. Gao and Y.-G. Zhou, Tet. Lett., 2012, 53, 
2556–2559. 
41 
 
96 Z.-W. Li, T.-L. Wang, Y.-M. He, Z.-J. Wang, Q.-H. Fan, J. Pan and L.-J. Xu, Org. 
Lett., 2008, 10, 5265–8. 
97 H. Zhou, Z. Li, Z. Wang, T. Wang, L. Xu, Y. He, Q.-H. Fan, J. Pan, L. Gu and A. S. 
C. Chan, Angew. Chem. Int. Ed., 2008, 47, 8464–7. 
98 T. Wang, L.-G. Zhuo, Z. Li, F. Chen, Z. Ding, Y. He, Q.-H. Fan, J. Xiang, Z.-X. Yu 
and A. S. C. Chan, J. Am. Chem. Soc., 2011, 133, 9878–91. 
99 D.-W. Wang, W. Zeng and Y.-G. Zhou, Tet. Asym., 2007, 18, 1103–1107. 
100 C. Wang, C. Li, X. Wu, A. Pettman and J. Xiao, Angew. Chem. Int. Ed., 2009, 48, 
6524–8. 
101 X.-F. Tu and L.-Z. Gong, Angew. Chem. Int. Ed., 2012, 51, 11346–9. 
102 M. Rueping, A. P. Antonchick and T. Theissmann, Angew. Chem. Int. Ed., 
2006, 45, 3683–6. 
103 Q.-S. Guo, D.-M. Du and J. Xu, Angew. Chem. Int. Ed., 2008, 47, 759–62. 
104 X.-F. Cai, R.-N. Guo, G.-S. Feng, B. Wu and Y.-G. Zhou, Org. Lett., 2014, 16, 
2680–3. 
105 M. Rueping, T. Theissmann, M. Stoeckel and A. P. Antonchick, Org. Biomol. 
Chem., 2011, 9, 6844–6850. 
106 M. Struder, C. Wedemeyer-exl, F. Spindler and H.-U. Blaser, Monatshefte für 
Chemie, 2000, 131, 1335–1343. 
107 F. Glorius, N. Spielkamp, S. Holle, R. Goddard and C. W. Lehmann, Angew. 
Chem. Int. Ed., 2004, 43, 2850–2. 
108 C. Y. Legault and A. B. Charette, J. Am. Chem. Soc., 2005, 8966–8967. 
109 X.-B. Wang, W. Zeng and Y.-G. Zhou, Tet. Lett., 2008, 49, 4922–4924. 
42 
 
110 Z.-S. Ye, M.-W. Chen, Q.-A. Chen, L. Shi, Y. Duan and Y.-G. Zhou, Angew. 
Chem. Int. Ed., 2012, 51, 10181–4. 
111 M. Chang, Y. Huang, S. Liu, Y. Chen, S. W. Krska, I. W. Davies and X. Zhang, 
Angew. Chem. Int. Ed., 2014, 53, 12761–4. 
112 M. Rueping and A. P. Antonchick, Angew. Chem. Int. Ed., 2007, 46, 4562–5. 
113 Y. Boutadla, D. L. Davies, R. C. Jones and K. Singh, Chemistry, 2011, 17, 3438–
48. 
114 J. Wu, J. H. Barnard, Y. Zhang, D. Talwar, C. M. Robertson and J. Xiao, Chem. 
Commun., 2013, 49, 7052–4. 
115 D. Talwar, H. Y. Li, E. Durham and J. Xiao, Chem. Eur. J., 2015, 21, 5370–5379. 
116 Y. Wei, D. Xue, Q. Lei, C. Wang and J. Xiao, Green Chem., 2013, 15, 629–634. 
117 J. Wu, D. Talwar, S. Johnston, M. Yan and J. Xiao, Angew. Chemie . Int. Ed., 
2013, 52, 6983–6987. 
118 J. H. Barnard, C. Wang, N. G. Berry and J. Xiao, Chem. Sci., 2013, 4, 1234. 
119 D. Talwar, A. Gonzalez-de-Castro, H. Y. Li and J. Xiao, Angew. Chemie Int. Ed., 
2015, 54, 5223–5227. 
120 Q. Zou, C. Wang, J. Smith, D. Xue and J. Xiao, Chem. Eur. J., 2015, 21, 9656–
9661.  
 
  
43 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Iridicycle 
Development and 
Synthesis 
  
44 
 
2.1 Introduction 
 Cyclometalated complexes have long been known as versatile catalysts, 
utilising a number of transition metals, including iridium, ruthenium and 
palladium.1,2 These complexes are capable of catalysing many transformations, 
including reductions. 
 A large amount of work has been conducted by Xiao et al. utilising 
cyclometalated iridium complexes (Figure 2.1).3–13 These complexes have been 
shown to be efficient and highly chemoselective catalysts for a range of reduction 
and oxidation reactions. The aim in this chapter is to build upon this chemistry and 
develop a wide range of chiral analogues for testing in later chapters.  
 
Figure 2.1 General structure of achiral iridicycles. 
2.2 Oxazoline based complexes 
2.2.1 Basic Oxazoline Complexes 
 The most effective method for installing chirality into the racemic motif 
(Figure 2.1) was to lock the imine into a ring, containing chiral substituents (Scheme 
2.1). This could be achieved with readily available chiral amino alcohols and also 
diamines (Chapter 2.3). The ligands were produced via a condensation reaction 
between 2-amino-1,2-diphenylethanol and a benzaldehyde derivative, following a 
procedure published by Glorius (Eq 1, Scheme 2.1).14 Once the ligand was obtained 
the cyclometalation was performed under the mild conditions reported (Eq 2, 
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Scheme 2.1).2 Upon running 1H NMR analysis of the complex two diastereoisomers 
were observed (Ir 1-a and b), indicating that the chirality at the iridium centre was 
undefined (Figure 2.2). This should have little impact upon the catalytic activity, as 
the chloride must be lost to activate the complex, forming a pro-chiral iridium 
centre. For the basic oxazoline motif, both the R,S (Ir 1) and S,S (Ir 2)  amino 
alcohols were used (Figure 2.3); however, the catalytic results reported later 
(Chapter 3.2) showed the R,S-ligand produced higher ee’s, so was selected for the 
remaining oxazoline complexes.  
 
Scheme 2.1 General procedure for the synthesis of oxazolines and standard conditions for 
the cyclometalation reaction. 
 
Figure 2.2 (R,S)-Oxazoline complex showing chirality at the iridium centre. 
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Figure 2.3 Simple oxazoline complexes from commercial benzaldehyde and the R,S and 
R,R amino alcohol. 
2,4-Dimethyl-5-bromobenzaldehye was synthesised to determine the effect 
of steric bulk ortho to the iridium centre (Scheme 2.2). This was done by 
bromination of m-xylene to afford 1,5-dibromo-2,4-dimethylbenzene.15 The product 
underwent a selective acylation to afford the desired benzaldehyde,16 which was 
subjected to the standard condensation and cyclometalation conditions to produce 
Ir 3 (shown in Scheme 2.1). 
 
Scheme 2.2 Synthesis of 2,4-dimethyl-5-bromobenzaldehyde. 
 To incorporate electron donating substituents, commercially available 
methoxybenzyaldehydes were used for the synthesis of oxazoline ligands (Ir 4 and Ir 
5, Figure 2.4). Two 2-phenol based oxazolines using the amino alcohol valinol, were 
obtained from the group of Dr H. Aspinall within the department,17 allowing for 
comparison of different substituents in subsequent studies. Following analysis these 
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were also subjected to cyclometalation to form the iridicycles, Ir 7 and Ir 8 (Figure 
2.4).  
 
Figure 2.4 Electron rich oxazoline complexes. 
2.2.2 Bulky oxazoline complex 
The crystal structures obtained (by C Wang of the Xiao group)18 of the simple 
oxazoline complexes show a large empty pocket where the chloride sits around the 
iridium (Figure 2.6). Bulky ligands may therefore offer a higher enantioselectivity, 
due to the tighter space available around the iridium centre, limiting the possible 
approaches of the substrates to the active iridium centre. 
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Figure 2.5 Crystal structures of the basic oxazoline complexes (left R,S, right R,R (shown in 
Figure 2.3)), with chloride shown in green. 
Commercially available 4-iso-propyl and 4-tert-butylbenzaldehyde were used 
as bulky substrates to test steric effects (Ir 9 and Ir 10, Figure 2.6). Bulkier aldehydes 
were prepared in order to evaluate the effect of sterics on catalytic activity, the first 
of which was the addition of a sterically hindered 2,4,6-iso-propylbenzene ring in 
the 4-position of benzaldehyde as initially synthesised by B. V. Marcos of the Xiao 
Group19 (Scheme 2.3). This was synthesised from its bromide through Suzuki 
coupling with 4-formylphenylboronic acid.20 The aldehyde could then undergo the 
standard condensation to afford the desired ligand before being subjected to the 
cyclometalation conditions, yielding Ir 11. 
 
Figure 2.6 Bulky oxazoline complexes synthesised from commercial benzaldehydes. 
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Scheme 2.3 Synthesis of 2,4,6-isopropyl complex. 
These complexes concentrated their steric hindrance away from the chiral 
centres, it was therefore decided that a meta-terphenyl motif might offer more 
promise. This motif could spread closer to the metal centre, potentially forming a 
pocket and forcing the substrates closer to the chiral environment. The terphenyl 
ligands were synthesised (with assistance of Dr W. Tang within the Xiao group) from 
1,3-dichlorobenzene (Scheme 2.4), which was treated with n-BuLi to form the 2-
lithium salt.21–23 The salt reacted with a freshly prepared Grignard solution in THF of 
the desired aryl substrate in situ and upon quenching with iodine, afforded the 
desired 2-iodo-terphenyl product. This was then subjected to a Suzuki coupling with 
4-formylphenylboronic acid as described earlier, before undergoing a standard 
condensation with the amino alcohol. Due to the steric bulk, some of these 
complexes required harsher cyclometalation conditions of heating to 50 oC under a 
sealed nitrogen atmosphere to produce Ir 12-16. 
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Scheme 2.4 General synthesis of meta-terphenyl aldehyde for oxazoline complexes. 
 Larger ligands were synthesised by the addition of a further aryl group upon 
the terphenyl. This was achieved once more by palladium catalysed coupling of the 
aryl boronic acid with a triflate (provided by a Dr W. Tang within the group) 
(Scheme 2.5). The resulting iridium complexes (Ir 17 and Ir 18) are shown in Figure 
2.7.  
 
Scheme 2.5 Addition of extra aryl group via Suzuki coupling. 
51 
 
 
Figure 2.7 Diaryl meta-terphenyl complexes. 
2.3 Imidazoline complexes 
 A second class of ligands was prepared by replacing the amino alcohols with 
diamines. The condensation conditions to form the imidazolines were mild (Scheme 
2.6) and the simplest imidazoline ligand was synthesised using benzaldehyde and 
(R,R)-DPEN. Upon cyclometalation three resonances were observed by 1H NMR, Ir 
19-a, b and c. As before two diastereoisomers resulted from chirality at the iridium 
centre, however, a regioisomer was formed through cyclometalation onto the DPEN 
ring Ir 19-c (Figure 2.8). 
 
Scheme 2.6 General conditions for the synthesis of imidazoline ligands. 
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Figure 2.8 Various positions of cyclometalation of standard imidazolines. 
 In order to determine if Ir 19a-c complex would be selective or even active in 
reduction reactions, a number of these complexes were prepared Ir 20 and Ir 21 
(Scheme 2.7). This was done by switching the benzaldehyde for an aliphatic 
aldehyde, resulting in just one phenyl ring being present for cyclometalation. Both 
the condensation and cyclometalation reaction occurred readily, yielding the 
desired complexes. With these complexes containing a chiral centre within the 
iridicycle, they may offer a higher selectivity if active. 
 
Scheme 2.7 Synthesis of iridicycles with a chiral centre. 
 To further determine the effect of the cyclometalation onto the aryl ring of 
the DPEN, the phenyl rings were removed. This was achieved by synthesising (S,S)-
1,2-bis(cyclohexyl)-1,2-diaminoethane,24 via a Diaza-Cope rearrangement (Scheme 
2.8), with the aid of Dr J Barnard. To achieve this bis-1,2-(2-hydroxydiphenyl)-1,2-
diaminoethane reacted with cyclohexanecarboxaldehyde, to yield the intermediate 
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(S,S)-N,N’-bis(salicylidene)-1,2-cyclohexyl-1,2-diaminoethane. After treatment with 
hydrochloric acid, the dihydrochloride salt of the diamine could be isolated. 
 
Scheme 2.8 Synthesis of 1,2-bis(cyclohexyl)-1,2-diaminoethane hydrochloride. 
 With this diamine in hand it was reacted with benzaldehyde (Ir 22, Figure 
2.9), under similar conditions as previously stated, except the potassium carbonate 
was added in the first step, to allow for free-basing in situ (Scheme 2.9). Upon 
cyclometalation the resulting complex was similar to the oxazoline complexes, with 
just the 2 diastereoisomers being obtained. The diamine then reacted with a 
number of commercial benzaldehydes, with various substitution patterns and 
electronic effects. 3,5-Bromobenzaldehyde was used (Ir 23, Figure 2.9), as this 
would show the effect of placing an electron withdrawing group ortho to the 
iridium. When piperonal was used, cyclometalation occurred solely in the most 
hindered position on the ring (Ir 24, Figure 2.10). When a dioxane ring (6-
membered) was present cyclometalation became unselective with an inseparable 
mixture of both regioisomers being observed (Ir 25, Figure 2.9). 
 
Scheme 2.9 General synthesis of the imidazoline from a diamine salt. 
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Figure 2.9 Dicyclohexyl diamine based imidazoline complexes. 
The dicyclohexyldiamine was expensive and challenging to synthesise, 
therefore further analogues were made from DPEN, with a focus on oxygenated 
complexes. This was initiated with a focus on commercial benzaldehydes. A number 
of methoxy containing complexes were synthesised (Ir 26 - Ir 29, Figure 2.10), along 
with a range of 5-membered rings, such as dioxolane (Ir 30 - Ir 32) and furan (Ir 33) 
based complexes (Figure 2.10). Despite the dioxolane and furan rings offering the 
opportunity to undergo cyclometalation in two positions, once cyclometalation only 
occurred in the more hindered position, producing the standard three complexes. 
Expanding the ring to dioxane (a 6-membered ring) previously had shown a loss in 
selectivity upon cyclometalation; which occurred in both the 2 and 6 positions. This 
was overcome by performing a selective bromination on the benzaldehyde (Scheme 
2.10), to block the 2 position; forcing cyclometalation to occur solely in the 6 
position (Ir 34), once the ligand had been formed. 
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Scheme 2.10 Selective bromination on the 2 position of 2,3-dihydrobenzo[b][1,4]dioxine-
6-carbaldehyde. 
 
Figure 2.10 A range of oxygen rich imidazoline complexes. 
 Further variation of the DPEN group was achieved using commercially 
available substituted para-methoxy and ortho-chloro DPEN salts. Condensation 
using the conditions shown in Scheme 2.9, with 2,3,4-trimethoxybenzaldehyde was 
successful, although slightly harsher conditions were required once more for the 
cyclometalation (Ir 35 and Ir 36, Figure 2.11). 
56 
 
 
Figure 2.11 Complexes bearing substitution on the imidazoline aryl rings. 
2.4 Conclusions 
 During this chapter a large number of novel chiral ligands and their 
corresponding cyclometallated iridium complexes were synthesised and 
characterised. A diverse range of stereo and electronic properties was incorporated 
into these iridicycles, with bulky and electron rich complexes being the two most 
abundant classes of complexes synthesised. These complexes are being untilised in 
the following chapters to determine their activity and selectivity for a range of 
reductive transformations, in both hydrogenation and transfer hydrogenation 
conditions. 
2.5 Experimental 
THF was dried over sodium with benzophenone indicator, DCM and toluene 
were dried on an MB-SPS 800 solvent drying system, methanol was dried over 
magnesium and iodine. 4Å MS were activated in an oven overnight; all other 
chemicals were used as purchased. NMR spectra were recorded on a Bruker 400 
MHz NMR spectrometer, with TMS as internal standard. 
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2.5.1 Standard Procedures 
 
Amino alcohol condensation14 
A round bottom flask was charged with amino alcohol (1 eq, 1 mmol), benzaldehyde 
(1 eq, 1 mmol), 4Å MS and a stirrer bar. DCM (5 mL) was added and the reaction 
was stirred at room temperature for 16 h. NBS (1 eq, 1 mmol) was added slowly 
(exothermic reaction) to the flask, producing an orange/yellow solution, which was 
stirred for a further 30 min. The reaction mixture was filtered and washed with aq 
NaHCO3 (10 mL x 3) and water (10 mL). The organics were dried over MgSO4 and 
concentrated under vacuum. The resulting residue was purified by column 
chromatography in 10% EtOAc in hexane, to give 60-80% isolated yields. 
 
Standard cyclometalation2 
A glass vial was charged with [IrCp*Cl2]2 (1 eq), ligand (2 eq), NaOAc (10 eq) and a 
stirrer bar. DCM was added and the resulting orange solution was left to stir at 
room temperature for 16 h. The reaction mixture was filtered through Celite and 
the solvent was removed under vacuum. The complex was recrystallised from 
DCM/hexane to yield a yellow solid, in quantitative yield. 
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2,4-Dimethyl-5-bromobenzaldehye synthesis15,16 
A round bottomed flask was charged with a stirrer bar and m-xylene (1 eq, 10 
mmol). Bromine (2.2 eq) was then added over 5 min, iodine (1.5 mol%) was then 
added slowly over 30 min and the resulting solution was stirred for 3 h at room 
temperature. The reaction was quenched by the addition of aq NaOH (4 M, 10 mL) 
and stirred for 30 min. The resulting precipitate was then filtered off and 
recrystallized from EtOH, to yield the desired 1,5-dibromo-2,4-dimethylbenzene. A 
round bottomed flask was charged with the 1,5-dibromo-2,4-dimethylbenzene and 
a stirrer bar, followed by THF (10 mL). The flask was then cooled to -78 oC, n-BuLi 
(1.6 M, 1 eq) was added and allowed to stir for 30 min. DMF (2 eq) in THF (5 mL) 
was then added and the mixture stirred at -78 oC for 30 min, then warmed to room 
temperature and allowed to stir for 2 h. The reaction was quenched by addition of 
aq NaOH and the organics were extracted into Et2O (10 mL) x 3. The organics were 
then dried over MgSO4 and evaporated under vacuum. The resulting residue was 
purified by column chromatography in 10% EtOAc in hexane, in an overall yield of 
75%. 
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Suzuki Coupling for the synthesis of 2',4',6'-triisopropyl-[1,1'-biphenyl]-4-
carbaldehyde 
A glass reaction tube was charged with Pd2(dba)3 (2 mol%), XPhos (4 mol%), K3PO4 
(3 eq), 4-formylphenylboronic acid (2 eq), 2,4,6-triisopropylbromide (1 eq, 0.5 
mmol) and a stirrer bar. The reaction tube was then flushed with nitrogen and t-
amylalcohol (10 mL) was added. The reaction mixture was heated to 110 oC and left 
to stir 16 h. Once cooled to room temperature the reaction was diluted with water 
(20 mL), and extracted into EtOAc (10 mL x 3). The organics were dried over MgSO4 
and evaporated under vacuum. The resulting residue was purified by column 
chromatography using 5% EtOAc in hexane and isolated in a yield of 70%. 
 
Terphenyl synthesis 
A two necked round-bottomed flask, equipped with a condenser and stirrer bar, 
was flushed with nitrogen and sealed. 1,3-Dichlorobenzene (10 mmol) and THF (15 
mL) were added and the flask was cooled to -78 oC. To this n-BuLi (1.6 M, 0.8 mL) 
was added and allowed to stir for 2 h. After this time the desired freshly prepared 
aryl magnesium bromide (synthesised from the bromide and magnesium, in the 
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presence of iodine at reflux in THF) (3 eq) was added and allowed to warm to room 
temperature with stirring overnight. Once complete the reaction mixture was 
cooled to 0 oC, and iodine (3 eq) in THF (10 mL) was injected and the mixture was 
stirred at room temperature for 30 min. The reaction was then quenched with aq 
Na2S2O4 (50 mL) and extracted with Et2O (30 mL x 3). The organics were then 
washed with water (30 mL) and brine (30 mL), dried over MgSO4 and evaporated 
under vacuum. The resulting residue was then purified by column chromatography, 
using neat hexane and isolated in 40-60% yields. 
 
General Suzuki coupling 
A glass reaction tube was charged with Pd(OAc)2 (5 mol%), PPh3 (10 mol%), K3PO4 (4 
eq), boronic acid (3 eq), the desired triflate or halide (1 eq, 0.1 mmol) and a stirrer 
bar. The reaction tube was then flushed with nitrogen and THF (3 mL) was added. 
The reaction mixture was heated to 65 oC and left to stir for 12 h. Once cooled the 
reaction mixture was filtered through Celite and evaporated under vacuum. The 
resulting residue was purified by column chromatography using 20% EtOAc in 
hexane. The products were isolated in 50-85% yield. 
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Diamine condensation 
A reaction tube was charged with diamine (1 eq, 1 mmol), benzaldehyde (1 eq, 1 
mmol) and a stirrer bar, tBuOH (5 mL) was then added and the resulting mixture 
stirred at room temperature for 16 h. K2CO3 (3 eq, 3 mmol) and I2 (1.25 eq, 1.15 
mmol) were then added and the resulting dark orange solution was heated to 70 oC 
and stirred for 3 h. Once cooled the reaction was quenched by addition of saturated 
aq Na2S2O4 (10 mL) and the organics extracted with EtOAc. The organic layer was 
washed with water (10 mL x 3) and dried over MgSO4. The solvent was then 
removed under vacuum and the residue purified by column chromatography in 50% 
EtOAc in hexane. The products were isolated in 60-85% yields. 
 
(S,S)-1,2-Bis(cyclohexyl)-1,2-diaminoethane synthesis 
A glass reaction tube was charged with 4Å MS, bis-1,2-(2-hydroxydiphenyl)-1,2-
diaminoethane (1 eq, 1 mmol), cyclohexanecarboxaldehyde (2.4 eq, 2.4 mmol) and 
a stirrer bar. Dry toluene was then added (5 mL) and this was stirred at 115 oC for 24 
h. After cooling the reaction mixture was evaporated under vacuum and methanol 
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was added to precipitate the intermediate, which was isolated by filtration. The 
intermediate was then loaded into a glass reaction tube along with a stirrer bar. To 
this THF (5 mL), followed by aq HCl (2M, 10 mL) was added and this was heated to 
50 oC and stirred for 3 h. After cooling and filtration the diamine 2HCl salt was 
isolated as a white solid, in 60-70% yield. 
 
Diamine hydrochloride salt condensation 
A reaction tube was charged with diamine (1 eq, 1 mmol), K2CO3 (4 eq, 4 mmol) 
benzaldehyde (1 eq, 1 mmol) and a stirrer bar, tBuOH (5 mL) was added and the 
resulting mixture stirred at room temperature for 16 h. I2 (1.25 eq, 1.15 mmol) was 
added and the resulting dark orange solution was heated to 70 oC and stirred for 3 
h. Once cooled the reaction was quenched by addition of aq Na2S2O4 (10 mL) and 
the organics extracted with EtOAc. The organic layer was washed with water (10 mL 
x 3) and dried over MgSO4. The solvent was removed under vacuum and the residue 
purified by column chromatography in 50% EtOAc in hexane. The product was 
isolated in yields of 50-80%. 
Bromination reaction 
A round bottomed flask was charged with 1,4-benzodioxan-6-carboxaldehyde (1 eq, 
1 mmol) and a stirrer bar was placed under a nitrogen atmosphere. To this acetic 
acid (4 mL) was added followed by bromine (1 eq), and the resulting mixture was 
stirred at room temperature for 20 h. After completion the reaction mixture was 
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cooled in an ice bath and water added (10 mL). The resulting product was then 
isolated by filtration. 
2.5.2 Analytical data 
 
(4R,5S)-2,4,5-Triphenyl-4,5-dihydrooxazole18 In accordance with published data. 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 8.19-8.17 (m, 2H), 7.59-7.55 (m, 1H), 
7.52-7.48 (m, 2H), 7.09-7.00 (m, 6H), 6.99-6.92 (m, 4H), 6.02 (d, J = 10.0 Hz, 1H), 
5.75 (d, J = 10.0 Hz, 1H). 13C NMR (CDCl3, 100 MHz)  (ppm) 165.3, 138.1, 137.0, 
132.2, 129.0, 128.9, 128.3, 128.1, 127.9, 127.8, 126.8, 85.7, 74.9. HRMS (ESI) 
[M+H]+ calculated 300.1388; found 300.1384. 
 
 
Ir 118 In accordance with published data. 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.86 (d, J = 7.7 Hz, 0.7H), 7.80 (d, J = 
7.6 Hz, 0.3H), 7.65 (d, J = 7.6 Hz, 0.7H), 7.59 (d, J = 7.6 Hz, 0.3H), 7.34-7.29 (m, 1H), 
7.10-7.03 (m, 9H), 6.96-6.89 (m, 2H), 6.28 (d, J = 9.1 Hz, 0.7H), 6.23 (d, J = 10.0 Hz, 
0.3H), 5.80 (d, J = 10.0 Hz, 0.3H), 5.42 (d, J = 9.1 Hz, .07H), 1.55 (s, 5H), 1.50 (s, 10H). 
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13C NMR (CDCl3, 100 MHz)  (ppm) 135.7, 134.3, 132.37, 128.0, 127.8, 127.6, 126.9, 
126.3, 121.9, 88.3, 87.6, 72.0, 9.4, 9.1. 
 
(4R,5R)-2,4,5-Triphenyl-4,5-dihydrooxazole18 In accordance with published data. 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 8.15-8.13 (m, 2H), 7.56-7.29 (m, 
13H), 5.41 (d, J = 7.6 Hz, 1H), 5.22 (d, J = 7.6 Hz, 1H). 13C NMR (CDCl3, 100 MHz)  
(ppm) 164.5, 142.2, 140.9, 132.1, 129.4, 129.3, 129.1, 128.9, 128.8, 128.2, 127.9, 
127.2, 126.1, 89.4, 79.5. HRMS (ESI) [M+H]+ calculated 300.1388; found 300.1385. 
CHN calculated C, 84.25; H, 5.72; N, 4.58; found C, 84.58; H, 5.78; N, 4.60. 
 
Ir 218 In accordance with published data. 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.83 (dd, J = 17.3, 7.9 Hz, 1H), 7.57-
7.53 (m, 2H), 7.45-7.41 (m, 4H), 7.38-7.28 (m, 6H), 7.05 (d, J = 6.4 Hz, 1H), 5.52 (d, J 
= 11.4 Hz, 1H), 5.19-5.14 (m, 1H), 1.56 (s, 6H), 1.51 (s, 9H). 13C NMR (CDCl3, 100 
MHz)  (ppm) 130.8, 129.1, 129.1, 128.9, 127.2, 126.5, 121.8, 119.3, 92.7, 88.2, 
87.6, 9.4, 9.2. 
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1,5-Dibromo-2,4-dimethylbenzene 
White solid. 1H NMR (CDCl3, 400MHz)  (ppm) 7.66 (s, 1H), 7.08 (s, 1H), 2.30 (s, 6H). 
13C NMR (CDCl3, 100MHz)  (ppm) 136.9, 134.9, 132.6, 122.1, 22.3. 
 
5-Bromo-2,4-dimethylbenzaldehyde 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 10.13 (s, 1H), 7.90 (s, 1H), 7.12 (s, 
1H), 2.57 (s, 3H), 2.41 (s, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 190.9, 144.2, 
139.4, 135.4, 134.2, 133.5, 122.4, 23.1, 18.9. HRMS (CI) calculated [M+H]+ 230.0175, 
found [M+H]+ 230.0165. 
 
(4R,5S)-2-(5-Bromo-2,4-dimethylphenyl)-4,5-diphenyl-4,5-dihydrooxazole 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 8.24 (s, 1H), 7.19 (s, 1H), 7.08-7.01 
(m, 6H), 6.96-6.93 (m, 4H), 5.95 (d, J = 10.1 Hz, 1H), 5.77 (d, J = 10.1 Hz, 1H), 2.68 (s, 
3H), 2.43 (s, 3H).  13C NMR (CDCl3, 100 MHz) (ppm) 164.1, 141.0, 138.6, 137.8, 
136.6, 133.9, 133.8, 127.9, 127.8, 127.7, 127.5, 127.0, 126.4, 125.9, 121.7, 84.7, 
75.0, 22.9, 21.9. HRMS (ESI) found [M+H]+ 406.0805. 
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Ir 3 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.23-6.91 (m, 11H), 6.19 (d, J = 9.1 
Hz, 0.7H), 5.99 (d, J = 10.1 Hz, 0.3H), 5.79 (d, J = 9.1 Hz, 0.7H), 5.30 (d, J = 9.1 Hz, 
0.3H), 2.54-2.51 (m, 6H), 1.55 (s, 9H), 1.51 (s, 6H). 13C NMR (CDCl3, 100 MHz)  
(ppm) 162.1, 129.2, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6, 127.5, 126.7, 126.4, 
126.1, 85.6, 20.1, 10.1, 9.8, 9.0. MS (ESI) calculated [M+H]+ 769.22, found [M+H]+  
769.30. 
 
(4R,5S)-2-(2,4-Dimethoxyphenyl)-4,5-diphenyl-4,5-dihydrooxazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.95 (d, J = 8.6 Hz, 1Hz), 7.04-6.92 
(m, 10H), 6.57-6.54 (m, 2H), 5.92 (d, J = 10.1 Hz, 1H), 5.73 (d, J = 10.1 Hz, 1H), 3.92 
(s, 3H), 3.84 (s, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 163.6, 163.5, 160.5, 138.2, 
137.0, 132.9, 128.0, 128.0, 127.7, 127.6, 127.6, 127.4. 127.2, 126.9, 126.8, 126.5, 
109.7, 99.1, 84.4, 74.8, 56.1, 55.6. 
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Ir 4 
Yellow solid.  1H NMR (CDCl3, 400 MHz) δ (ppm) 7.39 (d, J = 6.9 Hz, 1H), 7.12-6.93 
(m, 11H), 6.23 (d, J = 9.1 Hz, 0.6H), 6.18 (d, J = 9.9 Hz, 0.4H), 5.68 (d, J = 9.9 Hz, 
0.4H), 5.30 (d, J = 9.1 Hz, 0.6H), 3.93 (s, 3H), 3.83 (s, 1.8H), 3.82 (s, 1.2H), 1.48 (s, 
9H), 1.46 (s, 6H). 13C NMR (CDCl3, 100MHz) δ (ppm) 180.5, 164.0, 160.7, 136.9, 
135.2, 134.8, 129.6, 128.5, 127.9, 127.9, 127.7, 127.7, 127.6, 127.5, 127.2, 127.0, 
126.5, 113.1, 112.6, 112.2, 93.2, 93.1, 90.7, 88.4, 88.0, 87.7, 72.5, 71.0, 55.3, 55.2, 
9.4, 9.1. MS (ESI) calculated [M+H]+ 721.31; found [M+H]+ 721.10. CHN 
C33H35ClIrNO3 calculated C, 54.92; H, 4.89; N, 1.94; found C, 55.71; H, 4.84; N, 2.26.   
 
(4R,5S)-4,5-Diphenyl-2-(2,3,4-trimethoxyphenyl)-4,5-dihydrooxazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.74 (d, J = 8.9 Hz, 1H), 7.08-6.95 
(m, 10H), 6.77 (d, J = 8.9 Hz, 1H), 5.98 (d, J = 10.2 Hz, 1H), 5.73 (d, J = 10.2 Hz, 1H), 
4.01 (s, 3H), 3.93 (s, 3H), 3.92 (s, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 163.7, 
156.4, 154.0, 143.1, 138.0, 136.9, 127.9, 127.8, 127.7, 127.6, 127.3, 126.9, 126.4, 
126.3, 115.2, 107.3, 74.5, 61.9, 61.1, 56.5. 
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Ir 5 
Yellow solid.  1H NMR (CDCl3, 400 MHz) δ (ppm) 7.4 (d, J = 7.1 Hz, 1H), 7.15 (s, 1H), 
7.10-6.95 (m, 9H), 6.27 (d, J = 9.1 Hz, 0.6H), 6.19 (d, J = 9.9 Hz, 0.4H), 5.71 (d, J = 9.9 
Hz, 0.4H), 5.32 (d, J = 9.1 Hz, 0.6H), 4.01 (s, 3H), 3.99 (s, 1.8H), 3.92 (s, 1.2H), 3.87 (s, 
1.2H), 3.86 (s, 1.8H), 1.49 (s, 9H), 1.46 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 
180.4, 160.0, 157.7, 157.1, 153.2, 137.5, 157.4, 136.7, 135.1, 134.9, 134.7, 129.6, 
128.5, 128.0, 128.0, 127.9, 127.8, 127.8, 127.6, 127.5, 127.3, 126.9, 126.3, 117.1, 
114.1, 113.8, 90.8, 88.3, 88.0, 87.7, 72.5, 71.2, 62.2, 62.1, 60.9, 60.9, 55.8, 9.4, 9.1. 
MS (ESI) found [M+H]+ 751.3. CHN C34H37ClIrNO4 calculated C, 54.35; N, 4.96; H, 
1.86; found C, 54.27; H, 5.25; N, 1.64.   
 
(R)-2-(Benzo[d][1,3]dioxol-5-yl)-4-(tert-butyl)-4,5-dihydrooxazole 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.50 (d, J = 8.0 Hz, 1H), 7.43 (s, 1H), 
6.81 (d, J = 8.0 Hz, 1H), 6.00 (s, 2H), 4.33-4.28 (m, 1H), 4.20 (t, J = 8.1 Hz, 1H), 4.01 
(dd, J = 10, 7.6 Hz, 1H), 0.94 (s, 9H). 13C NMR (CDCl3, 100 MHz)  (ppm) 162.7, 150.0, 
147.5, 123.0, 121.9, 108.5, 107.9, 101.4, 76.0, 68.7, 34.0, 25.8. HRMS (ESI) found 
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[M+H] 248.1285. CHN C14H17NO3 calculated C, 68.00; H, 6.93; N, 5.66; found C, 
67.43; H, 6.87; N, 5.55. 
 
Ir 6 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.05 (d, J = 7.0 Hz, 1H), 6.53 (d, J = 
7.0 Hz, 1H), 6.02 (d, J = 1.5 Hz, 1H), 5.97 (d, J = 1.5 Hz, 1H), 4.77 (dd, J = 9.2, 4.0 Hz, 
1H), 4.55 (t, J = 8.8 Hz, 1H), 3.96 (dd, J = 9.4, 4.0 Hz, 1H), 1.75 (s, 15H), 1.09 (s, 9H). 
13C NMR (CDCl3, 100 MHz) δ (ppm) 179.5, 162.1, 150.7, 149.5, 141.4, 138.9, 124.9, 
122.8, 103.3, 100.0, 99.4, 87.8, 72.3, 70.9, 58.6, 35.8, 25.7, 9.6. MS (ESI, EtOAc) 
[M+H]+ 609.3. CHN C14H16ClIrNO3 calculated C, 47.32; H, 5.18; N, 2.30; found C, 
46.26; H, 5.06; N, 1.72. 
 
Ir 7 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.38 (d, J = 7.0 Hz, 1H), 7.12 (d, J 
=7.0 Hz, 1H), 4.46-4.43 (m, 1H), 4.30-4.19 (m, 2H),  2.68-2.56 (m, 1H), 2.93 (s, 3H), 
1.61 (s, 15H), 0.91 (dd, J = 24.1, 7.7 Hz, 6H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 
160.8, 133.6, 131.0, 126.5, 113.4, 108.2, 84.3, 74.2, 67.4, 29.7, 19.5, 17.8, 14.8, 9.0. 
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MS (ESI) found [M+H]+ 582.5. CHN C23H34ClIrNO2 calculated C, 47.53; H, 5.38; N 
2.41; found C, 45.92; H, 5.38; N, 1.82. 
 
Ir 8 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.14 (d, J = 7.1 Hz, 1H), 6.77 (d, J = 
7.1 Hz, 1H), 4.44-4.41 (m, 1H), 4.33-4.28 (m, 1H), 4.27-4.21 (m, 1H), 3.80 (s, 3H), 
2.73-2.58 (m, 1H), 1.6 (s, 15H), 0.89 (dd, J = 33.17, 7.80 Hz, 6H). 13C NMR (CDCl3, 100 
MHz) δ (ppm) 159.5, 152.9, 120.8, 114.9, 113.2, 109.7, 84.5, 73.9, 87.9, 56.5, 29.6, 
19.5, 9.2, 9.0. MS (ESI) found [M+H]+ 597.29. CHN C23H34ClIrNO3 calculated C, 46.26; 
H, 5.23; N 2.35; found C, 45.46; H, 5.27; N, 1.69. 
 
 (4R,5S)-2-(4-Iso-propylphenyl)-4,5-diphenyl-4,5-dihydrooxazole19 In accordance 
with published data. 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 8.03 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 
8.3 Hz, 2H), 6.98-6.91 (m, 6H), 6.88-6.83 (m, 4H), 5.91 (d, J = 10.0 Hz, 1H), 5.65 (d, J 
= 10.0 Hz, 1H), 2.91 (dt, J = 13.9, 6.9 Hz, 1H), 1.22 (d, J = 6.9 Hz, 6H). 13C NMR (CDCl3, 
100 MHz)  (ppm) 165.1, 153.2, 137.8, 136.7, 128.8, 127.9, 127.8, 127.7, 127.7, 
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127.6, 127.5, 127.4, 127.0, 126.8, 126.7, 126.5, 125.0, 85.3, 85.3, 76.9, 74.5, 74.4, 
34.4, 34.3, 24.0, 23.9. HRMS (ESI) calculated [M+H]+ 342.1858; found [M+H]+ 
342.1865. 
 
Ir 919 In accordance with published data. 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.65 (s, 0.7H) 7.59 (s, 0.3H), 7.52 (d, 
J = 7.8 Hz, 0.7H), 7.45 (d, J = 7.8 Hz, 0.3H), 7.33 (d, J = 7.0 Hz, 1H), 7.01-6.88 (m, 
10H), 6.48 (d, J = 9.1 Hz, 0.7H), 6.12 (d, J = 10 Hz, 0.3H), 5.70 (d, J = 10 Hz, 0.3H), 
6.33 (d, J = 9.1 Hz, 0.7H), 2.93 (dt, J = 13.7, 6.8 Hz, 1H), 1.42 (s, 15H), 1.27 (d, J = 6.8 
Hz, 6H). 13C NMR (CDCl3, 100 MHz)  (ppm) 134.0, 128.1, 128.0, 127.8, 128.6, 126.9, 
126.3, 120.5, 90.6, 71.9, 34.7, 23.7, 9.4, 9.2. 
 
(4R,5S)-2-(4-(tert-butyl)phenyl)-4,5-diphenyl-4,5-dihydrooxazole19 In accordance 
with published data. 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 8.11 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 
8.4 Hz, 2H), 7.06-7.01 (m, 6H), 6.96-6.92 (m, 4H), 6.00 (d, J = 10.0 Hz, 1H), 5.73 (d, J 
= 10.0 Hz, 1H), 1.38 (s, 9H). 13C NMR (CDCl3, 100 MHz)  (ppm) 165.0, 155.3, 137.9, 
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136.8, 128.5, 127.9, 127.7, 127.6, 127.3, 127.0, 126.4, 125.6, 124.7, 85.2, 74.5, 35.1, 
31.3. HRMS (ESI) calculated [M+H]+ 356.2010; found [M+H]+ 356.2012. 
 
Ir 1019 In accordance with published data. 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.91 (s, 0.7H), 7.85 (s, 0.3H), 7.60 (d, 
J = 8.0 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.15-7.03 (m, 10H), 6.26 (d, J = 9.1 Hz, 0.7H), 
6.19 (d, J = 9.9 Hz, 0.3H), 5.77 (d, J = 9.9 Hz, 0.3H), 5.40 (d, J = 9.1 Hz, 0.7H), 1.50 (s, 
10H), 1.49 (s, 5H), 1.42 (s, 9H).  13C NMR (CDCl3, 100 MHz) δ (ppm) 193.3, 154.8, 
151.0, 136.3, 134.5, 132.6, 129.6, 129.2, 128.6, 128.1, 128.0, 127.8, 126.9, 126.5, 
126.3, 125.6, 119.7, 90.7, 88.2, 88.0, 87.6, 76.3, 71.9, 35.3, 31.6, 9.5, 9.2. HRMS 
(ESI) found [M+H]+ 717.3455. 
 
2',4',6'-triisopropyl-[1,1'-biphenyl]-4-carbaldehyde19 In accordance with published 
data. 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 10.01 (s, 1H), 7.87-7.84 (m, 2H), 
7.31-7.29 (m, 2H), 7.00 (s, 2H), 2.88 (septet J = 6.9 Hz, 1H), 2.43 (septet, J = 6.9 Hz, 
2H), 1.24 (d, J = 6.9 Hz, 6H), 1.01 (d J = 6.9 Hz, 12H). 13C NMR (CDCl3, 100 MHz) 
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(ppm) 191.0, 147.6, 147.1, 145.0, 134.7, 133.9, 129.6, 128.4, 119.7, 33.3, 29.4, 
23.1, 23.0. HRMS (CI) calculated [M+H]+ 309.2213; found [M+H]+ 309.2223. 
 
(4R,5S)-4,5-Diphenyl-2-(2',4',6'-triisopropyl-[1,1'-biphenyl]-4-yl)-4,5-
dihydrooxazole19 In accordance with published data. 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 8.20 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 
9.2 Hz, 2H), 7.08-6.97 (m, 12H), 6.05 (d, J = 10.1 Hz, 1H), 5.78 (d, J = 10.1 Hz, 1H), 
2.95 (septet, J = 6.9 Hz, 1H), 2.63 (septet, J = 6.9 Hz, 2H), 1.32 (d, J = 6.9 Hz, 6H), 
1.11 (d, J = 6.9 Hz, 12H). 13C NMR (CDCl3, 100 MHz) (ppm) 165.0, 148.3, 146.3, 
145.0, 137.8, 136.7, 136.2, 130.2, 128.3, 128.0, 127.7, 127.7, 127.4, 127.0, 126.4, 
125.7, 120.7, 85.4, 74.6, 23.3, 30.4, 24.2, 24.1. HRMS (ESI) calculated [M+H]+ 
502.3110; found [M+H]+ 502.3109. CHN C36H34NO calculated C, 86.18; H, 7.84; N, 
2.79; found C, 85.48; H, 7.79; N, 2.88. 
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Ir 1119 In accordance with published data. 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.68 (d, J = 7.7 Hz, 0.7H), 7.62 (s, 
0.7H), 7.58 (d, J = 7.7 Hz, 0.3H) 7.56 (s, 0.3H), 7.42 (d, J = 7.2 Hz, 0.7H) 7.35 (d, J = 
7.2 Hz, 0.3H), 7.12-7.02 (m, 11H) 6.90 (d, J = 7.7 Hz, 0.7H), 6.87 (d, J = 7.7 Hz, 0.3H), 
6.30 (d, J = 9.2 Hz, 0.7H), 6.27 (d, J = 10.4 Hz, 0.3H), 5.80 (d, J = 10.4 Hz, 0.3H), 5.47 
(d, J = 9.2 Hz, 0.7H), 3.03-2.69 (m, 3H), 1.58 (s, 3H), 1.50 (s, 12H), 1.36 (d, J = 6.8 Hz, 
6H), 1.20-1.09 (m, 12H). 13C NMR (CDCl3, 100 MHz) (ppm) 181.1, 163.2, 147.5, 
145.9, 137.8, 137.3, 136.2, 134.4, 128.1, 128.0, 127.8, 126.3, 123.7, 120.7, 120.2, 
90.7, 88.2, 87.5, 72.1, 34.2, 30.5, 30.2, 25.0, 24.6, 24.0, 23.9, 9.4, 9.1.  HRMS (ESI) 
found [M+H]+ 863.5543. CHN calculated C, 63.98; H,6.19; N, 1.62; found C, 63.78, H, 
6.27; N, 1.45. 
 
2'-iodo-4,4''-dimethyl-1,1':3',1''-terphenyl 
White solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.57-7.75 (m, 4H), 7.37-7.3 (m, 1H),  
7.25-7.23 (m, 2H), 6.93-6.91 (m, 4H), 2.29 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ 
(ppm) 137.6, 135.4, 131.6, 130.6, 129.2, 127.3, 90.6, 21.4. 
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4''-Methyl-6'-(p-tolyl)-[1,1':2',1''-terphenyl]-4-carbaldehyde 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 10.04 (s, 1H), 7.97-7.92 (m, 4H), 
7.75-7.73 (m, 3H), 7.55-7.53 (m, 4H), 7.30-7.27 (m, 4H), 2.41 (s, 6H). 13C NMR 
(CDCl3, 100 MHz) δ (ppm) 192.3, 147.6, 138.9, 137.2, 135.4, 130.7, 130.2, 128.9, 
128.1, 127.8, 127.6, 125.9, 21.6. 
 
(4R,5S)-2-(4''-Methyl-6'-(p-tolyl)-[1,1':2',1''-terphenyl]-4-yl)-4,5-diphenyl-4,5-
dihydrooxazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 8.26-8.17 (m 2H), 7.74-7.68 (m, 3H), 
7.58-7.51 (m, 2H), 7.29-7.27 (m, 3H), 7.09-7.93 (m, 15H), 6.03 (d, J = 10.1 Hz, 1H), 
5.76 (d, J = 10.1 Hz, 1H), 2.4 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 165.3, 144.9, 
138.4, 138.2, 137.7, 137.1, 130.1, 129.5, 128.3, 128.1, 127.8, 127.7, 127.4, 126.8, 
126.4, 85.8, 74.9, 32.02, 23.1.  
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Ir 12 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 8.05-8.0 (m, 1H), 7.71 (d, J = 7.8 Hz, 
1H), 7.64 (dd, J = 8.1, 3.7 Hz, 1H), 7.60 (d, J = 8.1 Hz, 4H), 7.43-7.41 (m, 2H), 7.28 (d, 
J = 7.8 Hz, 3H), 7.11-7.08 (m, 6H), 7.05-7.01 (m, 6H), 6.3 (d, J = 9.0 Hz, 0.7H), 6.23 (d, 
J = 9.9 Hz, 0.3H), 5.82 (d, J = 9.9 Hz, 0.3H), 5.43 (d, J = 9.0 Hz, 0.7H), 2.43 (s, 3H), 2.28 
(s, 3H), 1.52 (s, 10H), 1.51 (s, 5H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 180.01, 
144.54, 139.27, 137.16, 136.16, 134.33, 129.6, 129.4, 128.6, 128.2, 128.0, 127.9, 
127.9, 127.5, 126.9, 126.3, 126.1, 90.8, 90.1, 88.4, 87.7, 85.8, 72.0, 21.3, 21.2, 9.5, 
9.2. MS (ESI) found [M+H]+ 919.3. 
 
2'-Iodo-4,4''-diisopropyl-1,1':3',1''-terphenyl 
White solid. 1H NMR (CDCl3, 400 MHz) (ppm) 7.41-7.27 (m, 11H), 3.01 (dt J = 13.8, 
7.0 Hz, 2H), 1.34 (d, J = 7.0 Hz, 12H). 13C NMR (CDCl3, 100 MHz) (ppm)148.1, 
148.1, 143.1, 129.3, 127.5, 125.9, 104.0, 76.7, 33.9, 24.0. 
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4''-Isopropyl-6'-(4-isopropylphenyl)-[1,1':2',1''-terphenyl]-4-carbaldehyde 
White solid. 1H NMR (CDCl3, 400 MHz) (ppm) 7.54-7.45 (m, 5H), 7.06-6.98 (m, 
10H), 2.89-2.82 (m, 2H), 1.23 (d, J = 7.1 Hz, 12H).  13C NMR (CDCl3, 100 MHz) 
(ppm) 192.4, 162.1, 147.1, 141.8, 138.7, 137.8, 133.8, 132.5, 129.8, 129.7, 128.6, 
127.9, 125.8, 33.6, 23.9. HRMS (CI) found [M+H]+ 419.2385. 
 
(4R,5S)-2-(4''-Isopropyl-6'-(4-isopropylphenyl)-[1,1':2',1''-terphenyl]-4-yl)-4,5-
diphenyl-4,5-dihydrooxazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz) (ppm) 7.86-7.79 (m, 2H), 7.50-7.47 (m, 
5H), 7.11-7.06 (m, 12H), 6.99-6.91 (m, 4H), 5.99 (d, J = 9.9 Hz, 1H), 5.72 (d, J = 9.9 
Hz, 1H), 2.91-2.88 (m, 2H), 1.26 (d, J = 6.8 Hz, 12H). 13C NMR (CDCl3, 100 MHz) 
(ppm)182.8, 162.1, 146.9, 141.9, 139.0, 132.0, 129.8, 129.6, 127.9, 127.7, 127.6, 
127.4, 127.0, 126.3, 125.8, 85.1, 37.9, 33.7, 24.0, 17.2. HRMS (ESI) found [M+H]+ 
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612.3276. CHN C45H41NO calculated C, 88.34; H, 6.75; N, 2.79; found C, 85.48; H, 
7.79; N, 2.88. 
 
Ir 13 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.48-7.46 (m, 3H), 7.42 (d, J = 1.0 
Hz, 1H), 7.38 (d, J = 1.0 Hz, 1H), 7.22 (d, J = 8.6 Hz, 2H), 7.10-7.02 (m, 14H), 6.87-
6.84 (m, 2H), 6.63-6.55 (m, 1H), 6.26 (d, J = 9.3 Hz, 0.65H), 6.13 (d, J = 9.8 Hz, 0.4H), 
5.74 (d, J = 9.8 Hz, 0.4H), 5.37 (d, J = 9.3 Hz, 0.6H), 2.89-2.78 (m, 2H), 1.22 (s, 15H), 
1.20 (s, 12H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 181.1, 162.1, 146.5, 143.8, 142.7, 
142.6, 141.1, 140.0, 139.8, 139.5, 139.3, 138.8, 136.4, 134.9, 134.6, 130.1, 129.8, 
129.7, 129.6, 129.2, 129.1, 128.2, 128.1, 128.0, 127.9, 127.8, 127.8, 127.5, 127.3, 
126.8, 126.3, 126.0, 125.9, 125.7, 90.4, 88.0, 87.2, 73.2, 72.0, 33.7, 24.3, 24.1, 24.0, 
23.8, 23.7, 9.2, 9.0. MS (ESI) found [M+H]+ 973.8. CHN calculated C, 67.84; H, 5.69; 
N, 1.44; found C, 67.41; H, 5.66; N, 1.30. 
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2'-Iodo-4,4''-dimethoxy-1,1':3',1''-terphenyl 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.40-7.37 (m, 1H), 7.34-7.32 (m, 4H), 
7.26-7.25 (m, 2H), 7.01-6.97 (m, 4H), 3.89 (s, 6H). 13C NMR (CDCl3, 100 MHz) 
(ppm) 159.0, 147.8, 138.4, 130.6, 128.6, 12.5, 113.2, 105.1, 55.3. 
 
4''-Methoxy-6'-(4-methoxyphenyl)-[1,1':2',1''-terphenyl]-4-carbaldehyde 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 9.89 (s, 1H), 7.57-7.43 (m, 5H), 7.07 
(d, J = 7.8 Hz, 2H), 6.99 (d, J = 8.6 Hz, 4H), 6.72 (d, J = 8.6 Hz, 4H), 3.77 (s, 6H).  13C 
NMR (CDCl3, 100 MHz) (ppm) 192.2, 158.3, 147.2, 141.4, 137.8, 133.7, 132.4, 
131.0, 129.5, 128.8, 128.0, 113.2, 55.1. HRMS (ESI) found [M+Na]+ 417.1473. 
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(4R,5S)-2-(4''-Methoxy-6'-(4-methoxyphenyl)-[1,1':2',1''-terphenyl]-4-yl)-4,5-
diphenyl-4,5-dihydrooxazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.84-7.82 (m, 2H), 7.52-7.43 (m, 
4H), 7.10-6.96 (m, 15H), 6.79-6.76 (m, 4H), 5.99 (d, J = 10.1 Hz, 1H), 5.72 (d, J = 10.1 
Hz, 1H), 3.81 (s, 6H). 13C NMR (CDCl3, 100 MHz) (ppm)182.8, 165.1, 162.1, 158.2, 
144.0, 141.5, 137.8, 136.6, 134.1, 131.9, 131.0, 129.5, 127.9, 127.7, 127.6, 127.5, 
127.4, 127.0, 126.4, 124.7, 113.3, 85.2, 74.4, 55.2. HRMS (ESI) found [M+H]+ 
588.2545.  
 
Ir 14 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.47-7.42 (m, 2H), 7.39 (dd, J = 6.7, 
1.1 Hz, 2H), 7.31 (d, J = 7.7 Hz, 1H), 7.22-7.19 (m, 2H), 7.09-6.99 (m, 10H), 6.90-6.88 
(m, 2H), 6.79-6.71 (m, 4H), 6.61 (dd, J = 7.8, 1.4 Hz, 0.7H), 6.58 (dd, J = 7.8, 1.4 Hz, 
0.3H), 6.26 (d, J = 9.3 Hz, 0.7H), 6.15 (d, J = 9.9 Hz, 0.3H), 5.75 (d, J = 9.9 Hz, 0.3H), 
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5.37 (d, J = 9.3 Hz, 0.7H), 3.78 (s, 2H), 3.76 (s, 1H), 3.75 (s, 2H), 3.75 (s, 1H), 1.25 (s, 
10H), 1.23 (s, 5H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 181.8, 181.1, 162.1, 158.1, 
158.0, 157.9, 145.0, 143.8, 142.2, 140.9, 140.5, 140.0, 139.7, 139.4, 139.2, 126.4, 
135.1, 134.8, 134.5, 133.8, 131.3, 131.1, 130.9, 129.4, 129.3, 129.3, 129.2, 129.1, 
128.3, 128.2, 128.1, 127.9, 127.8, 127.8, 127.6, 127.4, 126.9, 126.3, 126.0, 125.8, 
125.7, 125.4, 113.5, 113.3, 113.2, 90.5, 88.0, 87.2, 73.1, 72.0, 55.3, 55.3, 55.3, 55.2, 
9.2, 8.9. MS (ESI) found [M+H]+ 950.4. CHN calculated C, 64.51; H, 4.99; N, 1.48; 
found C, 64.00; H, 4.96; N, 1.33. 
 
(4R,5S)-2-(4''-(Benzyloxy)-6'-(4-(benzyloxy)phenyl)-[1,1':2',1''-terphenyl]-4-yl)-4,5-
diphenyl-4,5-dihydrooxazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.89 (d, J = 8.3 Hz, 2H), 7.54-7.38 
(m, 13H), 7.12-7.06 (m, 12H), 7.02-6.98 (m, 4H), 6.89 (d, J = 8.6 Hz, 4H), 6.02 (d, J = 
10.0 Hz, 1H), 5.75 (d, J = 10.0 Hz, 1H), 5.08 (s, 4H). 13C NMR (CDCl3, 100 MHz) 
(ppm) 165.1, 157.5, 144.0, 141.6, 138.2, 137.9, 137.0, 136.7, 134.4, 132.0, 131.1, 
129.6, 128.6, 128.0, 128.0, 127.7, 127.7, 127.4, 127.0, 126.5, 124.8, 114.3, 85.3, 
70.0. HRMS (ESI) found [M+H]+ 740.3161. 
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Ir 15 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.81 (d, J = 8.3 Hz, 1H), 7.47-7.29 
(m, 22H), 7.24-7.19 (m, 2H), 7.11-6.99 (m, 15H), 6.96-6.80 (m, 10H), 6.63-6.58 (m, 
1H), 6.26 (d, J = 9.3 Hz, 0.7H), 6.14 (d, J = 9.8 Hz, 0.3H), 5.97 (d, J = 10.1 Hz, 0.5H), 
5.75 (d, J = 9.8 Hz, 0.3H), 5.69 (d, J = 10.1 Hz, 0.5H), 5.38 (d, J = 9.3 Hz, 0.7H), 5.04-
4.99 (m, 6H), 1.26 (s, 10H), 1.23 (s, 5H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 181.1, 
157.4, 157.3, 144.0, 143.4, 142.1, 141.5, 139.7, 139.5, 139.2, 138.2, 137.9, 137.5, 
137.1, 137.0, 136.6, 136.4, 135.43, 134.6, 134.4, 134.0, 132.0, 131.4, 131.2, 131.2, 
131.0, 130.9, 130.3, 129.4, 129.3, 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.1, 
128.0, 127.9, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.4, 127.0, 126.9, 126.4, 
126.3, 126.0, 125.9, 114.5, 114.2, 114.1, 90.5, 88.0, 87.2, 85.2, 74.5, 72.0, 70.2, 
70.1, 70.0, 19.5, 9.3, 9.0. MS (ESI) found [M+H]+ 1104.3. 
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2'-Iodo-3,3'',5,5''-tetraisopropyl-1,1':3',1''-terphenyl 
Yellow solid. 1H NMR (CDCl3, 400 MHz) (ppm) 7.45-7.41 (m, 1H), 7.34 (s, 1H), 7.32 
(s, 1H), 7.15-7.12 (m, 6H), 3.04-2.97 (m, 4H), 1.36 (d, J = 6.8 Hz, 24H). 13C NMR 
(CDCl3, 100 MHz) (ppm) 148.8, 148.2, 145.5, 128.5, 127.5, 125.1, 124.0, 104.2, 
34.2, 24.1. 
 
6'-(3,5-Diisopropylphenyl)-3'',5''-diisopropyl-[1,1':2',1''-terphenyl]-4-carbaldehyde 
Yellow solid. 1H NMR (CDCl3, 400 MHz) (ppm) 9.86 (s, 1H), 7.54-7.52 (m, 5H), 7.03 
(d, J = 8.1 Hz, 2H), 6.87 (s, 2H), 6.78 (d, J = 1.5 Hz, 4H), 2.76 (dt, J = 13.7, 7.0 Hz, 4H), 
1.08 (d, J = 7.0 Hz, 24H). 13C NMR (CDCl3, 100 MHz) (ppm) 192.0, 148.2, 147.7, 
142.4, 141.0, 138.0, 133.7, 132.4, 129.2, 128.6, 128.0, 125.6, 123.4, 37.9, 39.9, 23.9. 
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(4R,5S)-2-(6'-(3,5-Diisopropylphenyl)-3'',5''-diisopropyl-[1,1':2',1''-terphenyl]-4-yl)-
4,5-diphenyl-4,5-dihydrooxazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz) (ppm) 7.81-7.75 (m, 3H), 7.04-7.00 (m, 
7H), 6.96-6.92 (m, 3H), 6.87-6.83 (m, 7H), 6.79 (d, J = 1.5 Hz, 3H), 5.92 (d, J = 9.9 Hz, 
1H), 5.65 (d, J = 9.9 Hz, 1H), 2.76 (dt, J = 13.8, 6.9 Hz, 4H), 1.11 (d, J = 6.9 Hz, 24H). 
13C NMR (CDCl3, 100MHz) (ppm) 148.1, 147.1, 142.5, 141.2, 131.9, 129.2, 129.1, 
127.9, 127.8, 127.7, 127.6, 127.6, 127.4, 126.9, 126.3, 125.7, 125.1, 123.3, 74.4, 
71.8, 34.0, 24.0, 23.0. HRMS (ESI) calculated [M+H]+ 696.4205; found [M+H]+ 
696.4191.  
 
Ir 16 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.5-7.48 (m, 2H), 7.4 (s, 1H) 7.19 (d, 
J = 7.8 Hz, 1H), 7.07-6.98 (m, 10H), 6.89-6.78 (m, 7H), 6.61 (dd, J = 6.9 Hz, 1H), 6.14 
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(m, 1H), 5.73 (d, J = 9.9 Hz, 0.4H), 5.31 (d, J = 9.9 Hz, 0.6H), 2.88-2.74 (m, 4H), 1.21 
(s, 8H), 1.19 (s, 7H), 1.17-1.08 (m,24H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 148.2, 
148.2, 147.8, 128.1, 128.0, 127.9, 127.8, 126.9, 126.2, 126.0, 126.0, 125.9, 87.8, 
87.1, 73.1, 71.8, 34.1, 34.0, 33.9, 33.8, 31.0, 24.4, 24.3, 24.2, 24.1, 24.0, 23.9, 23.8, 
9.2, 9.0. MS (ESI) found [M+H]+ 1058.8. 
 
Ir 17 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.91-7.79 (m, 2H), 7.72-7.58 (m, 
4H), 7.52-7.47 (m, 2H), 7.44-7.40 (m, 2H), 7.31-7.28 (m, 3H), 7.10-.08 (m, 8H), 7.06-
7.01 (m, 7H), 6.98-6.94 (m, 2H), 6.89 (bs, 2H), 6.28 (d, J = 9.1 Hz, 0.7H), 6.23 (d, J = 
10.0 Hz, 0.3H), 5.80 (d, J = 10.0 Hz, 0.3H), 5.41 (d, J = 9.1 Hz, 0.7H), 1.75-1.68 (m, 
2H), 1.52-1.47 (m, 23H), 1.39-1.37 (m, 4H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 
181.2, 136.1, 135.7, 135.4, 134.8, 134.7, 134.3, 133.2, 132.4, 131.5, 129.6, 128.6, 
128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.8, 127.6, 127.4, 127.3, 127.1, 
126.9, 126.7, 126.3, 125.7, 125.6, 122.0, 121.9, 90.7, 88.4, 88.1, 87.7, 73.3, 72.0, 
31.4, 9.5, 9.4, 9.3, 9.2. MS (ESI) found [M+H]+ 1126.4. 
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Ir 18 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.56-7.54 (m, 4H), 7.47 (d, J = 8 Hz, 
3H), 7.43 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.3 Hz, 2H), 7.31-7.28 (m, 3H), 7.24-7.18 (m, 
9H), 6.84-6.83 (m, 1H), 6.70-6.67 (m, 1H), 6.27 (d, J = 9.3 Hz, 0.7H), 6.13 (d, J = 9.9 
Hz, 0.3H), 5.7 (d, J = 9.9 Hz, 0.3H), 5.37 (d, J = 9.3 Hz, 0.7H), 2.96-2.90 (m, 4H), 1.30-
1.25 (m, 24H), 1.21 (s, 15H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 181.0, 149.3, 149.1, 
141.2, 141.2, 141.1, 140.1, 139.9, 139.8, 136.5, 130.4, 130.2, 129.9, 129.8, 129.5, 
128.5, 128.0, 127.9, 127.7, 127.5, 127.0, 126.9, 126.8, 126.3, 126.1, 123.9, 123.4, 
123.2, 123.1, 122.8, 90.4, 88.0, 87.2, 72.0, 34.4, 24.2, 9.2, 9.0. MS (ESI) found 
[M+H]+ 1209.7. CHN C73H75ClIrNO calculated C, 72.46; H, 6.25; N, 1.16; found C, 
71.68; H, 6.24; N, 1.40. 
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(4R,5R)-2,4,5-Triphenyl-4,5-dihydro-1H-imidazole18 In accordance with published 
data. 
White solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.93-7.90 (m, 2H), 7.50-7.24 (m, 
13H) 4.86 (s, 2H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 163.6, 143.9, 131.4, 130.5, 
129.1, 126.0, 127.9, 127.8, 127.1, 75.3. HRMS (ESI) calculated [M+H]+ 299.1548; 
found [M+H]+ 299.1535. 
 
Ir 1918 In accordance with published data. 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.45-7.15 (m, 14H), 6.54 (dd, J = 8.0, 
4.0Hz, 0.4H), 6.43 (dd, J = 8.0, 4.0 Hz, 0.6H), 5.65 (s, 0.6H), 5.31 (s, 0.4H), 5.04 (d, J = 
4.0 Hz, 0.4H), 4.89 (d, J = 12 Hz, 0.6H), 4.72 (d, J = 12Hz, 0.6H), 4.60 (s, 0.4H), 3.80 (s, 
3H), 1.37 (s, 15H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 176.7, 176.0, 166.4, 162.1, 
161.6, 143.8, 142.0, 140.1, 139.4, 128.9, 128.8, 128.7, 128.2, 127.5, 127.3, 127.2, 
126.0, 120.6, 120.2, 87.7, 87.1, 79.3, 72.3, 72.0, 55.0, 31.5, 22.6, 14.1, 9.3, 9.1. 
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2-Cyclohexyl-4,5-diphenyl-4,5-dihydro-1H-imidazole5 In accordance with published 
data. 
White solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.35-7.31 (m, 5H), 7.28-7.26 (m, 2H + 
CDCl3), 7.23-7.21 (m, 3H), 4.69 (s, 2H), 2.49-2.42 (m, 1H), 2.09-2.04 (m, 1H), 1.86-
1.83 (m, 2H), 1.74-1.68 (m, 2H), 1.60-1.52 (m, 2H), 1.40-1.25 (m, 3H). 13C NMR 
(CDCl3, 100 MHz) δ (ppm) 170.3, 143.9, 138.8, 128.7, 127.4, 126.4, 38.8, 31.0, 26.0, 
25.9. HRMS (ESI) calculated [M+H]+ 305.2018, found [M+H]+ 305.2024. 
 
Ir 205 In accordance with published data. 
Orange solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.50 (m, 3H), 7.44 (t, J = 8.0 Hz, 
2H), 7.36 (t, J = 8.0 Hz, 1H), 6.98 (td, J = 8.0, 2.0 Hz, 1H), 6.80 (m, 2H), 5.20 (s, br, 
1H), 4.90 (m, 2H), 2.95 (tt, J = 12.0, 4.0 Hz, 1H), 2.38 (d, J = 16.0 Hz, 1H), 2.10-0.8 (m, 
9H), 1.71 (s, 15H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 173.7, 156.2, 147.0, 142.0, 
136.8, 129.2, 128.4, 127.5, 127.4, 122.4, 118.4, 86.8, 83.0, 67.7, 40.4, 32.7, 31.3, 
26.2, 26.0, 25.9, 9.6. 
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(4R,5R)-2-(Tert-butyl)-4,5-diphenyl-4,5-dihydro-1H-imidazole 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.30-7.14 (m, 10H), 4.73 (s, 2H), 1.29 
(s, 9H). 13C NMR (CDCl3, 100 MHz)  (ppm) 129.3, 129.2, 129.2, 127.4, 126.7, 85.7, 
28.8, 9.8. 
 
Ir 21 
Orange solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.25-7.14 (m, 9H), 5.0 (d, J = 7.0 Hz, 
1H), 4.51 (d, J = 7.0 Hz, 1H), 1.33 (s, 6H), 1.30-1.29 (m, 18H). 13C NMR (CDCl3, 100 
MHz)  (ppm) 129.6, 129.3, 129.2, 129.1, 128.7, 128.6, 128.4, 128.1, 128.0, 127.8, 
127.6, 127.4, 126.7, 87.55, 85.7, 42.4, 28.8, 9.9, 9.8. 
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2,2'-((1E,1'E)-(((1S,2S)-1,2-Dicyclohexylethane-1,2-diyl)bis(azanylylidene))bis 
(methanylylidene))diphenol24  
White solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 8.24 (S, 2H), 7.31-7.2 (m, 4 + CD3), 
7.08-7.00 (m, 2H), 6.85-6.81 (m, 4H), 3.54 (m, 2H), 1.83-1.6 (m, 12H), 1.33-1.03 (m, 
10H). 
 
(1S,2S)-1,2-Bis(chloro-l5-azanyl)-1,2-dicyclohexylethane24 
White solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 3.43 (s, 2H), 1.88-1.61 (m, 12H), 
1.41-0.89 (m, 10H). 
 
Ir 22 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.76 (d, J = 8.0 Hz, 1H), 7.15 (d, J = 
8.0 Hz, 2H), 6.94 (m, 1H), 3.76 (bs, 1H), 3.70 (m, 1H), 1.73 (s, 15H), 1.59 (bs, 6H), 
1.34-1.04 (m, 14H), 0.88 (bs, 2H).  13C NMR (CDCl3, 100 MHz) δ (ppm) 173.9, 136.1, 
131.3, 124.0, 121.2, 87.0, 72.3, 62.4, 30.7, 29.7, 28.7, 27.0, 26.5, 26.1, 25.9, 25.5, 
9.4. HRMS (ESI, EtOAc) [M]+ 673.2856. 
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Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.86 (d, J = 1.8 Hz, 2H), 7.71 (t, J = 
1.8 Hz, 1H), 4.80 (bs, 1H), 3.70 (s, 1H), 3.40 (s, 1H), 0.9-1.80 (m, 22H). 
 
Ir 23 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 6.63 (d, J = 8.7 Hz, 1H), 6.35 (d, J = 
8.7 Hz, 1H), 6.30 (s, 1H), 3.63 (m, 1H), 3.56 (m, 1H), 0.6-1.8 (m, 37H). 13C NMR 
(CDCl3, 100 MHz) δ (ppm) 173.7, 157.9, 156.9, 153.2, 123.9, 116.0, 104.9, 87.7, 71.0, 
55.8, 43.6, 40.1, 30.2, 29.3, 29.1, 27.1, 26.9, 26.8, 26.5, 26.4, 10.0. 
  
(4R,5R)-4,5-Dicyclohexyl-2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4,5-dihydro-1H-
imidazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.29-7.32 (dd+s, 2H), 6.85 (d, J = 8.7 
Hz, 1H), 4.26 (m, 4H), 3.52 (d, J = 3.8 Hz, 2H), 1.80-1.60 (m, 10H), 1.40-0.92 (m, 
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12H). 13C NMR (CDCl3, 100 MHz)  (ppm) 161.5, 146.1, 143.7, 124.2, 121.2, 117.6, 
116.9, 64.6, 60.8, 43.8, 29.1, 29.0, 27.0, 26.7, 26.0. MS (CI) [M+H]+  369.0. 
 
Ir 25 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.19 (s, 0.3H), 6.78 (d, J = 8.4 Hz, 
0.7H), 6.74 (s, 0.3H), 6.54 (d, J = 8.4 Hz, 0.7H), 5.12 (bs, 0.7H), 5.02 (bs, 0.3H), 4.33-
4.22 (m, 4H), 3.81-3.79 (m, 0.7H), 3.76-3.74 (m, 0.3H), 3.68-3.63 (m, 1H), 1.99-1.84 
(m, 6H), 1.76 (s, 8H), 1.74 (s, 7H), 1.65- 1.59 (m, 8H), 1.35-1.21 (m, 8H).  HRMS (ESI) 
found [M+H]+ 730.2875. 
 
(4R,5R)-2-(2-Methoxyphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazole 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 8.33 (dd, J = 7.8, 1.7 Hz, 1H), 7.46 (dt, J 
= 7.8, 1.7 Hz, 1H), 7.37-7.25 (m, 11H, CHCl3 included), 7.08 (t, J = 7.6 Hz, 1H), 7.01 (d, 
J = 8.4 Hz, 1H), 6.39 (bs, 1H) 4.89 (s, 2H), 3.91 (s, 3H). 13C NMR (CDCl3, 100 MHz)  
(ppm) 162.3, 157.8, 143.7, 132.4, 131.8, 128.7, 127.5, 126.7, 121.4, 118.0, 111.5, 
74.3, 55.9. MS (CI) found [M+H]+ 329.17. 
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Ir 26 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.58-7.18 (m, 13H), 6.76 (s, 0.5H), 
6.72 (s, 0.2H), 6.53-6.5 (m, 0.9H), 5.01 (d, J = 6.2 Hz, 0.3H), 4.96 (s, 0.18H), 4.93 (s, 
0.41H), 4.86 (s, 0.17H), 4.73 (d, J = 6.2 Hz, 0.3H), 3.82 (s, 3H), 1.16 (s, 10H), 1.14 (s, 
5H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 176.9, 175.8, 168.2, 167.0, 157.7, 144.0, 
142.4, 140.5, 139.7, 133.3, 132.3, 129.2, 128.9, 128.9, 128.8, 128.8, 128.3, 128.2, 
128.1, 128.0, 127.5, 127.4, 123.5, 122.5, 103.8, 103.7, 87.8, 87.2, 78.7, 78.2, 72.5, 
72.3, 55.0, 55.0, 9.4, 9.2. HRMS (ESI) found [M+H]+ 690.1995. CHN C32H34ClIrN2O 
calculated C, 55.35; H, 4.96; N, 4.06; found C, 53.86; H 4.85; N, 3.35.   
 
(4R,5R)-2-(2,3-Dimethoxyphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazole 
Yellow oil. 1H NMR (CDCl3, 400 MHz) (ppm) 7.85 (dd, J = 8.1, 1.5 Hz, 1H), 7.37-7.28 
(m, 10H), 7.15 (t, J = 7.5 Hz, 1H), 7.05 (dd, J = 8.1, 1.5 Hz, 1H), 4.89 (s, 2H), 3.92 (s, 
3H), 3.91 (s, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 161.9, 152.9, 148.1, 143.9, 
128.7, 126.6, 124.5, 123.6, 122.7, 114.7, 61.6, 56.0. HRMS (ESI) calculated [M+H]+ 
359.1760; found [M+H]+ 359.1750. 
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Ir 27 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.52 (d, J = 6.8 Hz, 1H), 7.43-7.3 (m, 
9H), 7.00 (d, J = 8.1 Hz, 1H), 6.78 (s, 1H), 4.99 (d, J = 6.1 Hz, 0.36H) 4.96-4.88 (m, 
1.33H), 4.74 (d, J = 6.1 Hz, 0.35H), 3.98 (s, 2H), 3.96 (s, 1H), 3.86 (s, 1H), 3.85 (s, 2H), 
1.45 (s, 10H), 1.43 (s, 5H).  13C NMR (CDCl3, 100 MHz) δ (ppm) 176.8, 175.9, 155.9, 
147.7, 146.9, 140.5, 139.6, 130.7, 130.3, 128.9, 128.8, 128.4, 128.2, 128.1, 127.6, 
127.3, 126.9, 119.1, 118.2, 87.5, 87.0, 78.8, 78.3, 72.2, 71.9, 61.2, 56.6, 53.5, 9.4, 
9.2. HRMS (ESI) found [M+H]+ 721.2127. CHN C33H36ClIrN2O2 calculated C, 55.03; H, 
5.04; N, 3.89; found C, 52.33; H, 4.86; N, 2.92. 
 
(4R,5R)-2-(2,4-Dimethoxyphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 8.29 (d, J = 8.7 Hz, 1H), 7.35-7.26 
(m, 12H, CHCl3 included), 6.59 (dd, J = 8.7, 2.2 Hz, 1H), 6.52 (d, J = 2.2 Hz, 1H), 3.87 
(s, 3H), 3.84 (s, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 163.0, 162.0, 159.1, 144.1, 
133.0, 128.6, 127.3, 126.7, 111.4, 105.5, 98.8, 55.8, 55.6. HRMS (ESI) calculated 
[M+H]+ 359.1760; found [M+H]+ 359.1751. 
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Ir 28 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.51 (d, J = 6.9 Hz, 1H), 7.44-7.3 (m, 
9H), 7.03-6.98 (m, 1H), 6.61 (s, 1H), 6.12-6.08 (m, 1H), 4.98 (d, J = 6.0 Hz, 0.37H), 
4.93-4.82 (m, 1.37H), 4.7 (d, J = 6.0 Hz, 0.37H), 3.92 (s, 3H), 3.80 (s, 3H), 1.46 (s, 
10H), 1.44 (s, 5H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 176.3, 175.4, 169.7, 168.5, 
163.6, 163.0, 159.0, 158.9, 144.3, 142.5, 140.5, 139.9, 128.8, 128.7, 128.3, 128.2, 
128.0, 127.9, 127.5, 127.4, 116.7, 115.8, 112.7, 112.4, 92.7, 92.5, 87.7, 87.1, 86.3, 
78.4, 77.9, 77.3, 72.4, 72.3, 55.2, 55.1, 55.0, 9.9, 9.5, 9.2. MS (ESI) found [M+H]+ 
721.2. CHN C33H36ClIrN2O2 calculated C, 55.03; H, 5.04; N, 3.89; found C, 53.65; H, 
5.96; N, 3.16. 
 
(4R,5R)-4,5-Diphenyl-2-(2,3,4-trimethoxyphenyl)-4,5-dihydro-1H-imidazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz) (ppm) 8.04 (d, J = 8.9 Hz, 1H), 7.36-7.25 
(m, 11H CHCl3 included), 6.78 (d, J = 8.9 Hz, 1H), 4.86 (s, 2H), 3.97 (s, 3H), 3.91 (s, 
3H), 3.89 (s, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 161.6, 155.9, 152.9, 144.0, 
142.0, 128.7, 127.4, 126.6, 126.1, 116.1, 107.9, 61.8, 61.0. 56.2. HRMS (ESI) 
calculated [M+H]+ 389.1865; found [M+H]+ 389.1868. 
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Ir 29 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.51 (d, J = 6.9Hz, 1H), 7.41-7.28 (m, 
9H), 7.1 (m, 1H), 6.61 (s, 1H), 4.97 ( d, J = 6.0 Hz, 0.35H), 4.92-4.84 (m, 1.3H), 4.71 
(d, J = 6.0 Hz, 0.35H), 4.04 (s, 2H), 4.01 (s, 1H), 4.00 (s, 2H), 3.99 (s, 1H), 3.83 (s, 1H), 
3.79 (s, 2H), 1.46 (s, 10H), 1.44 (s, 5H).  13C NMR (CDCl3, 100 MHz) δ (ppm) 176.7, 
175.7, 161.4, 160.2, 156.7, 156.2, 151.5, 151.4, 144.1, 142.4, 140.4, 139.7, 136.0, 
135.8, 128.9, 128.7, 128.3, 128.2, 128.1, 128.0, 127.5, 127.3, 120.1, 118.9, 113.9, 
113.4, 87.6, 87.1, 78.5, 78.0, 72.3, 72.1, 61.2, 61.1, 60.4, 55.8, 9.5, 9.2. HRMS (ESI) 
found [M+H]+ 750.2206. CHN calculated C 54.42, H 5.10, N 3.73, found 53.92, H 
5.34, N 3.33. 
 
(4R,5R)-2-(6-Bromobenzo[d][1,3]dioxol-5-yl)-4,5-diphenyl-4,5-dihydro-1H-
imidazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz) (ppm) 7.35-7.26 (m, 11H plus CHCl3), 7.01 
(s, 1H), 5.99 (s, 1H), 4.82 (s, 2H). 13C NMR (CDCl3, 100 MHz)  (ppm) 162.8, 149.8, 
147.4, 143.3, 128.7, 127.5, 126.8, 125.7, 113.3, 111.1, 102.3, 75.3. HRMS (ESI) 
calculated [M+H]+421.0552 and 423.0531; found [M+H]+ 421.0546 and 423.0529. 
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CHN C22H17ClIrN2O2 calculated C, 62.72; H, 4.07; N, 6.65; found C, 63.17; H, 4.06; N, 
6.71. 
 
Ir 30 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.47-7.40 (m, 5H), 7.34-7.30 (m, 
5H), 6.78 (s, 0.35H), 6.76 (s, 0.65H), 6.13 (s, 0.65H), 6.01 (s, 0.75H), 5.98 (s, 0.56H), 
5.01 (d, J = 5.6 Hz, 0.3H), 4.93-4.86 (m, 1.3H), 4.70 (d, J = 5.6 Hz, 0.3H), 1.51 (s, 10H), 
1.47 (s, 5H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 175.8, 175.0, 151.3, 150.9, 148.7, 
148.1, 144.1, 143.7, 141.8, 140.4, 139.4, 129.0, 128.9, 128.5, 128.4, 128.4, 128.2, 
128.1, 128.0, 127.6, 127.3, 127.2, 126.6, 113.7, 113.4, 108.8, 108.7, 100.2, 99.9, 
88.9, 88.3, 79.1, 78.2, 72.1, 71.2, 9.8, 9.5. HRMS (ESI) found [M+H]+ 782.0875. CHN 
C32H31ClIrN2O2 calculated C, 49.07; H, 3.99; N, 3.58; found C, 48.58; H, 4.10; N, 
3.54. 
 
(4R,5R)-2-(7-Methoxybenzo[d][1,3]dioxol-5-yl)-4,5-diphenyl-4,5-dihydro-1H-
imidazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.35-7.27 (m, 11H), 7.06 (s, 1H), 
6.04 (s, 2H), 4.88 (s, 2H), 3.95 (s, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 171.1, 
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162.9, 148.9, 143.7, 143.2, 137.9, 128.8, 127.6, 126.6, 107.8, 102.1, 101.7, 56.9. MS 
(ESI) calculated 372.15; found [M+H]+ 373.2. 
 
Ir 31 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.44 (d, J = 6.4 Hz, 1H), 7.36-7.18 
(m, 9H), 6.83 (s, 1H), 6.06 (bs, 1H), 5.97 (bs, 1H), 5.08 (bs, 0.3H), 4.93 (d, J = 10.8 Hz, 
0.7H), 4.73 (d, J = 10.8 Hz, 0.7H), 4.62 (bs, 0.3H), 3.78 (s, 3H), 1.46 (bs, 15H).  13C 
NMR (CDCl3, 100 MHz) δ (ppm) 177.4, 171.2, 151.5, 140.5, 140.0, 139.8, 137.3, 
131.2, 129.0, 128.9, 128.7, 128.4, 128.2, 128.1, 127.4, 106.9, 100.0, 88.2, 87.5, 79.6, 
71.6, 56.5, 9.9, 9.6, 9.4. HRMS (ESI) found [M+H]+ 734.1880. CHN C33H34ClIrN2O3 
calculated C, 53.98; H, 4.67; N, 3.81; found C, 53.08; H, 4.66; N, 3.42. 
 
(4R,5R)-2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-4,5-diphenyl-4,5-dihydro-1H-
imidazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz) (ppm) 7.92 (d, J = 7.4 Hz, 2H), 7.53-7.42 
(m, 2H), 7.36-7.26 (m, 9H), 4.89 (s, 2H). 13C NMR (CDCl3, 100 MHz) (ppm) 171.1, 
163.4, 143.1, 131.3, 129.5, 128.7, 128.6, 127.6, 127.6, 126.6, 74.7. 
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Ir 32 
Brown solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.83 (dd, J = 7.4 Hz, 1H), 7.51 (d, J = 
6.7 Hz, 1H), 7.45 (d, J = 6.7 Hz, 1H), 7.38-7.23 (m, 8H), 8.0 (td, J = 7.4 Hz, 1H), 5.13 
(d, J = 5.5 Hz, 0.35H), 4.99 (d, J = 11.3 Hz, 0.64H), 4.84 (d, J = 11.3 Hz, 0.63H), 4.71 
(d, J = 5.5 Hz, 0.37H), 1.45 (s, 9H), 1.44 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 
177.4, 176.6, 165.2, 143.6, 141.9, 140.1, 139.3, 136.1, 135.8, 134.1, 132.3, 131.4, 
129.0, 128.8, 128.5, 128.4, 128.1, 127.7, 127.4, 127.3, 124.8, 124.7, 121.6, 121.5, 
87.3, 82.9, 79.5, 72.3, 72.0, 9.5, 9.4, 9.2. 
 
(4R,5R)-2-(2,3-dihydrobenzofuran-5-yl)-4,5-diphenyl-4,5-dihydro-1H-imidazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.86 (s, 1H), 7.63 (d, J = 8.3 Hz, 1H), 
7.35-7.25 (m, 10H), 6.78 (d, J = 8.3 Hz, 1H), 4.84 (s, 2H), 4.63 (t, J = 8.7 Hz, 2H), 3.21 
(t, J = 8.7 Hz, 2H). 13C NMR (CDCl3, 100 MHz)  (ppm) 171.1, 163.2, 162.7, 143.5, 
128.8, 128.7, 128.1, 128.0, 127.8, 127.5, 126.7, 126.6, 124.8, 122.1, 109.1, 74.8, 
71.9. HRMS (CI) calculated [M+H]+ 341.1648. found [M+H]+ 341.1651. 
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Ir 33 
Orange solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.5 (d, J = 6.9 Hz, 1H), 7.45-7.16 (m, 
11H), 5.77 (bs,0.5H) 5.43 (s, 0.25H), 5.10 (d, J = 5.1 Hz, 0.37H), 4.94 (d, J = 10 Hz, 
0.7H), 4.75-4.68 (m, 0.7H), 4.64 (d, J = 5.1 Hz, 0.35H), 4.60-4..49 (m, 2H), 3.19-3.04 
(m, 2H), 1.43 (s, 13H), 1.41 (s, 2H).  13C NMR (CDCl3, 100 MHz) δ (ppm) 176.7, 176.0, 
166.9, 163.6, 163.2, 143.9, 142.2, 140.4, 139.8, 128.9, 128.8, 128.7, 128.4, 128.3, 
128.2, 128.1, 128.0, 127.5, 127.4, 127.3, 126.5, 121.9, 121.0, 120.8, 116.4, 116.0, 
88.8, 88.1, 87.7, 87.3, 87.1, 79.3, 72.2, 71.9, 71.4, 21.1, 10.1, 9.6, 9.5, 9.4, 9.2. 
 
7-bromo-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 10.16 (s, 1H), 7.46 (s, 1H), 7.13 (s, 
1H), 4.34-4.26 (m, 4H). 13C NMR (CDCl3, 100 MHz)  (ppm) 190.6, 149.5, 143.4, 
127.3, 121.8, 118.7, 118.2, 64.8, 64.0. HRMS (CI) found [M+H]+ 242.9655. 
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(4R,5R)-2-(7-bromo-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4,5-diphenyl-4,5-
dihydro-1H-imidazole 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.46 (s, 1H), 7.36-7.32 (m, 10H), 7.14 
(s, 1H), 4.88 (s, 2H), 4.41-4.39 (m, 1H), 4.29-4.26 (m, 3H).  HRMS (ESI) found [M+H]+ 
435.0702. 
 
Ir 34 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.45-7.38 (m, 5H), 7.34-7.29 (m, 
5H), 7.08 (s, 0.4H), 6.81 (s, 0.6H), 5.03-5.00 (m, 0.3H), 4.94-4.86 (m, 1.3H), 4.69-4.66 
(m, 0.3H), 4.37-4.21 (m, 4H), 1.47 (s, 10H), 1.43 (s, 5H). 13C NMR (CDCl3, 100 MHz) δ 
(ppm) 176.1, 158.8, 146.1, 144.9, 141.9, 140.7, 139.5, 129.1, 129.0, 128.9, 128.5, 
128.4, 128.3, 128.1, 128.0, 127.5, 127.1, 127.0, 124.7, 117.1, 111.8, 88.9, 88.7, 88.2, 
87.9, 87.4, 82.9, 78.8. 78.0, 72.1, 71.0, 70.8, 64.5, 64.4, 63.8, 63.7, 53.5, 9.9, 9.5. 
HRMS (ESI) found [M+H]+ 809.1536. 
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(4R,5R)-4,5-bis(4-methoxyphenyl)-2-(2,3,4-trimethoxyphenyl)-4,5-dihydro-1H-
imidazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 8.02 (d, J = 8.9 Hz, 1H), 7.89 (d, J = 
8.9 Hz, 1H), 7.22 (d, J = 8.6 Hz, 4H), 6.87 (d, J = 8.6 Hz, 4H), 4.77 (s, 2H), 3.96 (s, 3H), 
3.92 (s, 3H), 3.89 (s, 3H), 3.85 (s, 6H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 161.4, 
159.0, 156.0, 152.9, 142.0, 136.0, 127.7, 126.1, 114.1, 114.0, 107.9, 61.9, 61.0, 56.1, 
55.3. 
 
Ir 35 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.44-7.34 (m, 2H), 7.13-7.02 (m, 
2H), 6.93- 6.82 (m, 3H), 6.59-6.38 (m, 2H), 5.64-5.51 (m, 0.35H), 5.13-5.04 (m, 
0.25H), 4.90 (d, J = 10.5 Hz, 0.3H), 4.83-4.74 (m, 0.5H), 4.62-4.53 (m, 0.2H), 4.02-4.0 
(m, 3H), 3.89-3.79 (m, 9H), 3.65-3.46 (m, 2H), 3.27-3.15 (m, 1H), 1.46 (s, 13H), 1.40 
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(s, 2H). 13C NMR (CDCl3, 100 MHz) δ (ppm) 176.4, 159.0, 156.7, 151.5, 135.8, 132.4, 
132.0, 130.0, 128.6, 128.4, 114.1, 113.9, 113.3, 88.2, 87.6, 87.2, 88.0, 78.0, 71.7, 
61.1, 60.7, 55.8, 55.4, 55.3, 55.0, 53.5, 9.5, 9.3, 9.3. HRMS (ESI) found [M+H]+ 
810.2417. 
 
(4R,5R)-4,5-bis(2-chlorophenyl)-2-(2,3,4-trimethoxyphenyl)-4,5-dihydro-1H-
imidazole 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 8.04 (d, J = 9.0 Hz, 1H), 7.55 (d, J = 
6.5 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 7.3-7.26 (m, 2.5H, CHCl3 included), 7.23-7.19 (m, 
2H), 6.80 (d, J = 8.9 Hz, 1H), 5.42 (bs, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 3.89 (s, 3H). 13C 
NMR (CDCl3, 100 MHz)  (ppm) 162.2, 156.1, 152.9, 142.1, 141.1, 133.0, 129.5, 
128.5, 127.3, 126.0, 115.8, 107.9, 61.8, 61.0, 56.2. HRMS (CI) calculated [M+H]+ 
457.1080. found [M+H]+ 457.1095. 
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Ir 36 
Yellow solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 7.69 (d, J = 7.8 Hz, 1H), 7.42-7.29 
(m, 5H), 7.24-7.17 (m, 2H), 7.11 (s, 0.4H), 7.07 (s, 0.6H), 6.52 (s, 1H), 5.62 (d, J = 10.7 
Hz, 0.65H), 5.52 (d, J = 4.5 Hz, 0.35H), 5.43 (d, J = 10.7 Hz, 0.63H), 5.27 (d, J = 4.5 Hz, 
0.37H), 4.02 (s, 2H), 4.01 (m, 3H), 3.99 (s, 1H), 3.82 (s, 1H), 3.79 (s, 2H), 1.49 (s, 9H), 
1.48 (s, 6H).  13C NMR (CDCl3, 100 MHz) δ (ppm) 177.0, 176.2, 161.6, 133.0, 132.7, 
130.1, 129.9, 129.3, 129.0, 128.9, 128.7, 128.3, 128.3, 127.4, 127.2, 113.9, 113.4, 
87.8, 87.1, 73.2, 67.8, 61.2, 60.8, 55.8, 53.4, 9.3, 9.1. HRMS (ESI) found [M+H]+ 
818.1422. 
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Chapter 3: Development 
of a Direct Asymmetric 
Reductive Amination 
System. 
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3.1 Introduction 
Direct asymmetric reductive amination (DARA) is a highly appealing method 
for the synthesis of chiral amines but has long been a challenge. Whilst many 
racemic methods have been developed,1–9 the challenge of a chiral system has still 
remained. This is due in part to the difficultly in developing a selective catalyst for 
imine over carbonyl reduction, as well as the challenge of forming the imine in 
conditions suitable for the reduction. 
 There have been several systems that have overcome these challenges and 
produced high selectivity. Most of these systems require high pressures of 
hydrogen gas,10,11 have a limited substrate scope12–14 or require the use of an 
additional chiral phosphoric acid.15,16 This highlighted the need for a new simple and 
universal system, preferably under TH conditions. There has been only one 
successful system developed utilising ATH conditions.17 Although successful in terms 
of ee and yield, this system still requires high temperatures and a large excess of 
ammonium formate in an ammonia-methanol solution (Scheme 3.1). 
 
Scheme 3.11 Best reported example of DARA under ATH conditions. 
The aim of this work was to build a chiral system for DARA based on the 
racemic version previously developed by Xiao et al,7–9 shown in Scheme 3.2, which 
has a large substrate scope and is active under TH conditions. This system uses high 
temperatures, but complete conversion can be achieved in very short times, which 
is promising for developing a mild chiral system. 
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Scheme 3.12 Racemic conditions reported for reductive amination. 
3.2 Screening Iridicycles 
An initial test was done to determine if the chiral catalysts developed (see 
Chapter 2) would be active under TH conditions. A test reaction was initiated using 
the imine, shown in Scheme 3.3. A simple oxazoline catalyst was chosen and 
subjected to the conditions reported for the achiral reaction, except at a lower 
temperature. This result was promising; a high conversion was attained overnight, 
along with a moderate enantioselectivity. As the developed catalyst motif was 
active for reduction under mild TH conditions, a range of the synthesised complexes 
were screened under these conditions. 
 
Scheme 3.13 Testing conditions for imine ATH. 
Initially the simple imidazoline and oxazoline iridicycles were examined as a 
basis for comparison. These results, shown in Table 3.1, showed that oxazolines 
were able to afford higher ee’s than the corresponding imidazoline, with the R,S-
ligand showing the greatest ee. 
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Entry Catalyst Conv (%) ee (%) 
1 
Ir 2 
83 14 
2 
Ir 1 
68 23 
3 
Ir 19 
50 4 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir cat, 
2.5 mL anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.1 Basic complexes tested for DARA. 
A range of bulky oxazoline complexes were tested for their activity in this 
reaction, to determine if the steric bulk on the ligand would improve the selectivity. 
These produced underwhelming results, shown in Table 3.2, providing little 
difference in ee from the un-substituted complex Ir 1 (Entry 2, Table 3.1). Further 
extending the bulky groups demonstrated both a slower rate of reaction, as well as 
a reduction in ee. Surprisingly it was the least bulky complex Ir 10 that yielded the 
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best ee, indicating that steric hindrance at this position was not the key to high 
enantioselectivity for this system. 
 
Entry R Conv (%) ee (%) 
1 tBu   Ir 10 87 40 
2 
Ir 11 
95 25 
3 
Ir 12 
90 25 
4 
Ir 13 
70 22 
5 
Ir 16 
71 17 
6 
 Ir 17 
62 10 
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7 
Ir 18 
60 10 
8 
Ir 14 
60 0 
9 
Ir 15 
89 14 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir cat, 
2.5 mL anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.2 Screening of bulky oxazolines for DARA. 
Having ruled out steric effects as the key to achieving a high ee, electronic 
effects were investigated with a range of less bulky oxazoline complexes (Table 3.3). 
These complexes showed varying results, with electron withdrawing groups 
showing a decrease in ee (Entry 1, Table 3.3). Electron donating groups in certain 
substitution patterns (Entries 2-6, Table 3.3) offered some improvement in ee 
compared to the un-substituted oxazoline complex (Entry 1, Table 3.1), although 
these results weren’t very promising, with a maximal ee of 30% being obtained. 
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Entry Catalyst Conv (%) ee (%) 
1 
Ir 3 
15 7 
2 
Ir 4 
74 22 
3 
Ir 5 
95 26 
4 
Ir 6 
80 30 
5 
Ir 7 
50 17 
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6 
Ir 8 
50 30 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir cat, 
2.5 mL anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.3 Screening of small oxazoline complexes for DARA. 
Looking back at the imidazoline complex Ir 19 screened (Entry 3, Table 3.1) it 
was known that three inseparable isomers had formed during cyclometalation, as 
opposed to two with the oxazoline, which may account for the reduced selectivity. 
It was decided to test those complexes formed in just 1 or 2 isomers, to determine 
which of these complexes were active. Complexes that lost their conjugation (Ir 20 
and Ir 21) also lost activity, producing < 5% conversion, even with a 3 day reaction 
time (Entries 1 and 2, Table 3.4). Complexes that maintained their conjugation, but 
were forced to cyclometalate on just the one ring maintained high activity (Entries 
3-6, Table 3.4), with the cyclohexane diamine complex offering a moderate 
enantioselectivity. Bulky substituents ortho to the iridium centre (Ir 23) showed a 
reduction in ee once more (Entry 4, Table 3.4). The presence of the dioxane ring (Ir 
25) also showed a reduced ee (Entry 6, Table 3.4), potentially due to the two 
regioisomers present. The highest selectivity was achieved with the dioxole 
containing complex Ir 24 (Entry 6, Table 3.4). 
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Entry Catalyst Conv (%) ee (%) 
1 
Ir 20 
0 - 
2 
Ir 21 
0 - 
3 
Ir 22 
41 27 
4 
Ir 23 
43 28 
5 
Ir 24 
49 50 
6 
Ir 25 
95 39 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir cat, 
2.5 mL anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.4 Screening of non-aryl imidazoline containing complexes for DARA. 
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Analogues of the dioxole ligands were then screened to determine if the ee 
could be further improved upon. It was firstly shown that the aryl imidazoline 
analogue (Ir 30) could be used just as successfully with the dioxole functional group 
present (Entry 1, Table 3.5), despite forming three isomers (Chapter 2.3). Further 
modified dioxole-containing complexes (Ir 31 - Ir 33) were screened; however these 
all showed a decrease in ee. The most significant loss in ee was observed in 
correlation with a loss of electron donating groups (Entries 3 and 4, Table 3.5). 
Whilst expanding the ring size (Ir 34) or adding an additional electron donating 
methoxy (Ir 31) offered little change in ee (Entries 2 and 5, Table 3.5). 
To determine if the dioxole ring, or simply the presence of electron donating 
groups, were crucial, a range of simple methoxy containing complexes were 
screened. These once more showed that varying the position of the electron rich 
groups had a significant impact upon the ee (Entries 6-9, Table 3.5). A relatively low 
ee of just 27% was achieved by the 6-methoxy complex Ir 26 (Entry 6, Table 3.5), 
the addition of a second methoxy to the 4-position (Ir 27) showed great 
improvement to 42% (Entry 7, Table 3.5). Moving the second group to the 5 
position (Ir 28) had no effect on ee (Entry 8, Table 3.5). The highest ee was achieved 
with the 4,5,6-trimethoxy complex, Ir 29 (Entry 9, Table 3.5), indicating a narrow 
band where the electron density is optimal for this reaction. 
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Entry Catalyst Conv (%) ee(%) 
1 
Ir 30 
72 50 
2 
Ir 34 
75 43 
3 
Ir 33 
70 28 
4 
Ir 
32 
73 28 
5 
Ir 31 
65 43 
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6 
Ir 26 
67 27 
7 
Ir 27 
75 42 
8 
Ir 28 
84 27 
9 
Ir 29 
78 56 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir cat, 
2.5 mL anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.5 Screening of oxygen rich phenyl imidazoline complexes for DARA. 
Variation of the aryl groups on the imidazoline was also investigated, Ir 35 
and Ir 36, to determine the impact upon the selectivity, in combination with the 
best 4,5,6-trimethoxy group. These complexes showed no further improvement to 
the ee (Table 3.6), with both an electron withdrawing and donating group 
producing a significant reduction in selectivity. These results further indicate that 
there is a narrow band where steric and electronic effects are optimal for this 
reaction. 
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Entry Catalyst Conv (%) ee (%) 
1 
Ir 35 
78 21 
2 
Ir 36 
75 39 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir cat, 
2.5 mL anhydrous IPA, 0.5 mL FT,  sealed, overnight.  
Table 3.6 Varying the diamine in trimethoxy complexes for DARA. 
 Having completed an extensive screening of complexes, it was determined 
that the 4,5,6-trimethoxy imidazoline complex (Ir 29) produced the greatest ee 
(56%), with a high conversion (78%). This complex was therefore taken forward for 
further optimisation of the reaction conditions. 
3.3 Optimisation of reaction conditions 
 To improve the ee and conversion obtained, a range of conditions were 
screened. Initial screenings were done by varying the solvent (Table 3.7). An initial 
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test was performed to ensure that both solvent and FT were required for the 
conversions and ee previously obtained. In neat FT a slight drop in conversion along 
with a decrease in ee was observed. The IPA was shown to be an inactive hydride 
source for this transformation, yielding no conversion in neat IPA. 
 
Entry Solvent Co-solvent Conv (%) ee (%) 
1 IPA (2.5 mL) FT (0.5 mL) 78 56 
2 FT (1 mL) - 70 27 
3 IPA (2.5 mL) - 0 - 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir 29, 
sealed in air, overnight.  
Table 3.7 Initial solvent test. 
A range of other solvents were also screened, from these results it was seen 
that non-protic solvents such as toluene and acetonitrile were ineffective (Entries 1 
and 2, Table 3.8), indicating that polar alcohol solvents were required. Simple 
MeOH gave a reduced ee, when compared to bulkier IPA (Entries 4 and 5, Table 
3.8); t-amyl alcohol, however also produced a lower conversion and ee (Entry 6, 
Table 3.8). Poly ethylene glycols and t-butanol offered no improvement on the 
conversion or ee (Entries 7-12, Table 3.8), possibly due to their viscosity leading to 
poor mixing of substrates with the complex. The best results were obtained in the 
121 
 
moderately bulky IPA (Entry 4, Table 3.8), in the presence of FT, with the best ee 
obtained in a moderate conversion at room temperature. 
 
Entry Solvent 
Conv 
(%) 
ee 
(%) 
Entry Solvent 
Conv 
(%) 
ee 
(%) 
1 PhMe 0 - 7 tBuOH 42 50 
2 MeCN 0 - 8 
Polyethyleneglycol 
(200) 
57 53 
3 TFE 25 - 9 
Polyethyleneglycol 
(300) 
53 51 
4 IPA 78 56 10 
Polyethyleneglycol 
(400) 
47 50 
5 MeOH 58 43 11 Ethylene glycol 80 44 
6 
tamyl 
alcohol 
30 42 12 
Ethylene glycol : IPA 
(1:1) 
73 48 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir 29, 
2.5 mL solvent, 0.5 mL FT,  sealed in air, overnight, (Room temperature was determined to 
be between 8 and 15 oC). 
Table 3.8 Solvent screening for DARA. 
To improve the conversion, 4Å MS were added, these yielded a positive 
effect in small amounts showing a 10% increase in conversion (Table 3.9). A large 
amount of 4Å MS proved detrimental to the reaction, potentially due to the acidity 
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of sieves leading to interactions between them and the amine substrate, resulting in 
a decrease in the concentration of free aniline and preventing the condensation 
reaction from occurring readily. 
 
Entry Additive Conv (%) 
1 - 78 
2 4Å MS – 30 mg 88 
3 4Å MS – 60 mg 84 
4 4Å MS – 100 mg 62 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir 29, 
2.5 mL anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.9 Effect of molecular sieves on conversion. 
In a further attempt to optimise the conversion and ee, various 
temperatures were investigated. Increasing the temperature slightly offered an 
increase in conversion, whilst maintaining the ee (Entry 1, Table 3.10), providing the 
optimal conditions. Reduced temperatures were also investigated to determine 
whether the selectivity could be increased. A detrimental effect was observed on 
both the conversion and ee (Entries 3 and 4, Table 3.10), potentially due to the 
limited solubility of the complex and amine at low temperatures. 
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Entry Temp (oC) Conv (%) ee (%) 
1 20 97 56 
2 15 78 56 
3 5 70 54 
4 -10 18 40 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir 29, 
2.5 mL anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.10 Effect of temperature variation on DARA. 
Other hydride sources were also screened. Hantszch esters (HEH) have been 
commonly used as a hydride source; when screened under standard conditions it 
provided no conversion (Entry 2, Table 3.11). This was thought to be due to the 
insolubility of the HEH in the reaction media. Toluene was therefore tested as 
solvent, which has been previously reported,18 once more this offered no 
conversion (Entry 3, Table 3.11).  Aqueous conditions were also tested, with a 
NaCO2H/HCO2H buffered solution (pH 4.5, which was shown to be active in the 
racemic studies).8 These conditions provided a much faster rate of reaction but 
offered a slight drop in ee (Entry 1, Table 3.11).  
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Entry Hydride source Solvent Conv (%) ee (%) 
1 NaCO2H/HCO2H H2O (pH 4.5) 100 40 
2 
  
IPA 0 - 
3 
 
PhMe 0 - 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol p-methoxy aniline, 1 mol% Ir 29, 3 
mL solvent, hydride source,  sealed in air, overnight.  
Table 3.11 Variation of hydride source for DARA. 
After the extensive screening of conditions it was determined that FT in IPA 
was the optimal reaction medium. A temperature of 20-25oC was also determined 
to give the best conversion and ee, in just 16 h. These conditions were carried 
forward to probe the range of substrates suitable for this system. 
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3.4 Substrate scope 
3.4.1 Ketone variation 
 The substrate scope was inititated by varying the acetophenone used and 
the results showed promise (Table 3.12). Placing substituents in the para position 
offered similar results to the un-substituted acetophenone, with electron donating 
and electron withdrawing groups being tolerated, (Entries 2 and 3, Table 3.12). 
However, an exception was observed in the case of a methoxy group which 
produced a lower conversion (Entry 3, Table 3.12). This may be due to the 
resonance forms possible with the methoxy group present, rendering the ketone 
less active towards the condensation reaction. Meta substitutions also proved to 
have little impact on the conversion and ee (Entries 5-7, Table 3.12), yielding above 
95% conversions and similar ee to standard acetophenone. 
 Switching to an ortho substitution pattern afforded a significant drop in ee 
(Entries 8 and 9, Table 3.12). These results also showed a switch in the major 
enantiomer formed, indicating that the ortho substituents interfere with reduction 
step, especially during the enantioselectivity determining step. Although a high 
conversion was obtained with an electron withdrawing chloride, a very poor 
conversion was obtained with an electron donating methyl group. 
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Entry Acetophenone 
Conv 
(%) 
ee 
(%) 
Entry Acetophenone 
Conv 
(%) 
ee 
(%) 
1 
 
92 56 6 
 
100 56 
2 
 
96 50 7 
 
100 56 
3 
 
96 54 8 
 
50 20 
4 
 
60 58 9 
 
94 34 
5 
 
82 54     
Reaction conditions: 0.5 mmol ketone, 0.6 mmol p-methoxy aniline, 1 mol% Ir 29, 2.5 mL 
anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.12 Variation of acetophenone substrates scope. 
Lengthening the alkyl chain of the ketone from a methyl to ethyl produced a 
higher ee than seen previously (Entry 1, Table 3.13), showing this system (unlike 
some biological systems)18 can tolerate alteration at this position and could even 
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offer improved results. The ee was also improved by adding a phenyl group into this 
position (Entry 3, Table 3.13), agreeing with the above observations; however the 
bulkiness of this group resulted in a slower rate of reaction. Unfortunately adding a 
longer alkyl chain into this position caused a decrease in ee (Entry 2, Table 3.13), 
demonstrating a limit to the functionalisation that can be tolerated in this position, 
although it had less of an impact on the rate. 
 
Entry Ketone Conv (%) ee (%) Entry Ketone Conv (%) ee (%) 
1 
 
90 63 3 
 
41 63 
2 
 
78 38 4 
 
100 0 
Reaction conditions: 0.5 mmol ketone, 0.6 mmol p-methoxy aniline, 1 mol% Ir 29, 2.5 mL 
anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.13 Variation of ketone for DARA 
 Switching from an aryl to an alkyl ketone afforded complete conversion 
(Entry 4, Table 3.13). However, this improved rate of reaction was accompanied by 
formation of racemic products, indicating that this catalytic system is not suitable 
for alkyl ketones. 
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3.4.2 Amine variation 
 Varying the aniline was next investigated to determine the versatility of the 
catalytic system regarding the amine partner. These results revealed a new 
problem, whilst the ee’s achieved were similar to those previously produced, the 
conversions all showed a dramatic reduction (Table 3.14). This indicated that the 
electron donating methoxy group was crucial to the rate of reaction, probably 
increasing the rate of imine formation, due to the increased electron density on the 
nitrogen.  
 
Entry Aniline 
Conv 
(%) 
ee 
(%) 
Entry Aniline 
Conv 
(%) 
ee 
(%) 
1 
 
92 56 4 
 
10 52 
2 
 
40 53 5 
 
51 53 
3 
 
40 55 6 
 
53 62 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol aniline, 1 mol% Ir 29, 2.5 mL 
anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.14 Screening of anilines for DARA under standard conditions 
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 To overcome this issue, further screening was undertaken for the aniline 
substrates. This was initially done by testing a range of additives for promoting 
imine formation. Altering the pH of the solution with the addition of catalytic 
amounts of formic acid or triethylamine offered little impact upon the rate of 
reaction or the ee observed (Entries 3 and 4, Table 3.15). The addition of catalytic 
amounts of PTSA or 4Å MS, although commonly used for imine formation, resulted 
in a drop in the conversion (Entries 1 and 3, Table 3.15). This may again be due to 
the solution becoming too acidic for the condensation reaction to readily occur. 
 
Entry 
Additive 
(10 mol%) 
Conv (%) ee (%) Entry 
Additive 
(10 mol%) 
Conv (%) ee (%) 
1 4Å MS (50 mg) 31 42 3 HCO2H 55 51 
2 PTSA 26 54 4 NEt3 51 50 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol aniline, 1 mol% Ir 29, 10 mol% 
additive, 2.5 mL anhydrous IPA, 0.5 mL FT,  sealed in air, overnight.  
Table 3.15 Additives for DARA on aniline. 
 As these methods offered no improvement on the conversions obtained, it 
was necessary to refer back to the previous optimisation reactions and re-examine 
the aqueous system briefly tested. Previously this system offered a faster rate of 
reaction but a slight drop in ee (Entry 3, Table 3.11). As such it was decided to test 
the aniline substrates under these conditions. As observed previously the 
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conversion showed significant improvement under the aqueous conditions, though 
as before the ee was reduced slightly (Entry 2, Table 3.14 vs. Entry 1, Table 3.16). An 
improvement in ee was offered by the addition of a co-solvent, whilst maintaining a 
high conversion. Use of DCM caused a significant drop in conversion (Entry 2, Table 
3.16), whilst IPA, MeOH and 2-methyltetrahydrofuran (2-MeTHF) all offered 
similarly high conversions (Entries 3-5, Table 3.16). Although all solvents screened 
resulted in some drop in ee from the FT system, the smallest drop was seen with 2-
MeTHF, showing this to be the optimal co-solvent for use in this biphasic reduction. 
 
Entry Co-solvent Conv (%) ee (%) Entry Co-solvent Conv (%) ee (%) 
1 - 78 46 4 MeOH 82 47 
2 DCM 25 - 5 2-MeTHF 80 55 
3 IPA 83 50     
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol aniline, 1 mol% Ir 29, 3 mL 
NaCO2H/HCO2H pH 4.5, 0.3 mL co-solvent, sealed in air, overnight.  
Table 3.16 Screen of co-solvents for a biphasic system. 
 The same range of anilines was once more studied using this optimised 
system (Table 3.17). Under these conditions all the conversions greatly improved. 
Although the conversion of the electron withdrawing 4-bromo species was still 
moderate, a significant improvement from that seen in the FT system was observed. 
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Pleasingly there was also little to no drop in ee seen with these anilines, showing 
that this biphasic system holds great promise. 
 
Entry Aniline 
Conv 
(%) 
ee 
(%) 
Entry Aniline 
Conv 
(%) 
ee 
(%) 
1 
 
86 48 3 
 
45 54 
2 
 
90 53 4 
 
70 60 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol aniline, 1 mol% Ir 29, 3 mL 
NaCO2H/HCO2H pH 4.5, 0.3 mL co-solvent, sealed in air, overnight.  
Table 3.17 Testing of anilines under a biphasic system. 
 To determine how versatile this aqueous system was, these conditions were 
tested on a variety of previously screened ketones with p-anisidine. It was of 
particular interest to determine if this could achieve similar results in shorter times, 
improving the lower conversions seen in some of the previous examples. The results 
showed great potential (Table 3.18), with similar ee’s afforded and an improvement 
in most conversions being observed, in half the time (just 8 hours compared to 
those achieved in 16 hours under FT conditions). The alkyl chain was able to gain 
some ee, although only to a very poor 5% (Entry 3, Table 3.18).  The only 
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disappointing result was achieved with the 2-methylacetophenone where the 
conversion remained the same but the ee dropped further (Entry 6, Table 3.18). 
 
Entry Time (h) Ketone 
NaCO2H/HCO2H IPA FT* 
Conv (%) ee (%) Conv (%) ee (%) 
1 16 
 
80 59 41 63 
2 16 
 
86 36 78 38 
3 8 
 
100 5 100 0 
4 8 
 
81 48 96 54 
5 8 
 
79 55 100 56 
6 8 
 
50 15 50 20 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol aniline, 1 mol% Ir 29, 3 mL 
NaCO2H/HCO2H pH 4.5, 0.3 mL co-solvent, sealed in air, overnight. *results from Tables 
3.12 and 3.13 above. 
Table 3.18 Comparison of various ketones under biphasic system and the FT system. 
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Further variation of the amine was undertaken by screening of 
benzylamines, in both the original FT and the aqueous conditions (Table 3.19). 
These results showed that the benzylamine was in fact active in this system with 
both conditions giving high to full conversion. This was a pleasing result as it was 
feared that the benzylamine may bind to the iridium centre, inhibiting the reaction. 
The ee’s, however, were disappointing with the highest ee achieved being just 22%. 
Again little variation was observed between the ee’s obtained under the two 
conditions. 
 
Entry Benzylamine 
IPA/FT NaCO2H/HCO2H 
Conv (%) ee (%) Conv (%) ee (%) 
1 
 
83 16 100 10 
2 
 
71 14 100 16 
3 
 
80 17 100 22 
4 
 
97 10 100 2 
Reaction conditions: 0.5 mmol acetophenone, 0.6 mmol benzylamine, 1 mol% Ir 29, 3 mL 
NaCO2H/HCO2H pH 4.5, 0.3 mL co-solvent, sealed in air, overnight.  
Table 3.19 Screen of benzylamines for DARA. 
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3.5 Conclusions 
 The results presented above show great promise for the chiral iridicycles, 
after an extensive complex screen, the electron rich 4,5,6-trimethoxy imidazoline 
complex, showed great activity and moderate to high enantioselectivity towards 
direct reductive amination. The transformation was shown to be successful under 
two different conditions; an organic system utilising IPA in the presence of FT and 
an aqueous system utilising formic acid and sodium formate in water.  It was 
observed that the organic system produced the highest enantioselectivity, whilst 
the biphasic system provided a greater rate of reaction. It was demonstrated that a 
range of ketones and amines were active in this system, with only aliphatic ketones 
producing racemic products. Although lower ee’s were achieved than in previously 
published work, the reaction conditions used are milder. 
3.6 Experimental 
The iridium complexes were synthesised as described in Chapter 2. IPA, DCM 
and toluene were dried on a MB-SPS 800 and methanol was dried over magnesium 
and iodine. All other chemicals were obtained commercially and used without 
further purification. NMR spectra were recorded on a Bruker 400 MHz NMR 
spectrometer, with TMS as internal standard. HPLC analysis was recorded on an 
Agilent 1260 Infinity equipped with either Chiralpak IB-3 or Chiralcel OJ-H. 
3.6.1 Standard Procedures 
Standard procedure for DARA under FT conditions 
A glass vial was charged with the iridium catalyst (1 mol%), amine (0.6 mmol) and 
ketone (0.5 mmol) along with a stirring bar, IPA (2.5 mL) was added, followed by FT 
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(0.5 mL) to initiate the reaction. The glass vial was sealed and stirred at the stated 
temperature and time. After the reaction time was complete, the reaction mixture 
was quenched by the addition of aq 10% NaOH and extracted into EtOAc. The 
organic phase was dried over MgSO4, filtered and evaporated under vacuum. The 
resulting residue was purified by column chromatography, in 15% EtOAc in hexane, 
upon which HPLC analysis was performed. 
Standard procedure for DARA under aqueous conditions 
A glass vial was charged with the iridium catalyst (1 mol%), amine (0.6 mmol) and 
ketone (0.5 mmol) along with a stirring bar, 2-MeTHF (0.3 mL) was added, followed 
finally by an aqueous solution of sodium formate/formic acid (3 mL) to initiate the 
reaction. The glass vial was sealed and stirred at the stated temperature and time. 
After the reaction time was complete the reaction mixture was quenched by the 
addition of saturated aq K2CO3 and extracted into EtOAc. The organic phase was 
dried over MgSO4, filtered and evaporated under vacuum. The resulting residue was 
purified by column chromatography, in 15% EtOAc in hexane, upon which HPLC 
analysis was performed. 
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3.6.2 Analytical data 
 
4-Methoxy-N-(1-phenylethyl)aniline7 In accordance with published data. 
White solid isolated in 90% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.37-7.29 (m, 
4H), 7.23-7.20 (m, 1H), 6.79 (d, J = 8.4 Hz, 2H), 6.49 (d, J = 8.4 Hz, 2H), 4.21 (q, J = 6.6 
Hz, 1H), 3.69 (s, 3H), 1.51 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 
152.1, 145.2, 141.2, 128.6, 126.9, 126.0, 114.9, 114.8, 55.7, 54.5, 25.0. HRMS (CI) 
[M+H]+ Calculated 228.1383; [M+H]+ found 228.1386. CHN C15H17NO calculated C, 
79.26; H, 7.54; N, 6.16; found C, 79.42; H, 7.50; N, 5.95. HPLC (Chiralpak IB-3, 98:2 
Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 7.14 min (major) and 8.61 min. 
 
4-Methoxy-N-(1-(p-tolyl)ethyl)aniline8 In accordance with published data. 
White solid isolated in 95% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.24 (d, J = 7.9 
Hz, 2H), 7.12 (d, J = 7.9 Hz, 2H), 6.69 (d, J = 8.8 Hz, 2H), 6.48 (d, J = 8.8 Hz, 2H), 4.38 
(q, J = 6.7 Hz, 1H), 3.69 (s, 3H), 3.32 (s, 3H), 1.48 (d, J = 6.7 Hz, 3H). 13C NMR (CDCl3, 
100 MHz)  (ppm) 142.5, 141.7, 136.3, 129.3, 128.5, 125.8, 114.8, 114.6, 55.8, 54.0, 
25.1, 21.1. HRMS (CI) [M+H]+ Calculated 242.1539; [M+H]+ found 242.1544. CHN 
C16H19NO calculated C, 79.63; H, 7.94; N, 5.80; found C, 79.88; H, 7.81; N, 4.7. HPLC 
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(Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 11.16 min and 
11.99 min (major).  
 
N-(1-(4-Chlorophenyl)ethyl)-4-methoxyaniline8 In accordance with published data. 
Orange oil isolated in 94% yield (from the organic system) and 80% (in the aqueous 
system). 1H NMR (CDCl3, 400 MHz)  (ppm) 7.31-7.25 (m, 4H), 6.69 (d, J = 8.9 Hz, 
2H), 6.43 (d, J = 8.9 Hz, 2H), 4.37 (q, J = 6.7 Hz, 1H), 3.69 (s, 3H), 1.47 (d, J = 6.7 Hz, 
3H). 13C NMR (CDCl3, 100 MHz)  (ppm)152.1, 144.0, 141.1, 132.3, 128.8, 127.3, 
114.8, 114.7, 55.7, 53.8, 25.1. HRMS (CI) [M+H]+ Calculated 262.0993; [M+H]+ found 
262.0992. CHN C15H16ClNO calculated C, 68.83; H, 6.16; N, 5.35; found C, 69.73; H, 
6.33; N, 5.12. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 
nm) 17.23 min and 18.83 min (major).  
  
4-Methoxy-N-(1-(4-methoxyphenyl)ethyl)aniline7 In accordance with published 
data. 
White solid isolated in 59% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.29-2.76 (m, 
2H), 6.87-6.84 (m, 2H), 6.70-6.68 (m, 2H), 6.49-6.46 (m, 2H), 4.37 (q, J = 6.7 Hz, 1H), 
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3.78 (s, 3H), 3.69 (s, 3H), 1.47 (d, J = 6.7 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  
(ppm)158.4, 151.8, 141.7, 137.5, 114.7, 114.6, 114.0, 113.7, 55.7, 55.5, 55.2, 25.2. 
CHN C16H19NO2 calculated C, 74.68; H, 7.44; N, 5.44; found C, 74.25; H, 7.41; N, 
3.65. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 
16.05 min and 16.93 min (major). 
 
N-(1-(2,3-Dihydro-1H-inden-5-yl)ethyl)-4-methoxyaniline 
Orange oil isolated in 80% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.22 (s, 1H), 7.13 
(q, J = 7.7 Hz, 2H), 6.69 (d, J = 8.9 Hz, 2H), 6.49 (d, J = 8.9 Hz, 2H), 4.38 (q, J = 6.7 Hz, 
1H), 3.69 (s, 3H), 2.87 (t, J = 7.7 Hz, 4H), 2.05 (quin, J = 7.5 Hz, 2H), 1.48 (d, J = 6.7 
Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm)151.9, 144.7, 143.4, 142.9, 124.4, 123.8, 
121.8, 114.8, 114.6, 55.8, 54.3, 32.9, 32.5, 25.5, 25.3. HRMS (CI) [M+H]+ Calculated 
268.1696; [M+H]+ found 268.1706. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 
1 mL/min, 25 oC, 254 nm) 10.85 min and 11.80 min (major).  
 
4-Methoxy-N-(1-(m-tolyl)ethyl)aniline15 In accordance with published data. 
Yellow oil isolated in 96% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.21-7.14 (m, 
3H), 7.03 (d, J = 7.1 Hz, 1H), 6.69 (d, J = 8.5 Hz, 2H), 6.48 (d, J = 8.9 Hz, 2H), 4.36 (q, J 
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= 6.7 Hz, 1H), 3.69 (s, 3H), 2.33 (s, 3H), 1.48 (d, J = 6.7 Hz, 3H). 13C NMR (CDCl3, 100 
MHz)  (ppm)152.0, 145.4, 141.5, 138.2, 128.5, 127.7, 126.6, 123.0, 114.8, 114.7, 
55.8, 54.4, 25.0, 21.5. HRMS (CI) [M+H]+ Calculated 242.1539; [M+H]+ found 
242.1536. CHN C16H19NO calculated C, 79.63; H, 7.94; N, 5.80; found C, 80.43; H, 
7.98; N, 5.57. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 
nm) 11.12 min and 12.25 min (major). 
 
4-Methoxy-N-(1-(3-(trifluoromethyl)phenyl)ethyl)aniline15 In accordance with 
published data. 
Yellow oil isolated in 95% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.63 (bs, 1H), 
7.55 (d, J = 6.4 Hz, 1H), 7.48 (d, J = 6.4 Hz, 1H), 7.42 (d, J = 7.1 Hz, 1H), 6.69 (d, J = 6.9 
Hz, 2H), 6.43 (d, J = 7.0 Hz, 2H), 4.45 (m, 1H), 3.69 (s, 3H), 1.49 (d, J = 6.2 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz)  (ppm)152.2, 146.8, 141.1, 129.3, 129.1, 123.8, 123.8, 
122.8, 122.8, 114.8, 114.6, 55.7, 54.2, 25.2. HRMS (CI) [M+H]+ Calculated 296.1257; 
[M+H]+ found 296.1267. CHN C16H16F3NO calculated C, 65.08; H, 5.46; N, 4.74; 
found C, 65.78; H, 5.52; N, 4.33. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 
mL/min, 25 oC, 254 nm) 15.81 min and 20.08 min (major).  
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4-Methoxy-N-(1-(o-tolyl)ethyl)aniline15 In accordance with published data. 
Orange liquid isolated in 45% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.42 (d, J = 
7.3 Hz, 1H), 7.17-7.12 (m, 3H), 6.68 (d, J = 8.9 Hz, 2H), 6.40 (d, J = 8.9 Hz, 2H), 4.60 
(q, J = 6.6 Hz, 1H), 3.69 (s, 3H), 2.43 (s, 3H), 1.45 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 
100 MHz)  (ppm)151.8, 143.0, 141.6, 134.6, 130.6, 126.6, 126.5, 124.7, 114.8, 
114.2, 55.8, 50.5, 23.1, 19.0. CHN C16H19NO calculated C, 79.63; H, 7.94; N, 5.80; 
found C, 80.80; H, 8.00; N, 5.66.  HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 
mL/min, 25 oC, 254 nm) 10.01 min (major) and 12.17 min.  
 
N-(1-(2-Chlorophenyl)ethyl)-4-methoxyaniline15 In accordance with published data. 
Orange oil isolated in 88% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.45 (dd, J = 7.5, 
1.8 Hz, 1H), 7.34 (dd, J = 7.5, 0.9 Hz, 1H), 7.20-7.12 (m, 2H), 6.68 (d, J = 8.8 Hz, 2H), 
6.40 (d, J = 8.8 Hz, 2H), 4.83 (q, J = 6.6 Hz, 1H),3.86 (bs, 1H),  3.68 (s, 3H), 1.48 (d, J = 
6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm)152.0, 142.3, 141.0, 132.5, 129.7, 
128.0, 127.2, 126.8, 114.8, 114.3, 55.7, 50.9, 23.0. HRMS (CI) [M+H]+ Calculated 
262.0993; [M+H]+ found 262.1002. CHN C15H16ClNO calculated C, 68.83; H, 6.16; N, 
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5.35; found C, 68.75; H, 6.20; N, 4.94. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% 
HNEt2, 1 mL/min, 25 
oC, 254 nm) 10.38 min (major) and 11.56 min.  
 
4-Methoxy-N-(1-phenylpropyl)aniline15 In accordance with published data. 
Orange oil isolated in 88% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.34-7.28 (m, 
4H), 7.23-7.20 (m, 1H), 6.70-6.66 (m, 2H), 6.79-6.45 (m, 2H), 4.15 (t, J = 6.7 Hz, 1H), 
3.68 (s, 3H), 1.80 (dq, J = 16.1, 7.4 Hz, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3, 
100 MHz)  (ppm)151.8, 144.2, 141.8, 128.5, 126.8, 126.6, 114.8, 114.4, 60.6, 55.8, 
31.7, 10.9. HRMS (CI) [M+H]+ Calculated 242.1539; [M+H]+ found 242.1547. CHN 
C16H19NO calculated C, 79.63; H, 7.94; N, 5.80; found C, 80.94; H, 8.03; N, 5.58. HPLC 
(Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 8.57 min and 
9.21 min (major).  
 
4-Methoxy-N-(1-phenylpentyl)aniline20  In accordance with published data. 
Yellow oil isolated 75% yield (in the organic system) and 84% yield (in the aqueous 
system). 1H NMR (CDCl3, 400 MHz)  (ppm) 7.34-7.20 (m, 5H), 6.68-6.62(m, 4H), 4.2 
(t, J = 7.0 Hz, 1H), 3.68 (s, 3H), 1.96-1.87 (m, 2H), 1.31-1.21 (m, 4H), 0.84 (t, J = 7.0 
Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm)141.6, 128.6, 127.3, 127.0, 116.7, 114.6, 
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55.7, 45.7, 37.4, 28.4, 22.5, 14.7, 14.0, 6.6. HRMS (CI) [M+H]+ Calculated 270.1852; 
[M+H]+ found 270.1863. CHN C18H23NO calculated C, 80.26; H, 8.61; N, 5.20; found 
C, 81.26; H, 8.64; N, 4.78 HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 
mL/min, 25 oC, 254 nm) 7.60 min and 8.16 min (major).  
 
N-(1,2-Diphenylethyl)-4-methoxyaniline21 In accordance with published data. 
Yellow oil isolated in 38% yield (in the organic system) and 76% yield (in the 
aqueous system). 1H NMR (CDCl3, 400 MHz)  (ppm)  8.02-7.97 (m, 2H), 7.55-7.44 
(m, 3H), 7.32-7.30 (m, 3H), 7.12 (d, J = 7.2 Hz, 2H), 6.64 (d, J = 8.8 Hz, 2H), 6.41 (d, J 
= 8.8 Hz, 2H), 4.50 (dd, J = 8.0, 5.9 Hz, 1H), 3.11 (dd, J = 13.9, 5.9 Hz, 1H), 2.99 (dd, J 
= 14.0, 8.3 Hz, 1H). 13C NMR (CDCl3, 100 MHz)  (ppm) 129.9, 129.5, 129.2, 129.0, 
128.7, 128.6, 1285, 127.0, 126.7, 126.5, 114.9, 114.7, 60.1, 55.7, 45.3. HRMS (CI) 
[M+H]+ Calculated 304.1696; [M+H]+ found 304.1709. HPLC (Chiralpak IB-3, 98:2 
Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 10.51 min and 13.99 min (major). 
 
4-Methoxy-N-(4-phenylbutan-2-yl)aniline8 In accordance with published data.  
Yellow oil isolated in 97% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.30-7.28 (m, 
2H), 7.19-7.17 (m, 3H), 6.78-6.74 (m, 2H), 6.53-6.50 (m, 2H), 3.74 (s, 3H), 3.42-3.37 
(m, 1H), 2.78-2.70 (m, 2H), 1.89-1.71 (m, 2H), 1.19 (d, J = 6.2 Hz, 3H). 13C NMR 
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(CDCl3, 100 MHz)  (ppm)151.9, 142.1, 141.7, 128.5, 128.4 (q), 126.1, 125.8, 115.0, 
114.8, 55.8, 49.0, 38.9, 32.5, 20.9. HRMS (CI) [M+H]+ Calculated 256.1696; [M+H]+ 
found 256.1703. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 
254 nm) 11.84 min and 12.39 min. 
 
N-(1-Phenylethyl)aniline8 In accordance with published data. 
Yellow oil isolated in 37% and 82% yield (in the organic and aqueous system 
respectively). 1H NMR (CDCl3, 400 MHz)  (ppm) 7.38-7.30 (m, 4H), 7.24-7.20 (m, 
1H), 7.11-7.06 (m, 2H), 6.64 (t, J = 7.3 Hz, 1H), 6.52-6.50 (m, 2H), 4.48 (q, J = 6.7 Hz, 
1H), 1.52 (d, J = 6.7 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm)129.1, 129.0, 128.7, 
128.4, 126.9, 125.9, 119.4, 113.3, 53.5, 25.0. HRMS (CI) [M+H]+ calculated 198.1277; 
[M+H]+ found 198.1280. CHN C14H15N calculated C, 85.24; H, 7.66; N, 7.10; found C, 
86.33; H, 7.91; N, 7.25. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 mL/min, 
25 oC, 254 nm) 8.25 min (major) and 9.57 min. 
 
4-Methyl-N-(1-phenylethyl)aniline8 In accordance with published data. 
White solid isolated in 37% and 84% yield (in the organic and aqueous systems 
respectively). 1H NMR (CDCl3, 400 MHz)  (ppm) 7.37-7.29 (m, 4H), 7.23-7.20 (m, 
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1H), 6.90 (d, J = 8.2 Hz, 2H), 6.43 (d, J = 8.2 Hz, 2H), 4.45 (q, J = 6.7 Hz, 1H), 2.18 (s, 
3H), 1.50 (d, J = 6.7 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm)129.6, 129.5, 128.6, 
127.1, 126.8, 125.8, 119.4, 113.5, 53.7, 25.1, 20.4. HRMS (CI) [M+H]+ Calculated 
212.1434; [M+H]+ found 212.1442. CHN C15H17N calculated C, 85.26; H, 8.11; N, 
6.63; found C, 85.01; H, 8.19; N, 6.60. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% 
HNEt2, 1 mL/min, 25 
oC, 254 nm) 7.96 min  and 8.73 min (major). 
 
4-Bromo-N-(1-phenylethyl)aniline8 In accordance with published data. 
Yellow oil isolated in 8% and 42% yield (in the organic and aqueous systems 
respectively). 1H NMR (CDCl3, 400 MHz)  (ppm) 7.32-7.29 (m, 4H), 7.23-7.21 (m, 
1H), 7.14 (d, J = 8.5 Hz, 2H), 6.36 (d, J = 8.5 Hz, 2H), 4.42 (q, J = 6.7 Hz, 1H), 1.50 (d, J 
= 6.7 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm)146.2, 144.6, 131.8, 128.8, 127.1, 
125.8, 114.9, 108.9, 55.5, 25.0. HRMS (CI) [M+H]+ Calculated 276.0382; [M+H]+ 
found 276.0382. CHN C14H14BrN calculated C, 60.89; H, 5.11; N, 5.07; found C, 
61.59; H, 5.43; N, 4.77. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 mL/min, 
25 oC, 254 nm) 9.77 min  and 11.59 min (major). 
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3-Methyl-N-(1-phenylethyl)aniline22 In accordance with published data. 
Orange oil isolated in 47% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.38-7.31 (m, 
4H), 7.24-7.22 (m, 1H), 6.97 (t, J = 7.8 Hz, 1H), 6.47 (d, J = 7. Hz, 1H), 6.36 (s, 1H), 6.3 
(dd, J = 8, 2.2 Hz, 1H), 4.47 (q, J = 6.7 Hz, 1H), 2.21 (s, 3H), 1.50 (d, J = 6.7 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz)  (ppm)147.3, 145.4, 138.9, 129.0, 128.6, 126.8, 125.9, 
118.2, 114.1, 110.3, 53.4, 25.0, 21.6. HRMS (CI) [M+H]+ Calculated 212.1434; [M+H]+ 
found 212.1443. CHN C15H17N caluculated C, 85.26; H, 8.11; N, 6.63; found C, 85.19; 
H 8.27; N, 6.79. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 
254 nm) 7.24 min (major) and 8.66 min. 
 
3,5-Dimethyl-N-(1-phenylethyl)aniline23 In accordance with published data. 
Yellow oil isolated in 50% and 65% yields (in the organic and aqueous systems 
respectively). 1H NMR (CDCl3, 400 MHz)  (ppm) 7.37-7.29 (m, 4H), 7.23-7.20 (m, 
1H), 6.31 (s, 1H), 6.16 (s, 2H), 4.47 (q, J = 6.7Hz, 1H), 2.16 (s, 6H), 1.48 (d, J = 6.7Hz, 
3H). 13C NMR (CDCl3, 100 MHz)  (ppm)147.4, 145.5, 138.8, 128.6, 126.8, 125.9, 
119.3, 111.2, 53.3, 25.0, 21.5. HRMS (CI) [M+H]+ calculated 226.159; [M+H]+ found 
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226.1591. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 
nm) 6.21 min (major) and 6.84 min.  
 
N-Benzyl-1-phenylethanamine7 In accordance with published data. 
Yellow oil isolated in 80 and 97% yields (in the organic and aqueous systems 
respectively). 1H NMR (CDCl3, 400 MHz)  (ppm) 7.36-7.21 (m, 10H), 3.81 (q, J = 6.6 
Hz, 1H), 3.62 (q, J = 13.1 Hz, 2H), 1.63 (bs, 1H), 1.37 (d, J = 6.6 Hz, 3H).  13C NMR 
(CDCl3, 100 MHz) (ppm) 145.6, 140.6, 128.5, 128.4, 128.2, 127.0, 126.9, 126.7, 
57.5, 51.7, 24.6. HRMS (CI) [M+H]+ Calculated 212.1434; [M+H]+ found 212.1444. 
HPLC (Chiralpak IB-3, 99:1 Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 5.65 min 
(major) and 6.09 min. 
 
N-(4-Methylbenzyl)-1-phenylethanamine24 In accordance with published data. 
Yellow oil isolated in 66% and 94% yields (in the organic and aqueous systems 
respectively). 1H NMR (CDCl3, 400 MHz)  (ppm) 7.35-7.34 (m, 4H), 7.6-7.26 (m, 1H), 
7.17-7.10 (m, 4H), 3.80 (q, J = 6.6 Hz, 1H), 3.58 (q, J = 13.0 Hz, 2H), 2.33 (s, 3H), 1.60 
(bs, 1H), 1.35 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 145.6, 137.6, 
136.4, 129.1, 128.5, 128.1, 126.9, 126.8, 57.4, 51.4, 24.5, 21.3. HRMS (CI) [M+H]+ 
calculated 226.1590; [M+H]+ found 226.1596. HPLC (Chiralpak IB-3, 99.8:0.2 Hex:IPA 
(+ 0.1% HNEt2), 0.5 mL/min, 25 
oC, 254 nm) 16.83 min (major) and 17.72 min. 
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N-Benzyl-1-(4-nitrophenyl)ethanamine25 In accordance with published data. 
Yellow oil isolated in 77% and 93% yields (in the organic and aqueous systems 
respectively). 1H NMR (CDCl3, 400 MHz)  (ppm) 7.35-7.33 (m, 4H), 7.26-7.25 (m, 
1H), 7.19 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 3.82-3.77 (m, 4H), 3.56 (q, J = 
12.9 Hz, 2H), 1.36 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz) (ppm)158.6, 
145.7, 132.8, 129.3, 128.5, 126.9, 126.7, 113.8, 57.4, 55.3, 51.1, 24.6. HRMS (CI) 
[M+H]+ Calculated 242.1539; [M+H]+ found 242.1545. HPLC (Chiralpak IB-3, 99.8:0.2 
Hex:IPA (+ 0.1% HNEt2), 0. 5mL/min, 25 
oC, 254 nm) 25.69 min (major) and 27.27 
min. 
 
N-(2-Chlorobenzyl)-1-phenylethanamine 
Yellow oil isolated in 90% and 93% yields (in the organic and aqueous systems 
respectively). 1H NMR (CDCl3, 400 MHz,)  (ppm) 7.39-7.30 (m, 6H), 7.26-7.23 (m, 
1H), 7.22-7.16 (m, 2H), 3.82-3.67 (m, 3H), 1.8 (bs, 1H), 1.37 (d, J = 6.5 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz)  (ppm) 145.3, 137.8, 133.8, 130.5, 129.5, 128.5, 128.3, 
127.0, 126.8, 57.4, 49.3, 24.6. HRMS (CI) [M+H]+ Calculated 246.1044; [M+H]+ found 
246.1055. HPLC (Chiralpak IB-3, 99.8:0.2 Hex:IPA (+ 0.1% HNEt2), 0.5 mL/min, 25 
oC, 
254 nm) 17.63 min (major) and 18.77 min. 
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Chapter 4: Asymmetric 
Transfer Hydrogenation 
of Quinolines 
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4.1 Introduction 
 The reduction of quinolines has long been a desirable process, due to the 
biological activity of the tetrahydroquinoline motif.1 Whilst a number of AH systems 
have been reported, the ATH of quinolines has proved a more challenging process, 
with the majority of systems utilising chiral phosphoric acids2–5 and only a few metal 
catalysed systems published.6–8  Of the metal catalysed systems a rhodium DPEN 
based complex proved the most successful, allowing for highly selective reduction 
of 2-substituted quinolines, as well as two 2,3-disubstituted quinolines (Scheme 
4.1).7  
 
Scheme 4.14 Rhodium catalysed ATH of quinolines. 
4.2 Complex Screening 
 To further explore the activity of the chiral iridium complexes developed in 
Chapter 2, quinoline ATH was investigated. A test reaction showed activity in both 
the IPA/FT conditions, as well as the aqueous conditions previously reported for use 
with the racemic iridicycles.9 A variety of complexes were screened under both 
conditions to determine the impact upon the conversion and selectivity. With a 
range of complexes tested, IPA/FT conditions afforded the highest selectivity, 
although only low to moderate conversions were observed (Table 4.1). Aq 
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NaCO2H/HCO2H (pH 4.5) afforded a slight reduction in selectivity with complete 
conversion (Table 4.1). These aqueous conditions were therefore deemed 
favourable and taken forward for further complex screening. 
The results in Table 4.1 show that the bulky oxazoline complexes were the 
most selective for this transformation, with both terphenyl complexes (Ir 14 and Ir 
17) screened providing the highest ee’s of 55-60% (Entries 3 and 4, Table 4.1). Less 
bulky oxazolines (Entries 1 and 2, Table 4.1) yielded much lower selectivities, with 
the imidazoline complex (Ir 30) producing an almost racemic product (Entry 5, Table 
4.1). 
 
Entry Catalyst 
IPA (2 mL) FT 
(0.5 mL) 
NaCO2H/HCO2H (aq)  
(pH 4.5)  (2.5 mL) 
Conv (%) ee (%) Conv (%) ee (%) 
1 
Ir 7 
42 20 100 14 
2 
Ir 9 
38 21 100 17 
153 
 
3 
Ir 14 
35 60 100 57 
4 
 
26 60 100 55 
5 
Ir 30 
40 5 - - 
Reaction conditions: 0.5 mmol quinoline, 1 mol% iridium complex, 2.5 mL solvent/hydride 
source, sealed, overnight. 
Table 4.20 Comparison of organic and aqueous conditions for ATH of quinoline. 
 Further terphenyl complexes were screened to determine if the selectivity 
could be improved upon. The simple p-methyl terphenyl Ir 12 yielded a surprisingly 
low ee (Entry 3, Table 4.2), whilst the 4-iso-propyl terphenyl Ir 13 and 2,4,6-iso-
propyl phenyl Ir 11 complexes (Entries 1 and 2 respectively, Table 4.2) provided the 
greatest selectivities. 
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Entry Catalyst Conv (%) ee (%) 
1 
Ir 13 
100 66 
2 
Ir 11 
100 58 
3 
Ir 12 
100 10 
Reaction conditions: 0.5 mmol quinoline, 1 mol% iridium complex, 3 mL aq NaCO2H/HCO2H 
pH 4.5, sealed, overnight. 
Table 4.21 Screening of bulky oxazoline complexes. 
 With a complex in hand able to produce moderate ee and complete 
conversion under mild conditions, the versatility of this system was investigated. 
Although higher selectivity was shown by the Ir 13, this catalyst is more expensive 
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and challenging to synthesise than Ir 11, which was the second best complex, 
therefore this is utilised for further screening of the substrate range.  
4.3 Additive screening 
 Investigation of substrate scope was initiated with commercially available 8-
chloroquinaldine. This substrate provided just 30% conversion and 37% ee (Entry 1, 
Table 4.3) under the standard conditions. The lower conversion was attributed to 
the insolubility of the substrate in the aqueous reaction medium with both complex 
and substrate on the surface of the water with little interaction. In the racemic 
system, this problem was circumvented by heating the mixture at reflux. 
A range of co-solvents were investigated for improving the solubility of the 
solid substrates. Apart from methanol and polyethylene glycol (Entries 1 and 6, 
Table 4.3) all co-solvents screened offered an increase in conversion and ee. The 
highest ee was observed when the reaction was carried out in the presence of 2-
MeTHF (Entry 4, Table 4.3). Although the conversion was lower than with that 
achieved when DCM or IPA was used (Entries 3 and 4, Table 4.3), the conversion 
and ee were satisfactory for this co-solvent to be taken forward for further 
screening.  
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Entry 
Co-
solvent 
Conv 
(%) 
ee 
(%) 
Entry Co-solvent 
Conv 
(%) 
ee 
(%) 
1 - 30 37 4 2-MeTHF 60 60 
2 MeOH 30 45 5 DCM 93 58 
3 IPA 100 52 6 
Polyethylene 
glycol 
8 36 
Reaction conditions: 0.5 mmol quinoline, 1 mol% Ir 11, 0.3 mL co-solvent, 3 mL aq 
NaCO2H/HCO2H pH 4.5, sealed, overnight. 
Table 4.22 Screening of co-solvents for ATH of 8-chloroquinaldine. 
To further improve the conversion and the interaction between the organic 
and aqueous phases, a range of sulphate, sulphonates and functional groups 
capable of hydrogen bonding with the quinoline substrate were screened to 
determine their effect as surfactants. 2,3-Butandiol and ethylene sulfite impacted 
negatively on both the conversion and selectivity (Entries 3 and 5, Table 4.4), whilst 
diethylmalonate offered a slight reduction in ee but enhanced conversion (Entry 2, 
Table 4.4). Improved results were seen with sulfonates, with those screened 
showing increased conversion, whilst generally maintaining the ee (Entries 6-8, 
Table 4.4). The most promising results were achieved when sulfates were 
employed, with both the ammonium and sodium dodecyl sulfates (SDS) offering an 
increase in selectivity (Entries 1 and 4, Table 4.4). SDS also improved conversion to 
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90% with 70% ee and so the combination of this with 2-MeTHF was taken forward 
to further explore the scope of this transformation. 
 
Entry 
Additive 
(10 mol%) 
Conv 
(%) 
ee 
(%) 
Entry 
Additive 
(10 mol%) 
Conv 
(%) 
ee 
(%) 
1 SDS 90 70 5 
 
30 57 
2 Diethylmalonate 84 57 6 
 
63 54 
3 2,3-Butandiol 35 41 7 
 
67 59 
4 
 
62 65 8 
 
75 59 
Reaction conditions: 0.5 mmol quinoline, 1 mol% Ir 11, 10 mol% additive,  0.3 mL 2-MeTHF, 
3 mL aq NaCO2H/HCO2H pH 4.5, sealed, overnight. 
Table 4.23 Screening of additives for ATH of 8-chloroquinaldine. 
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4.4 Substrate Scope 
4.4.1 2-Substituted quinolines 
 A range of commercially available 2-substituted quinolines were screened to 
explore the activity of this ATH system. The addition of SDS had shown great benefit 
to the 8-chloroquinaldine; however its presence with the liquid substrate quinaldine 
had a detrimental effect with little conversion being observed (Entries 1 and 2, 
Table 4.5). Further substrates were screened for both systems, in the presence and 
absence of SDS, using 2-MeTHF as a co-solvent (Table 4.5). 
 
Entry Substrate 
Without SDS With SDS 
Conv (%) ee (%) Conv (%) ee (%) 
1 
 
100* 68 5 - 
2 
 
60 60 90 70 
3 
 
90 - / / 
4 
 
95 - / / 
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5 
 
100 66 100 60 
6 
 
100 51 100 36 
7 
 
100 50 100 36 
8 
 
100 52 100 40 
9 
 
100 73 100 65 
Reaction conditions: 0.5 mmol quinoline, 1 mol% Ir 11, (10 mol% SDS), 0.3 mL 2-MeTHF, 3 
mL aq NaCO2H/HCO2H pH 4.5, sealed, overnight. (* ran for 7 h) 
Table 4.24 Substrate scope for ATH of quinolines. 
 The most readily available substitution pattern available is 2,7-quinolines. 
From these it can be see that the electronics of the substituents have an impact 
upon the selectivity although not conversion, with 7-methoxy and 7-methyl 
quinaldine providing the highest ee’s in the absence of SDS, 73% and 66% 
respectively (Entries 5 and 9, Table 4.5). Although lower in the presence of SDS the 
ee’s were still moderately high (65% and 60% respectively). Electron withdrawing 
groups showed a larger drop in selectivity in the presence of SDS, down to roughly 
35% ee from 50% (Entries 6-8, Table 4.5). 2,8-dimethyltetrahydroquinoline and 2-
methyl-7-chlorotetrahydroquinoline proved active under the described system, 
however chiral HPLC analysis proved unsuccessful.  
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4.4.2  3- and 4-Substituted quinolines 
 With a range of 2-substituted quinolines investigated, attention was turned 
to the more challenging 3- and 4- substituted quinolines. Initially, the commercially 
available 3-methylquinoline was investigated. Under the standard conditions the 
rate of reaction remained high, although a racemic product was yielded (Entry 1, 
Table 4.6). Upon varying the catalyst to a less bulky, electron-rich imidazoline 
complex, the conversion was improved but once more a racemic product was 
obtained (Entry 2, Table 4.6), indicating the 3-substituted quinolines may not be a 
suitable substrates for this catalytic system. 
 
Entry Catalyst Conv (%) ee (%) 
1 
Ir 11 
93 0 
2 
Ir 29 
100 0 
Reaction conditions: 0.5 mmol quinoline, 1 mol% iridium complex, 0.3 mL 2-MeTHF, 3 mL 
aq NaCO2H/HCO2H pH 4.5, sealed, overnight. 
Table 4.25 ATH of 3-methylquinoline. 
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 Lepidine showed greater promise, however, under standard conditions, an 
ee of 15% and a low conversion of 20% was observed (Entry 1, Table 4.7). Removal 
of the 2-MeTHF offered a slight improvement in both selectivity and conversion by 
5% (Entry 2, Table 4.7). Varying the iridicycle used to the less bulky imidazolines 
improved conversion, to < 90% (Entries 3-5, Table 4.7). The trimethoxy imidazoline 
complex also showed an improvement in selectivity up to 30% (Entries 4 and 5, 
Table 4.7). Although only a moderate ee, this proved to be only the second ATH 
system for reduction of 4-substituted quinolines reported, using milder conditions 
and shorter reaction times.10 
Variation of the substituent from a methyl group to an electron withdrawing 
halogen gave complete conversion, to 1,2,3,4-tetrahydroquinoline, arising from 
complete C-X bond cleavage during the reaction (Scheme 4.2). Indicating that 
halides, and potentially other good leaving groups, are unlikely to be suitable 
substrates for this transformation. This reaction potentially occurred via an initial 
1,4-hydride addition, the aromaticity could then be reinstated by the loss of the 4-
halide, allowing for a second 1,4-addition, isomerisation and a 1,2-hydride addition, 
as reported in the racemic system (Figure 4.1).9 
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Entry Catalyst 2-MeTHF Conv (%) ee (%) 
1 
Ir 11 
0.3 mL 20 15 
2 - 25 20 
3 
Ir 30 
- 97 16 
4 
Ir 29 
0.3 mL 80 30 
5 - 90 30 
Reaction conditions: 0.5 mmol quinoline, 1 mol% iridium complex, (0.3 mL 2-MeTHF), 3 mL 
aq NaCO2H/HCO2H pH 4.5, sealed, overnight. 
Table 4.26 ATH of lepidine.
 
 
Scheme 4.15 Attempted ATH of 4-bromo and chloro quinoline. 
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Figure 4.12 Proposed mechanism for halide elimination during ATH. 
4.5 Conclusion 
 The asymmetric reduction of quinolines proved successful with the 
developed iridium complexes. The greatest results were seen in the presence of a 
bulky oxazoline complex on an aqueous medium. The presence of a co-solvent was 
able to further improve the conversion and enantioselectivites, particulary for solid 
substrates, which are insoluble in the aqeous medium. Although the conversions 
and ee’s obtained were lower than other published systems, it demonstrated a 
further use for these asymmetric iridium complexes. Whilst 3-substituted quinolines 
proved to be inactive under these reaction conditions, greater promise was shown 
for 4-substituted quinolones, with low conversion and a moderate 
enantioselecitivty being achieved under the standard conditions. Halide groups 
were shown to be unstable under the ATH conditions, resulting in exchange of the 
halide for a proton.  
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4.6 Experimental 
The iridium complexes were synthesised as described in Chapter 2. IPA was 
dried on a MB-SPS 800. All other chemicals were obtained commercially and used 
without further purification. NMR spectra were recorded on a Bruker 400 MHz NMR 
spectrometer, with TMS as internal standard. HPLC analysis was recorded on an 
Agilent 1260 Infinity equipped with a Chiralcel OJ-H column. 
4.6.1 General Procedures 
ATH under organic conditions 
A glass vial was charged with the iridium catalyst (1 mol%) and quinoline (0.5 
mmol), along with a stirrer bar. IPA (2.5 mL) was added, followed finally by FT (0.5 
mL) to initiate the reaction. The glass vial was sealed and stirred at 20 oC for 16 h. 
After the reaction time, it was quenched by the addition of 10% NaOH and 
extracted into EtOAc. The organic phase was dried over MgSO4, filtered and 
evaporated under vacuum. The resulting residue was purified by column 
chromatography, using 15% EtOAc in hexane, upon which HPLC analysis was 
performed. 
ATH under aqueous conditions 
A glass vial was charged with the iridium catalyst (1 mol%), quinoline (0.5 mmol) 
and an additive when desired (10 mol%) along with a stirrer bar and co-solvent (0.3 
mL), followed by an aqueous solution of NaCO2H/HCO2H pH 4.5 (3 mL) to initiate 
the reaction. The glass vial was sealed and stirred at 20 oC for 16 h. After the 
reaction time it was quenched by the addition of saturated aq K2CO3 and extracted 
into EtOAc. The organic phase was dried over MgSO4, filtered and evaporated under 
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vacuum. The resulting residue was purified by column chromatography, using 15% 
EtOAc in hexane, upon which HPLC analysis was performed. 
4.6.2 Analytical data 
 
2-Methyl-1,2,3,4-tetrahydroquinoline7 In accordance with published data. 
Yellow oil isolated in up to 98% yield. 1H NMR (CDCl3, 400 MHz) (ppm) 6.97-6.94 
(t, J = 6.2 Hz, 2H), 6.60 (t, J = 7.3 Hz, 1H), 6.46 (d, J = 8.6 Hz, 1H), 3.68 (bs, 1H), 3.43-
3.35 (m, 1H), 2.83 (ddd, J = 16.5, 11.3, 5.6 Hz, 1H), 2.72 (dt, J = 16.2, 4.4 Hz, 1H), 
1.95-1.89 (m, 1H), 1.63-1.53 (m, 1H), 1.20 (d, J = 6.2 Hz, 3H). 13C NMR (CDCl3, 100 
MHz)  (ppm) 144.8, 129.3, 126.7, 121.1, 117.0, 114.0, 47.2, 30.2, 26.6, 22.6. HRMS 
(CI) calculated [M+H]+ 148.1121. found [M+H]+ 148.1127. HPLC (Chiralcel OJ-H, 95:5 
Hex:IPA +0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 12.45 min and 13.70 min (major). 
 
8-Chloro-2-methyl-1,2,3,4-tetrahydroquinoline9 In accordance with published data. 
Yellow solid isolated in up to 87% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.06 (d, J 
= 7.9 Hz, 1H), 6.86 (d, J = 7.4 Hz, 1H), 6.51 (t, J = 7.7 Hz, 1H), 4.26 (bs, 1H), 3.50-3.43 
(m, 1H), 2.88-2.73 (m, 1H), 1.94 (ddt, J = 12.8, 5.4, 3.5 Hz, 1H), 1.58 (dddd, J = 12.8, 
11.2, 9.9, 5.5 Hz, 1H), 1.27 (d, J = 6.2 Hz, 3H). 13C NMR (CDCl3, 100 MHz) (ppm) 
140.7, 127.4, 126.7, 122.4, 117.8, 116.3, 47.2, 29.6, 26.8, 22.5. HPLC (Chiralcel OJ-H, 
95:5 Hex:IPA +0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 5.03 min and 5.31 min (major). 
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2,8-Dimethyl-1,2,3,4-tetrahydroquinoline 
Yellow oil isolated in up to 85% yield. 1H NMR (CDCl3, 400 MHz) (ppm) 6.86 (t, J = 
6.3 Hz, 2H), 6.55 (t, J = 7.4 Hz, 1H), 3.47-3.40 (m, 2H), 2.90-2.82 (m, 1H), 2.08 (s, 3H), 
1.96-1.90 (m, 1H), 1.63, 1.53 (m, 1H), 1.25 (d, J = 6.3 Hz, 3H). 13C NMR (CDCl3, 100 
MHz) (ppm) 142.7, 129.5, 127.9, 127.2, 125.5, 116.4, 47.4, 30.1, 26.9, 22.9, 17.2. 
 
7-Chloro-2-methyl-1,2,3,4-tetrahydroquinoline11 In accordance with published 
data. 
Yellow solid isolated in up to 93% yield. 1H NMR (CDCl3, 400 MHz) (ppm) 6.83 (d, J 
= 7.9 Hz, 1H), 6.53 (dd, J = 8.0, 2.0 Hz, 1H), 6.41 (d, J = 2.0 Hz, 1H), 3.41-3.34 (m, 1H), 
2.79-2.65 (m, 2H), 1.93-1.88 (m, 1H), 1.56-1.49 (m, 1H), 1.19 (d, J = 6.2 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz) (ppm) 145.8, 131.9, 130.2, 119.3, 116.6, 113.3, 47.0, 29.8, 
26.1, 22.5.  
 
2,6-Dimethyl-1,2,3,4-tetrahydroquinoline7 In accordance with published data. 
Yellow solid isolated in up to 97% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 6.78-6.77 
(m, 2H), 6.4 (d, J = 7.9 Hz, 1H), 3.57 (bs, 1H), 3.35 (ddd, J = 9.7, 6.5, 2.8 Hz, 1H), 2.85-
2.77 (m, 1H), 2.72-2.65 (m, 1H), 2.20 (s, 3H), 1.94-1.88 (m, 1H), 1.57 (tdd, J = 12.1, 
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10.1, 5.5 Hz, 1H), 1.19 (d, J = 6.3 Hz, 3H). 13C NMR (CDCl3, 100 MHz) (ppm) 141.5, 
129.8, 127.2, 121.3, 114.3, 47.3, 30.4, 26.6, 22.6, 20.4. HPLC (Chiralcel OJ-H, 95:5 
Hex:IPA +0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 18.5 min (major) and 23.2min. 
 
6-Chloro-2-methyl-1,2,3,4-tetrahydroquinoline7 In accordance with published data. 
Yellow solid isolated in up to 98% yield. 1H NMR (CDCl3, 400 MHz) (ppm) 6.91-6.87 
(m, 2H), 6.37 (d, J = 8.4 Hz, 1H), 3.69 (bs, 1H), 3.37 (ddd, J = 9.7, 6.4, 2.9 Hz, 1H), 
2.79 (ddd, J = 16.6, 11.3, 5.7 Hz, 1H), 2.68 (dt, J = 16.3, 4.5 Hz, 1H), 1.91-1.88 (m, 
1H), 1.53 (m, 1H), 1.2 (d, J = 6.2 Hz, 3H). 13C NMR (CDCl3, 100 mHz)  143.3, 128.8, 
126.5, 122.6, 121.3, 114.9, 47.2, 29.7, 26.5, 22.5. HPLC (Chiralcel OJ-H, 95:5 Hex:IPA 
+0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 14.9 min (major) and 17.9 min. 
 
6-Bromo-2-methyl-1,2,3,4-tetrahydroquinoline7 In accordance with published data. 
Yellow solid isolated in up to 94% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.06-7.01 
(m, 2H), 6.34 (d, J = 8.5 Hz, 1H), 3.71 (bs, 1H), 3.37 (dqd, J = 9.6, 6.4, 2.8 Hz, 1H), 
2.84-2.75 (m, 1H), 2.72-2.66 (m, 1H), 1.94-1.88 (m, 1H), 1.59-1.49 (m, 2H), 1.20 (d, J 
= 6.2Hz, 3H). 13C NMR (CDCl3, 100 MHz) (ppm) 143.8, 131.7, 129.3, 123.1, 115.4, 
108.3, 47.1, 29.6, 26.4, 22.5. HPLC (Chiralcel OJ-H, 95:5 Hex:IPA +0.1% HNEt2, 1 
mL/min, 25 oC, 254 nm) 17.1 min (major) and 21.28 min. 
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6-Fluoro-2-methyl-1,2,3,4-tetrahydroquinoline7 In accordance with published data. 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 6.69-6.65 (m, 2H), 6.41-6.38 (m, 
1H), 3.38-3.30 (m, 1H), 2.82 (ddd, J = 16.9, 11.4, 5.8 Hz, 1H), 2.73-2.66 m, 1H), 1.94-
1.88 (m, 1H), 1.56 (tdd J = 12.8, 10.3, 5.5 Hz, 1H), 1.2 (d, J = 6.2 Hz, 3H). 13C NMR 
(CDCl3, 100 MHz) (ppm) 156.7, 154.3, 140.9, 122.5, 122.5, 115.2, 115.3, 114.8, 
114.7, 113.3, 133.1, 47.3, 29.9, 26.7, 26.7, 22.5. HPLC (Chiralcel OJ-H, 95:5 Hex:IPA 
+0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 11.1 min (major)  and 11.5 min. 
 
6-Methoxy-2-methyl-1,2,3,4-tetrahydroquinoline7 In accordance with published 
data. 
Yellow oil isolated in up to 96% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 6.61-6.58 
(m, 2H), 6.49 (d, J = 8.4 Hz, 1H), 3.72 (s, 3H), 3.36-3.31 (m, 1H), 2.88-2.80 (m, 1H), 
2.74-2.68 (m, 1H), 1.95-1.89 (m, 1H), 1.64-1.54 (m, 1H), 1.21 (d, J = 6.2 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz) (ppm) 152.1, 138.3, 122.9, 115.7, 114.6, 112.9, 55.8, 47.6, 
30.2, 26.9, 22.4. HPLC (Chiralcel OJ-H, 95:5 Hex:IPA +0.1% HNEt2, 1 mL/min, 25 
oC, 
254 nm) 24.8 min (major) and 31.4 min. 
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3-Methyl-1,2,3,4-tetrahydroquinoline9 In accordance with published data. 
Yellow oil isolated in up to 96% yield. 1H NMR (CDCl3, 400 MHz) (ppm)6.97-6.92 
(m, 2H), 6.60 (t, J = 7.4 Hz, 1H), 6.47 (t, J = 7.9 Hz, 1H), 3.27-3.24 (m, 1H), 2.89 (t, J = 
10.3 Hz, 1H), 2.77 (dd, J = 16.0, 4.6 Hz, 1H), 2.42 (dd, J = 16.0, 10.2 Hz, 1H), 2.09-2.02 
(m, 1H), 1.04 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz) (ppm) 144.3, 129.5, 
126.7, 121.1, 116.9, 113.9, 48.9, 35.5, 27.2, 19.1. HPLC (Chiracel IB-3, 98:2 Hex:IPA + 
0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 7.35 min and 8.27 min. 
 
4-Methyl-1,2,3,4-tetrahydroquinoline9 In accordance with published data. 
Yellow oil isolated in up to 90% yield. 1H NMR (CDCl3, 400 MHz) (ppm) 7.06 (d, J = 
7.7 Hz, 1H), 6.96 (td, J = 7.7, 1.2 Hz, 1H), 6.63 (td, J = 7.4, 1.1 Hz, 1H), 6.48 (dd, J = 
7.9, 1 Hz, 1H), 3.36-3.24 (m, 2H), 2.91 (sxt, J = 6.5 Hz, 1H), 2.02-1.95 (m, 1H), 1.68 
(dtd, J = 13.0, 6.4, 3.6 Hz, 1H), 1.29 (d, J = 7.0 Hz, 3H). 13C NMR (CDCl3, 100 MHz) 
(ppm) 144.3, 128.5, 126.7, 126.7, 116.9, 114.2, 39.0, 30.2, 29.9, 22.7. HRMS (CI) 
calculated [M+H]+ 148.1121. found [M+H]+ 148.1125.  HPLC (Chiracel IB-3, 98:2 
Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 8.09 min (major with Ir 11) and 
8.62 min (major with Ir 29 and 30). 
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1,2,3,4-Tetrahydroquinoline9 In accordance with published data. 
Yellow solid isolated in up to 95% yield. 1H NMR (CDCl3, 400 MHz) (ppm) 6.98-6.94 
(m, 2H), 6.60 (td, J = 1.1, 7.4 Hz, 1H), 6.47 (d, J = 7.9 Hz, 1H), 3.30 (t, J = 5.4 Hz, 2H), 
2.76 (t, J = 6.4 Hz, 2H), 1.98-1.91 (m, 2H).  
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Chapter 5: Asymmetric 
Transfer Hydrogenation 
of Pyridinium Salts 
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5.1 Introduction 
The reduction of pyridine and derivatives is a desirable process, with the 
piperidine motif being found in many natural and pharmaceutical products. 
However, this remains one of the most challenging C=N bond reductions to achieve. 
Few successful systems have been reported for the hydrogenation of pyridine and 
its salts, all of which require pressurised hydrogen gas as the hydride source1–5 or a 
chiral auxiliary,6 with some achieving only partial reduction of the aromatic system.7 
Only one ATH system has been reported (Scheme 5.1); this system is very substrate 
specific and is only able to partially hydrogenate a limited substrate motif.8 
 
Scheme 5.16 Partial reduction of pyridines via phosphoric acid catalysed ATH. 
The aim of this chapter is to build on the previous systems reported within 
Chapters 3 and 4, further extending the scope of the ATH conditions for the 
reduction of pyridines, with the intention of achieving this transformation under 
unprecedentedly mild ATH conditions. 
 
174 
 
5.2 Screening of Chiral Iridicycles 
 An initial test, using the conditions developed in Chapter 3 for DARA, was 
trialled for the ATH of 2-phenylpyridine (Eq 1, Scheme 5.2). Initial results showed no 
conversion, potentially due to the low electrophilicity of the substrate and its ability 
to bind to the iridium centre rendering it inactive. Therefore the 2-phenylpyridine 
was subjected to an alkylation reaction forming the N-benzyl-2-phenylpyridium 
bromide salt, which has a greater activity towards nucleophilic attack. This species 
was treated to the same ATH conditions with much greater success (Eq 2, Scheme 
5.2). 
 
Scheme 5.17 Model ATH, showing alkylation of the pyridine is required. 
 A range of the developed iridicycles are screened, with a focus on the ee 
achieved. Initial results indicated that the bulky complexes (Ir 11, Ir 14 and Ir 17) 
produced a low ee (Entries 1-3, Table 5.1). More promising results were seen with 
the less bulky oxygenated (Ir 6 - Ir 8) complexes giving an ee up to 34% (Entry 5, 
Table 5.1). The aqueous workup, however, made conversion challenging to 
determine due to the solubility of any remaining starting salt; therefore conversions 
are not quoted. 
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Entry Complex ee (%) 
1 
Ir 17 
20  
2 
Ir 14 
10 
3 
Ir 11 
15 
176 
 
4 
Ir 8 
6 
5 
Ir 7 
34 
6 
Ir 6 
25 
Reaction conditions: 0.5 mmol pyridinium salt, 1 mol% Ir cat, 2.5 mL anhydrous IPA, 0.5 mL 
FT, sealed, overnight.  
Table 5.27 Iridicycle screening for ATH of pyridinium salts. 
 Following the same trend as seen in the DARA (Chapter 3), the small 
electron rich imidazoline-containing complexes were tested to determine if the ee 
could be improved. Once more the 4,5,6-trimethoxy complex Ir 29 offered an 
improved ee (Entry 1, Table 5.2). As seen in the DARA, modification of the phenyl 
rings of the imidazoline with either an electron donating (Ir 35) or electron 
withdrawing group (Ir 36) offered no improvement in ee , once more showing a 
small range for optimal electronic effects (Entry 4 and 5, Table 5.2). Further testing 
showed that the dioxole complex Ir 30 provided the highest ee of 51% (Entry 6, 
Table 5.2). Further modification of the dioxole motif (Ir 31 - Ir 34), with both 
177 
 
electron donating and withdrawing groups, had a negative effect on the ee (Entries 
7-10, Table 5.2). 
 
Entry Complex ee (%) 
1 
Ir 29 
44 
2 
Ir 27 
33 
3 
Ir 21 
2 
4 
Ir 35 
24  
178 
 
5 
Ir 36 
20  
6 
Ir 30 
51 
7 
Ir 31 
46  
8 
Ir 32 
17  
9 
Ir 34 
38 
10 
Ir 33 
10  
Reaction conditions: 0.5 mmol pyridinium salt, 1 mol% Ir cat, 2.5 mL anhydrous IPA, 0.5 mL 
FT, sealed, overnight.  
Table 5.28 Further iridicycle screening for ATH of the pyridinium salt. 
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5.3 Condition Optimisation 
 In an attempt to further improve the ee, the conditions were modified 
utilising the best catalyst (Ir 30) shown above. An initial test was done to determine 
if the ATH would proceed with a greater selectivity under aqueous conditions. The 
reaction did progress, however, the ee showed a significant drop (down to 20% 
from 51%), a much greater difference than seen with aqueous conditions in 
Chapters 3 and 4. This difference may be due to the reduced interaction between 
substrate and complex, whilst the pyridine salt is soluble in these conditions, the 
catalyst is insoluble and therefore effectively sat on the water. As a result no further 
aqueous conditions were trialled. 
Reduced temperatures were also investigated (Table 5.3) to determine the 
impact upon the selectivity, with an increase in ee expected. This showed great 
promise with an increase up to 76% ee at -10 oC (Entry 4, Table 5.3), further 
reduction in temperature offered little improvement. 
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Entry Temp (oC) ee (%) 
1 20 50 
2 10 65 
3 5 69 
4 -10 76 
5 -20 77 
Reaction conditions: 0.5 mmol pyridinium salt, 1 mol% Ir 30, 2.5 mL anhydrous IPA, 0.5 mL 
FT, sealed, overnight.  
Table 5.29 Effect of temperature upon ee. 
 A range of additives were next screened to determine the effect upon the ee 
(Table 5.3). The presence of water had a detrimental impact on the ee (Entry 1, 
Table 5.3), indicating that continued use of dry IPA was essential. Alteration of pH 
by addition of a small amount of formic acid resulted in a significant drop in ee 
(Entry 2, Table 5.4). Addition of triethylamine offered no improvement in ee, whilst 
the addition of a large excess of base resulted in complete loss of activity (Entries 3 
and 4, Table 5.4). Further indicating that the presence of free amine may poison the 
catalyst, as previously observed with the unprotected pyridine. Alternatively, 
significant variation in pH may hinder the reaction, preventing decomposition of the 
FT to the desired hydride and carbon dioxide. 
181 
 
 
Entry Additive ee (%) 
1 H2O (0.1 mL) 52 
2 HCO2H (0.1 mL) 36 
3 NEt3 (0.2 mL) 74 
4 NEt3 (0.3 mL) n.r 
Reaction conditions: 0.5 mmol pyridinium salt, 1 mol% Ir 30, 2.5 mL anhydrous IPA, 0.5 mL 
FT, additive, -10 oC, sealed, overnight.  
Table 5.30 Effect of additives on the ATH of pyridinium salt. 
 In an attempt to determine if the system required the low temperature of     
-10 oC to be maintained for the entire reaction in order to achieve high ee’s, the 
time was shortened and two reactions were run simultaneously. The first was run 
for 9 h at -10 oC and the second was run initially at -10 oC for 4.5 hours, then the 
reaction temperature increased to 20 oC. These showed vastly different ee’s, with 
the first maintaining the ee previous seen (Entry 1, Table 5.5), whilst the second 
returned to that previously seen at 20 oC (Entry 2, Table 5.5). These results show 
that the low temperature must be maintained in order to produce the high ee, 
indicating the ATH reaction is likely to proceed via the known mechanism:9 where 
the reaction occurs via a 1,4-addition, followed by isomerisation and finally a 1,2-
addition (Scheme 5.3). 
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Entry Temp (oC) / Time (h) ee (%) 
1 -10 oC / 9 h 76 
2 -10 oC / 4.5 h + 20 oC / 4.5 h 56 
Reaction conditions: 0.5 mmol pyridinium salt, 1 mol% Ir 30, 2.5 mL anhydrous IPA, 0.5 mL 
FT, -10 oC, sealed, 9 h.  
Table 5.31 Effect of varying temperature half way through reaction time. 
 
Scheme 5.18 Potential mechanism of reduction for 2-substituted pyridinium salts. 
 With the ee optimised, the yield was next investigated using the optimised 
conditions. Under these conditions the yield was only moderate, with 
approximately 50% of the product isolated. To overcome this issue the solvent 
volumes and ratios were altered to improve the conversion. Initial attempts to 
concentrate the mixture down to 2 mL and vary the ratio of IPA to FT proved 
ineffective, maintaining the yield around 50% (Entries 1-4, Table 5.6). The low 
conversion was likely due to the insolubility of the starting salt in the reaction 
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media. Doubling the IPA volume offered an improvement in yield but caused a drop 
in ee (Entry 5, Table 5.6), maintaining the original IPA/FT ratio, whilst doubling the 
volume, showed great improvement allowing for 97% of the product to be isolated, 
with the same high ee as previous (Entry 6, Table 5.6). 
 
Entry IPA (mL) FT (mL) Yield (%) ee (%) 
1 2.5 0.5 52 77 
2 2.5 0.2 56 66 
3 2.5 1 58 73 
4 1.5 0.5 50 74 
5 5 0.5 60 68 
6 5 1 97 77 
Reaction conditions: 0.5 mmol pyridinium salt, 1 mol% Ir 30, X mL anhydrous IPA, X mL FT, -
10 oC, sealed, overnight.  
Table 5.32 Optimisation of yield for ATH of pyridine salt. 
These conditions were deemed optimal for the reaction as > 95% isolated 
yield could be attained with the high ee of 77%. The next stage was to determine 
how widely applicable the ATH could be. 
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5.4 Substrate Scope 
 To explore the substrate scope a range of pyridines were activated via an 
alkylation reaction. This was performed by reflux of the pyridine in benzyl bromide 
until a solid had formed (Scheme 5.4), followed by washing off the excess benzyl 
bromide. 
 
Scheme 5.19 Alkylation of pyridines to form the desired pyridinium salts. 
 Initial salts synthesised were mono substituted and offered varying steric 
and electronic effects at the 2-position, with the phenyl ring being substituted with 
electron donating or withdrawing groups, also being replaced with a alkyl or benzyl 
group. 3-Substituted pyridines were synthesised, bearing different steric and 
electronic effects, using methyl and phenyl groups. Pyridines containing 4-
substitents were prepared, to determine their activity, although the products could 
not be chiral.  
Once subjected to the ATH conditions, the substrates screened showed 
great promise with good yields obtained in all reactions. Upon varying the 
substituent at the 2-position, the isolated yield was seen to decrease (Entries 1-6, 
Table 5.7), even for the less bulky 2-benzyl substituted pyridinium salt, which 
produced a very low ee of just 10% (Entry 4, Table 5.7). The addition of a methoxy 
group upon the phenyl ring produced a similarly high ee, in a moderate yield of 68% 
(Entry 2, Table 5.7).  A similar drop in yield was also seen with various substituents 
at the 3-position (Entries 7 and 8, Table 5.7). The ee’s for the remaining substrates 
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could not be determined, due to a lack of separation on the available chiral HPLC 
columns using various solvent systems. High yields could be achieved for 4-
substituted pyridinium salts (Entries 9 and 10, Table 5.7); whilst these examples 
cannot be chiral, they indicate that substitution in this position is tolerable. 
 
Entry Substrate Yield (%) ee (%) 
1 
 
97 77 
2 
 
68 75 
 
3 
 
65 nd 
4 
 
75 10 
5 
 
40 nd 
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6 
 
60 nd 
7 
 
60 nd 
8 
 
53 nd 
9 
 
75 NA 
10 
 
80 NA 
Reaction conditions: 0.5 mmol pyridinium salt, 1 mol% Ir 30, 5 mL anhydrous IPA, 1 mL FT, -
10 oC, sealed, overnight.  
Table 5.33 ATH of various pyridinium salts. 
Next, the alkylating group on the pyridine nitrogen was varied in an attempt 
to further improve the ee. The bulkier 1-(bromomethyl)naphthylene was chosen in 
the hope that the larger group would make the hydride addition more face 
selective, therefore improving the enantioselectivity. The 2-phenylpyridine was 
alkylated as before (Scheme 5.4) and subjected to the optimised conditions 
(Scheme 5.5). The ATH showed promising results with a high isolated yield (96%); 
however once more the HPLC trace could offer no separation of the peaks. 
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Scheme 5.20 Variation of alkylating group for ATH of pyridinium salt. 
5.5 Conclusions 
The first ATH system for the reduction of pyridinium salts to the 
corresponding fully hydrogenated piperdine. After an extensive complex screen of 
the iridicycles to hand it was determined an electron rich imidazoline containing 
iridicycle was the most active. The selected complex was able to yield high activity 
and moderate enantioselectivity under mild reaction conditions, with a greater 
enantioselectivty being observed when conducted at a reduced temperature whilst 
maintaining a moderate reaction rate. Although ee’s could not be determined for all 
substrates tested, it is believed this would have be possible with the use of SFC.5  
5.6 Experimental 
The iridium complexes were synthesised as described in Chapter 2. 
Anhydrous IPA was purchased from Sigma Aldrich. All other chemicals were 
obtained commercially and used without further purification. NMR spectra were 
recorded on a Bruker 400 MHz NMR spectrometer, with TMS as internal standard. 
HPLC analysis was recorded on an Agilent machine equipped with Chiralcel OJ-3 
column. 
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5.6.1 Standard procedures 
Preparation of pyridinium salts 
A pyridine derivative (5-10 mmol) was weighed into a Schlenk tube loaded with a 
stirrer bar. Benzyl bromide was injected in excess (2.5 eq) and the reaction mixture 
was heated to reflux. Reaction was deemed complete when a solid had formed. The 
solid was washed with hexane until the excess benzyl bromide was removed. 1H 
NMR was used to determine whether the salt had formed and was clean. 
ATH of pyridinium salt 
To a Schlenk tube charged with a stirrer bar, the benzyl protected pyridine (0.5 
mmol) and an iridium complex (1 mol%) were loaded, followed by IPA (5 mL). The 
Schlenk tube was inserted into an Integrity 10 machine, pre-set to -10 oC. FT (1 mL) 
was injected into the Schlenk tube and the reaction mixture left to stir for 16 h. The 
reaction was quenched by the addition of aq NaOH solution (5 mL); the reaction 
mixture was warmed to room temperature. The organics were extracted with EtOAc 
x 3, dried over MgSO4 and concentrated under vacuum. The resulting residue was 
purified by column chromatography, using an eluent of 20% EtOAc in hexane, upon 
which HPLC analysis was performed. 
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5.6.2 Analytical data 
 
1-Benzyl-2-phenylpyridin-1-ium bromide 
White solid. 1H NMR (DMSO-d6, 400 MHz)  (ppm) 9.34 (d, J = 7.0 Hz, 1H), 8.74 (td, J 
= 7.9, 1.4 Hz, 1H), 8.27 (ddd, J = 7.9, 6.3, 1.5 Hz, 1H), 8.13 (dd, J = 7.9, 1.3 Hz, 1H), 
7.66-7.59 (m, 1H), 7.57-7.52 (m, 4H), 7.32-7.26 (m, 3H), 6.92-6.89 (m, 2H), 5.82 (s, 
2H). 13C NMR (DMSO-d6, 100 MHz,) (ppm) 155.56, 146.93, 146.84, 134.25, 132.12, 
131.49, 131.34, 129.47, 129.45, 129.31, 129.17, 128.06, 127.95, 61.68.  
 
1-Benzyl-2-(4-methoxyphenyl)pyridin-1-ium bromide 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 9.65 (d, J = 6.3 Hz, 1H), 8.57 (t, J = 7.9 
Hz, 1H), 8.09 (ddd, J = 7.9, 6.3, 1.5 Hz, 1H), 7.86 (d, J = 7.9Hz, 1H), 7.49 (d, J = 8.7 Hz, 
2H), 7.30-7.27 (m, 3H), 7.07-7.05 (m, 4H), 6.16 (s, 2H), 3.80 (s, 3H). 13C NMR (CDCl3, 
100 MHz) (ppm) 162.06, 155.97, 147.21, 145.46, 133.37, 130.91, 130.31, 129.39, 
129.34, 128.44, 126.94, 123.28, 115.00, 61.89, 55.68. 
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1-Benzyl-2-(4-(trifluoromethyl)phenyl)pyridin-1-ium bromide 
White solid. 1H NMR (CDCl3, 400 MHz) (ppm) 8.61 (td, J = 7.9, 1.3 Hz, 1H), 8.23 
(ddd, J = 7.9, 6.3, 1.5 Hz, 1H), 7.85 (dd, J = 7.9, 1.5 Hz, 1H), 7.8 (s, 4H), 7.32-7.25 (m, 
4H), 7.0 (d, J = 7.9 Hz, 2H), 6.08 (s, 2H). 13C NMR (CDCl3, 100 MHz) (ppm) 154.24, 
147.74, 145.83, 134.74, 132.57, 130.03, 129.96, 129.62, 129.46, 128.49, 128.04, 
126.37, 126.63, 77.25, 63.02. 
 
1,2-Dibenzylpyridin-1-ium bromide 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 9.62 (d, J = 6.1 Hz, 1H), 8.39 (t, J = 7.9 
Hz, 1H), 7.99 (t, J = 6.8 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.38-7.26 (m, 8H), 7.17-7.15 
(m, 2H), 6.31 (s, 2H), 4.85 (s, 2H). 13C NMR (CDCl3, 100 MHz)  (ppm) 157.96, 147.07, 
145.46, 133.22, 131.95, 129.68, 129.65, 129.62, 129.56, 129.53, 128.26, 128.23, 
126.25, 61.46, 39.09.  
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1-Benzyl-2-(4-(trifluoromethyl)phenyl)pyridin-1-ium bromide 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 9.57 (d, J = 5.9 Hz, 1H), 8.43 (td, J = 
7.8, 1.2 Hz, 1H), 8.0-7.96 (m, 2H), 7.37-7.30 (m, 5H), 6.22 (s, 2H), 2.93 (s, 3H). 13C 
NMR (CDCl3, 100 MHz)  (ppm) 155.77, 146.78, 145.59, 131.95, 130.54, 129.57, 
129.37, 128.09, 126.14, 61.82, 21.51. 
 
1-Benzyl-2-ethylpyridin-1-ium bromide 
White solid. 1H NMR (CDCl3, 400 MHz) (ppm) 9.68 (dd, J = 6.1, 1.3 Hz), 8.53 (dt, J = 
7.9, 1.3 Hz, 1H), 8.01 (t, J = 6.90 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.37-7.29 (m, 5H), 
6.27 (s, 2H), 3.24 (q, J = 7.4 Hz, 2H), 1.34 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3, 100 
MHz)  (ppm) 159.96, 147.24, 145.81, 132.41, 129.58, 129.34, 127.80, 125.96, 
61.31, 26.34, 11.91. 
 
1-Benzyl-3-methylpyridin-1-ium bromide 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 9.72 (s, 1H), 9.47 (d, J = 5.9 Hz, 1H), 
8.48 (d, J = 8.3 Hz, 1H), 8.06 (dd, J = 8.3, 5.9 Hz, 1H), 7.84 (dd, J = 8, 1.5 Hz, 2H), 7.71 
192 
 
(dd, J = 6.8, 2.5 Hz, 2H), 7.53-7.45 (m, 3H), 7.35 (t, J = 2.9 Hz, 3H), 6.44 (s, 2H). 13C 
NMR (CDCl3, 100 MHz)  (ppm) 142.37, 141.40, 133.14, 132.67, 130.62, 129.93, 
129.85, 129.70, 129.60, 129.03, 128.13, 127.71, 64.18. 
 
1-Benzyl-3-methylpyridin-1-ium bromide 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 9.46 (s, 1H), 9.36 (d, J = 5.4 Hz, 1H), 
8.15 (d, J = 8.0 Hz, 1H), 7.9 (t, J = 7.0 Hz, 1H), 7.69 (t, J = 3.2 Hz, 2H), 7.38 (d, J = 1.6 
Hz, 3H), 6.25 (s, 2H), 2.58 (s, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 145.63, 144.59, 
142.17, 133.03, 129.96, 129.68, 129.60, 127.58, 63.96, 18.77. 
 
1-Benzyl-4-phenylpyridin-1-ium bromide 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 9.58 (d, J = 7.0 Hz, 2H), 8.12 (d, J = 
7.0 Hz, 2H), 7.72-1.69 (m, 4H), 7.59-7.53 (m, 3H), 7.4-7.35 (m, 3H), 6.31 (s, 2H). 13C 
NMR (CDCl3, 100 MHz) (ppm) 156.58, 144.93, 133.55, 133.06, 132.48, 129.98, 
129.96, 129.66, 129.65, 127.81, 124.84, 63.42. 
 
193 
 
 
1-Benzyl-4-methylpyridin-1-ium bromide 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 9.50 (d, J = 6.4 Hz, 2H), 7.79 (d, J = 
6.4 Hz, 2H), 7.72-7.70 (m, 2H), 7.38-7.31 (m, 3H), 6.24 (s, 2H), 2.59 (s, 3H). 13C NMR 
(CDCl3, 100 MHz)  (ppm) 158.99, 144.17, 133.32, 129.80, 129.57, 129.52, 128.71, 
63.10, 22.26. 
 
1-(Naphthalen-1-ylmethyl)-2-phenylpyridin-1-ium bromide 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 9.82 (d, J = 6.1 Hz, 1H), 8.63 (t, J = 7.8 
Hz, 1H), 8.16 (t, J = 7.0 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.71 
(d, J = 8.4 Hz, 2H), 7.62 (m, 1H), 7.56-7.45 (m, 7H), 7.1 (d, J = 8.4 Hz, 1H), 6.28 (s, 
2H). 13C NMR (CDCl3, 100 MHz)  (ppm) 155.75, 147.36, 145.87, 133.22, 132.92, 
131.60, 131.31, 130.26, 130.20, 129.52, 129.41, 129.17, 128.65, 127.70, 127.52, 
127.21, 126.95, 124.98, 62.36. 
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1-Benzyl-2-phenylpiperidine5 In accordance with published data. 
White solid isolated in 97% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.45 (d, J = 7.3 
Hz, 2H), 7.32 (t, J = 7.3 Hz, 2H), 7.27-7.18 (m, 6H), 3.76 (d, J = 13.6 Hz, 1H), 3.10 (dd, 
J = 11.0, 2.6 Hz, 1H), 2.96 (d, J = 11.5 Hz, 1H), 2.80 (d, J = 13.5 Hz, 1H), 1.96-1.90 (m, 
1H), 1.77 (d, J = 12.5 Hz, 2H),1.62-1.56 (m, 4H). 13C NMR (CDCl3, 100 MHz)  (ppm) 
148.73, 139.82, 128.70, 128.49, 128.00, 127.46, 126.87, 126.51, 69.20, 59.79, 53.36, 
37.01, 26.00, 25.25. HRMS (CI) [M+H]+ calculated 252.1747; found 252.1753. HPLC 
(Chiracel OJ-3, 100% EtOH, 1 mL/min, 25 oC, 220 nm) 1.31 min and 1.66 min. 
 
1-Benzyl-2-(4-methoxyphenyl)piperidine5 In accordance with published data. 
White solid isolated in 68% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.36 (d, J = 9.0 
Hz, 2H), 7.28-7.24 (m, 4H +CDCl3), 6.87 (d, J = 7.9 Hz, 2H), 3.79 (s, 3H), 3.05 (d, J = 
10.9 Hz, 1H), 2.95 (d, J = 11.4 Hz, 1H), 2.78 (d, J = 13.5 Hz, 1H), 1.92 (dt, J = 11.4, 3.1 
Hz, 1H), 1.76 (t, J = 11.9 Hz, 2H), 1.60-1.56 (m, 4H), 1.37 (t, J = 13.3 Hz, 1H). 13C NMR 
(CDCl3, 100 MHz) (ppm) 158.48, 139.95, 137.85, 128.70, 128.41, 127.98, 126.47, 
113.85, 68.46, 59.63, 55.26, 53.45, 37.05, 26.06, 25.30. HPLC (Chiralcel OJ-3, 100% 
EtOH, 1 mL/min, 25 oC, 220 nm) 1.19 min and 1.39 min. 
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1-Benzyl-2-(4-(trifluoromethyl)phenyl)piperidine 
White solid, isolated in 65% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.64-7.55 (m, 
5H), 7.32-7.2 (m, 4H + CDCl3), 3.69 (d, J = 13.8 Hz, 1H), 3.19 (d, J = 11.4 Hz, 1H), 2.99 
(d, J = 11.4 Hz, 1H), 2.84 (d, J = 13.6 Hz, 1H), 1.96 (t, J = 11.4 Hz, 1H), 1.78 (t, J = 13.7 
Hz, 3H), 1.61 (d, J = 9.3 Hz, 2H), 3.39 (t, J = 12.0 Hz, 1H). 13C NMR (CDCl3, 100 MHz) 
(ppm) 149.93, 139.27, 128.57, 128.11, 127.70, 126.73, 125.52, 125.48, 77.23, 
68.75, 29.90, 53.20, 36.99, 25.86, 25.06. HRMS (CI) calculated [M+H]+ 320.1621; 
found [M+H]+ 320.1625. 
 
1,2-Dibenzylpiperidine5 In accordance with published data. 
White solid isolated in 75% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.37-7.27 (m, 
5H), 7.24-7.13 (m, 5H), 4.05 (d, J = 13.6 Hz, 1H), 3.49 (d, J = 13.6 Hz, 1H), 3.70 (d, J = 
9.7 Hz, 1H), 2.8-2.74 (m, 1H), 2.68-2.59 (m, 2H), 2.22 (dt, J = 11.7, 6.0 Hz, 1H), 1.66-
1.61 (m, 1H), 1.54-1.5 (m, 3H), 1.36-1.26 (m, 2H). 13C NMR (CDCl3, 100 MHz)  (ppm) 
129.4, 129.3, 128.8, 128.3, 128.2, 128.1, 128.0, 61.71, 58.5, 50.8, 36.5, 29.3, 25.4, 
22.4. HRMS (ESI) [M+H]+ calculated 266.1909; found 266.1910. HPLC (Chiracel OJ-3, 
100% EtOH, 1 mL/min, 25 oC, 220 nm) 1.41 min and 1.99 min. 
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1-Benzyl-2-methylpiperidine5 In accordance with published data. 
White solid isolated in 40% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.32-7.29 (m, 
4H), 7.24-7.21 (m, 1H), 4.00 (d, J = 13.4 Hz, 1H), 3.48 (s, 1H), 3.2 (d, J = 13.4 Hz, 1H), 
2.73 (d, J = 11.3 Hz, 1H), 2.32-2.29 (m, 1H), 1.95 (t, J = 10.9 Hz, 1H), 1.64 (d, J = 9.6 
Hz, 3H), 1.55-1.47 (m, 2H),1.17 (d, J = 6.3 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 
129.17, 128.05, 126.63, 60.41, 58.52, 52.18, 34.73, 26.05, 24.04, 21.06, 14.22. 
HRMS (CI) calculated [M+H]+ 190.1590;  found [M+H]+ 190.1595.  
 
1-Benzyl-2-ethylpiperidine9 In accordance with published data. 
White solid isolated in 60% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.34-7.29 (m, 
4H), 7.24-7.19 (m, 1H), 3.98 (d, J = 13.5 Hz, 1H), 3.2 (d, J = 13.5 Hz, 1H), 2.74 (dt, J = 
11.6, 3.8 Hz, 1H), 2.23-2.17 (m, 1H), 2.0 (ddd, J = 11.7, 9.5, 4.0 Hz, 1H), 1.71-1.61 (m, 
4H), 1.50-1.42 (m, 3H), 1.31-1.28 (m, 1H), 0.92 (t, J = 7.5 Hz, 3H). 13C NMR (CDCl3, 
100 MHz)  (ppm) 139.96, 128.95, 128.08, 126.57, 61.87, 57.59, 51.97, 29.76, 25.37, 
24.45, 23.87, 9.1. HRMS (CI) calculated [M+H]+ 204.1747. found [M+H]+ 204.1752. 
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1-Benzyl-3-phenylpiperidine 
White solid isolated in 60% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.39-7.16 (m, 
10H), 3.54 (s, 2H), 2.98 (ddt, J = 15.7, 11.0, 1.8 Hz, 1H), 2.84 (tt, J = 12.0, 3.6 Hz, 1H), 
2.07-1.90 (m, 2H), 1.77-1.70 (m, 2H), 1.61 (bs, 1H), 1.45 (dq, J = 12.0, 5.0 Hz, 1H), 
1.26 (s, 1H). 13C NMR (CDCl3, 100 MHz)  (ppm) 144.9, 138.3, 129.2, 128.3, 128.2, 
127.3, 127.0, 126.3, 63.5, 61.0, 53.8, 42.9, 31.7, 25.8. HRMS (CI) calculated [M+H]+ 
252.1747; found [M+H]+ 252.1755. 
 
1-Benzyl-3-methylpiperidine 
White solid isolated in 53% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.31-7.28 (m, 
4H), 7.25-7.21 (m, 1H), 3.47 (s, 2H), 2.79 (t, J = 10.9 Hz, 2H), 1.86 (td, J = 11, 3.6 Hz, 
1H), 1.71-1.50 (m, 6H), 0.83 (d, J = 6.4 Hz, 3H). 13C NMR (CDCl3, 100 MHz) (ppm) 
138.7, 129.2, 128.1, 126.8, 63.6, 62.0, 54.0, 33.0, 31.1, 25.6, 19.8. HRMS (CI) 
calculated [M+H]+ 190.1590. found [M+H]+ 190.1587. 
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1-Benzyl-4-phenylpiperidine 
White solid isolated in 75% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.39-1.30 (m, 
9H), 7.24-7.20 (m, 1H), 6.06 (dt, J = 3.4, 1.8 Hz, 1H), 3.64 (s, 2H), 3.18 (q, J = 2.8 Hz, 
2H), 2.72 (t, J = 5.8 Hz, 2H), 2.58-2.55 (m, 2H), 1.83-1.80 (m, 1H), 1.58-1.56 (m, 1H). 
13C NMR (CDCl3, 100 MHz)  (ppm) 135.00, 129.26, 128.29, 128.27, 127.12, 124.92, 
121.93, 62.76, 53.35, 49.99, 28.06. HRMS (CI) calculated [M+H]+ 252.1747. found 
[M+H]+ 252.1753. 
 
1-Benzyl-4-methylpiperidine 
White solid isolated in 80% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.32-7.29 (m, 
4H), 7.24-7.22 (m, 1H), 3.48 (s, 2H), 2.93 (quin, J = 2.05 Hz, 1H), 2.83 (dt, J = 11.9 3.0 
Hz, 2H), 2.55 (t, J = 5.8 Hz, 1H), 1.93 (td, J = 11.5, 2.4 Hz, 2H), 1.67 (d, J = 1.2 Hz, 1H), 
1.58 (dd, J = 12.6, 1.6 Hz, 2H), 0.91 (d, J = 6.3 Hz, 3H). 13C NMR (CDCl3, 100 MHz) 
(ppm) 129.24, 128.19, 128.10, 126.82, 63.59, 53.98, 53.98, 34.39, 30.81, 21.94. 
HRMS (CI) calculated [M+H]+ 190.1590. found [M+H]+ 190.1594. 
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1-(Naphthalen-1-ylmethyl)-2-phenylpiperidine 
White solid isolated in 96% yield. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.78-7.73 (m, 
3H), 7.65 (s, 1H), 7.5 (d, J = 7.2 Hz, 2H), 7.44-7.39 (m, 3H), 7.34 (t, J = 7.4 Hz, 2H), 
7.22 (t, J = 7.4 Hz, 1H), 3.91 (d, J = 13.5 Hz, 1H), 3.14 (d, J = 10.8 Hz, 1H), 3.00-2.93 
(m, 2H), 2.03-1.93 (m, 1H), 1.79 (d, J = 11.6 Hz, 2H), 1.7-1.58 (m, 3H), 1.42-1.34 (m, 
1H). 13C NMR (CDCl3, 100 MHz) (ppm) 145.78, 137.49, 133.37, 132.65, 128.59, 
127.66, 127.64, 127.55, 127.28, 127.13, 129.96, 125.80, 125.31, 69.40, 60.05, 53.50, 
37.10, 26.08, 25.33. HRMS (ESI) [M+H]+ calculated 302.1909; found 302.1904.  
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Chapter 6: Asymmetric 
Hydrogenation of 
Acyclic Imines 
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6.1 Introduction 
 The reduction of acyclic imines has long been investigated, with chiral 
systems reported as early as the 1970s.1 Although a difficult process to achieve, 
great effort has been put into this area of research,2 leading to a number of 
successful systems. A range of hydrogenation systems have been published with 
iridium the most common and successful metal for the transformation,3–7 although 
a range of metal free  ATH systems have also been established.8–12   
6.2 Catalyst Screening 
 Using the range of complexes described in Chapter 2, an initial reaction was 
performed for the AH of benzyl imine. This was initiated by screening of the small 
simple oxazoline complex (Ir 1) shown in Scheme 6.1, to determine if these 
iridicycles were active. This test proved successful, producing complete conversion 
with 45% ee, in 2,2,2-trifluoroethanol (TFE) under 20 bar hydrogen. 
 
Scheme 6.21 Test reaction for benzyl imine reduction. 
 An extensive screening was undertaken, with a focus on the bulky oxazoline 
complexes described in Chapter 2, all of these provided greater than 90% 
conversion to the desired product. The addition of bulky groups para to the 
oxazoline showed an increase in ee, with a trend of H (Ir 1) < iPr (Ir 9) < tBu (Ir 10), 
with 45%, 70% and 75% respectively (Entries 1-3, Table 6.1). Additional groups on 
the terphenyl ring had varying effects, with most offering no improvement, with 
203 
 
ee’s around 50% as shown in Entries 4 and 5 in Table 6.1. The 4-iso-propyl terphenyl 
complex (Ir 13) showed a significant improvement in ee, achieving 77% (Entry 6, 
Table 6.1). Further extension of the terphenyl group (Ir 17 and Ir 18) offered no 
improvement, with ee’s maintained between 70 and 75% (Entries 8 and 9, Table 
6.1). The best ee of 78%, was achieved using the much smaller 2,4,6-iso-propyl 
complex Ir 11 (Entry 4, Table 6.1). 
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Entry R ee (%) 
1 H Ir 1 45 
2 tBu Ir 10 70 
3 iPr Ir 9 70 
4 
Ir 11 
78 
5 
Ir 12 
52 
6 
Ir 13 
77 
   
7 
Ir 16 
52 
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8 
Ir 17 
73 
9 
Ir 18 
73 
Reaction conditions: 0.5 mmol benzyl imine, 1 mol% Ir cat, 2.5 mL TFE, 20 bar H2, overnight. 
Table 6.1 Screening of complexes for AH of benzyl imine. 
6.3 Condition Optimisation 
 Further examination of the conditions was undertaken to determine if the 
TFE was necessary, or if the transformation could be performed in a cheaper 
solvent. A range of alcohols were screened, as well as other common laboratory 
solvents, none of which showed any conversion (Table 6.2). These results indicated 
that the acidity of the TFE is crucial for the reactivity observed, potentially assisting 
in chloride dissociation from the iridium centre and shifting the equilibrium in 
favour of the active species (Figure 6.1). 
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Entry Solvent Conv (%) ee (%) Entry Solvent Conv (%) ee (%) 
1 TFE 100 78 8 Hexane 0 - 
2 MeOH 0 - 9 PhMe 0 - 
3 EtOH 0 - 10 Benzene 0 - 
4 IPA < 1 - 11 Heptane 0 - 
5 tBuOH 0 - 12 CHCl3 0 - 
6 Ethoxy ethanol 0 - 13 EtOAc 0 - 
7 Ethylene glycol 0 - 14 DMSO 0 - 
Reaction conditions: 0.5 mmol benzyl imine, 1 mol% Ir 11, 2.5 mL solvent, 20 bar H2, 
overnight. 
Table 6.2 Screening of solvents for benzyl imine AH. 
 
Figure 6.13 Potential activation pathway of iridium complex by TFE. 
 A range of fluorinated solvents were screened to further investigate this 
effect. Pleasingly, all of the fluorinated alcohols tested showed great activity for the 
desired reaction with greater than 95% conversion; however the non-protic -
trifluorotoluene showed no activity, further indicating that the acidity of the alcohol 
groups is crucial. The longer chain alcohols (trifluorobutanol and trifluoropentanol) 
showed a reduction in ee to 62% and 56% respectively (Entries 4 and 5, Table 6.3). 
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The shorter chain 2,2-difluoroethan-1-ol once more showed a reduction in ee to 
68% (Entry 3, Table 6.3). Increasing the number of fluorides present on the alcohol 
had little impact on the observed ee, with hexafluoro-iso-propanol producing an ee 
of 71% similar to that observed with TFE (Entries 1 and 2, Table 6.3). 
 
Entry Solvent Conv (%) ee (%) 
1 TFE > 99 78 
2 Hexafluoro-iso-propanol > 95 71 
3 2,2-difluoroethan-1-ol > 95 68 
4 4,4,4-trifluorobutan-1-ol > 95 62 
5 5,5,5-trifluoropentan-1-ol > 95 56 
6 Perfluoro-tert-butanol > 95 40 
7 -trifluoro toluene 0 - 
Reaction conditions: 0.5 mmol benzyl imine, 1 mol% Ir 11, 2.5 mL solvent, 20 bar H2, 
overnight 
Table 6.3 Screening of fluorinated solvents for AH. 
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6.4 Substrate Screening 
 Substrate scope was investigated using the optimised conditions determined 
above, by varying the benzylamine used; this was a good starting point as the 
benzyl group has the potential to be cleaved allowing for the formation of the chiral 
primary amine. Electronics in the para position had little influence upon the 
enantioselectivity with both electron donating (Entries 2 and 4, Table 6.4) and 
electron withdrawing (Entry 3, Table 6.4) groups producing high ee’s, of 71% and 
70% respectively. Having a substituent in the meta position caused a significant 
decrease in ee (Entries 5 and 6, Table 6.4); with the 3,5-ditrifluoromethyl 
substituted imine being reduced down to 16% ee, whilst the electron donating 
dioxole group showed less of a drop in ee, to 34%. Ortho substituents were well 
tolerated, with an electron donating methyl group producing once more a high ee 
of 72% (Entry 7, Table 6.4). Electron withdrawing groups had a similar effect, 
showing only a slight reduction of ee (Entries 8 and 9, Table 6.4). The addition of a 
methoxy group in the ortho position showed a significant drop in conversion, 
although a moderately high ee of 60% was maintained (Entry 10, Table 6.4). 
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Entry R Conv (%) ee (%) Entry R Conv (%) ee (%) 
1 
 
100 78 7 
 
100 72 
2 
 
100 71 8 
 
100 65 
3 
 
100 70 9 
 
100 68 
4 
 
100 77 10 
 
40 60 
5 
 
100 34 11 
 
100 70 
6 
 
100 16     
Reaction conditions: 0.5 mmol benzyl imine, 1 mol% Ir 11, 2.5 mL TFE, 20 bar H2, overnight 
Table 6.4 Effect of variation of the benzyl group on AH. 
 Having established that variation of the benzyl group of the imine showed 
good results, variation of the ketone group was next investigated. Once again 
addition of para groups showed similarly high ee’s whilst maintaining complete 
conversion (Entries 1 and 2, Table 6.5). Variation of the meta group showed more 
varied results with an electron donating group providing a high ee (Entry 3, Table 
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6.5), whilst the use of the electron withdrawing 3-trifluoromethyl group resulted in 
a drop in ee to 50% (Entry 4, Table 6.5). Extension of the R’ group to an ethyl had a 
detrimental impact upon the ee, reducing it to 24% (Entry 5, Table 6.5). 
 
Entry R R’ Conv (%) ee (%) 
1 
 
Me 100 71 
2 
 
Me 100 77 
3 
 
Me 100 70 
4 
 
Me 100 50 
5 Ph Et 100 24 
Reaction conditions: 0.5 mmol benzyl imine, 1 mol% Ir 11, 2.5 mL TFE, 20 bar H2, overnight. 
Table 6.5 Effect of varying substrates on selectivity. 
 To further probe the range of substrates suitable for this system, aniline-
based imines were prepared. Upon being subjected to these standard conditions 
complete conversion was obtained, however, a racemic product was produced 
(Scheme 6.2). This intriguing result led to a mechanistic investigation. 
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Scheme 6.22 Hydrogenation of aniline based imines. 
6.5 Mechanistic Investigation 
6.5.1 Benzyl Imine AH 
An initial reaction, utilising 1 eq of catalyst with respect to the imine, 
showed a decrease in ee to 50%, although 100% conversion was still obtained 
(Scheme 6.3). After the reaction was complete, the starting iridicycle was no longer 
present, with the free oxazoline ligand being observed, indicating the ligand is 
susceptible to reductive elimination in the presence of hydrogen. 
 
Scheme 6.23 AH of benzylimine using 1 eq of complex. 
 An NMR investigation was initiated to probe the mechanistic route and 
identify any intermediates formed. The iridium complex was dissolved in non-
deuterated TFE in a sapphire NMR tube equipped for high pressure experiments13 
(Scheme 6.4). A standard 1D 1H spectra was run, with solvent suppression around 
the 3.88 and 5.02 ppm regions. This removed some areas of the complex spectra, 
but key diagnostic peaks were unaffected (Figure 6.2). 5 eq of imine was then 
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added; upon this addition the iridium complex peaks shifted and a new set of 
resonances, indicative of a new complex was observed. Once the hydrogen pressure 
had reached 20 bar and stabilised (approximately 10 min) the imine was consumed, 
but the new iridium complex remained intact. Hydride peaks were observed at -
15.1 and -15.4 ppm after the reaction was complete (bottom spectra, Figure 6.2), 
these however did not integrate with respect to the complex, indicating a second 
minor iridium species is present. Hydrides around -15 ppm have previously been 
reported for the non-chiral cyclometallated iridium complexes, implying this minor 
species maybe the hydride species of the initial complex (Ir 11).14 
 
Scheme 6.24 High pressure imine hydrogenation for an in situ study. 
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Figure 6.14 Complex in TFE, + 5 eq's of imine, + 20 bar H2 over 10 min at 298 K. 
 Repeating this high pressure reaction at a lower temperature of 253 K, a 
hydride peak can be observed at -8.45 ppm (Figure 6.3). This hydride is only seen in 
a few spectra and at varying intensities with respect to the TFE quartet, indicating 
this may potentially be the active hydride forming and being used in the catalytic 
cycle. Once more the hydride peak did not intergrate with respect to the iridium 
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imine complex, indicating a second minor iridium hydride species is present during 
the catalytic cycle. 
 
Figure 6.15 Low temperature, high pressure imine hydrogenation at 2.5 min intervals. 
To probe the reaction occurring in situ, the iridium complex was dissolved in 
d3-TFE, with 1 eq of the imine and the 1H NMR spectrum recorded (Figure 6.4). This 
showed the formation of a new species. Splitting of the CH2 protons of the benzyl 
group was observed to an AB quartet, with the two peaks shifting upfield to 3.23 
and 3.50 ppm, indicating the formation of one distinct diastereoisomer. The iso-
propyl groups from the ligand also became better defined into distinctly separate 
peaks, as well as showing the downfield shift of the Cp* protons seen previously. In 
TFE, only one set of resonances for the complex is observed (compared to the 2 
seen in CDCl3), showing a loss of chirality at the iridium centre, through loss of 
chloride from the iridium centre forming a pro-chiral species (Figure 6.1). 
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Figure 6.16 Original Ir complex, Ir complex bound to 1 eq of imine after 2 days. 
 Low pressure and temperature in situ NMR reactions were conducted to 
sufficiently slow the rate of reaction in order to better observe the intermediates 
formed in this transformation. The first combined 4 eq of imine with the iridium 
complex (Scheme 6.5), which showed complete formation of a new catalytic 
species. The mixture was cooled to 253 K and sealed under an atmospheric H2 
pressure, before being warmed to 298 K over 6 h. The newly formed complex did 
not appear to alter during the reaction although reduction of the imine was 
observed from 253 K (Figure 6.5 and 6.6). No hydride species were observed, at the 
low pressure, possibly due to the low concentration of hydrogen in the system. 
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Scheme 6.25 Low pressure in situ imine hydrogenation.  
 
Figure 6.17 Atmospheric pressure reduction of benzyl imine. 
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Figure 6.18 Ir cat + 4 eq imine at atmospheric H2 pressure cooled to 253 K, warmed to 263 
K, 298 K, Below spectra is close up of new complex peaks remaining intact and product 
forming. 
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6.5.2 Modelling of the New Iridium Species 
After running 1H, 13C, COSY, HMQC and 1H-1H NOESY NMR analysis upon the 
new complex in d3-TFE, it could be determined how the two species lay in relation 
to one another. This data was compared to a molecular mechanics (MM) model of 
the iridium imine complex, with both iridium diastereoisomers being modelled. The 
lowest energy structures that were in agreement with the proton-proton 
correlations observed in the NOESY NMR, i.e. < 3 Å apart, were carried forward for 
DFT calculations by Dr Neil Berry. Three structures were selected; two E imines as 
an energy difference was observed, dependent upon the face of the iridium it was 
bound to and one Z imine, as no energy difference was observed between these 
structures. The structures obtained by DFT calculations are shown below (Figure 6.7 
and 6.8). The Z imine showed the lowest energy with the imine group on the 
opposite face from the chiral groups. The top E imine showed an energy difference 
of +2.55 kcal/mol from the Z imine, once more with the imine on the opposite face 
to the chiral groups. The structure, shown on the bottom, shows an energy 
difference of +13.41 kcal/mol from the Z imine, this structure also shows the imine 
group in close proximity to the chiral groups, indicating this species may be the 
chiral inducing form, whilst the others enable the formation of the racemic product. 
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Figure 6.19 Z imine bound to the iridium complex with an energy of -1639042.89 
kcal/mol. 
 
Figure 6.20 E imine on opposite faces of the iridium; Top showing an energy of                         
-1639040.333 kcal/mol, Bottom with an energy of -1639029.482 kcal/mol. 
 Once bound the imine could undergo either intramolecular hydrogenation, 
reducing the bound imine, or intermolecular hydrogenation, in which the imine 
would stay bound and a second molecule of imine would be reduced. To determine 
Key 
Black = C 
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Blue = N 
Purple = O 
Key 
Black = C 
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Purple = O 
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the feasibility both the S and R amine were modelled bound onto the iridium 
(Figure 6.9). Although both the R and S amines showed similar energies an energy 
difference of 4.12 kcal/mol was observed between them. A much greater difference 
in energy from the starting imine was observed at +25413.38 kcal/mol. This shows a 
significantly large energy difference, indicating the intramolecular pathway would 
be slow to occur.  
 
Figure 6.21 Top R amine  bearing an energy of -1664429.454 kcal/mol, Bottom S amine 
with an energy of -1664433.572 kcal/mol. 
 The pre-formed imine iridium complex was subjected to atmospheric H2 at 
298 K, however, no reduction of the bound imine was observed, although the small 
excess of free imine was reduced. After 24 h a small amount of iridium complex had 
decomposed, with free ligand being observed (Scheme 6.6). After decomposition 
Key 
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had been observed, several hydride species could be detected around -15 ppm 
(Figure 6.10), indicating multiple inactive hydride formed on the free iridium centre. 
 
Scheme 6.26 Attempted hydrogenation of the imine bound complex. 
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Figure 6.22 Ir cat + 1eq of imine, left 2 days for complex formation, add H2, 10 hours later2 
7 hours later. 
6.5.3 Changing Benzyl imine 
 To further determine if the hydrogenation would occur via an intra- or 
intermolecular mechanism the iridium complex was mixed with 6 eq of the benzyl 
imine until complete formation of the new species was observed by 1H NMR. 3 eq 
of p-methylbenzyl imine was then added (Scheme 6.7) and monitored for an hour at 
room temperature. During this time it was observed that scrambling of the bound 
imine iridium complex occurred, shown by the formation of additional doublets 
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between 3.0 and 3.5 ppm, demonstrating at room temperature the bound imine is 
labile, without decomposition of the complex (Figure 6.11). 
 
Scheme 6.27 Scrambling of the benzyl imine bound complex with p-methylbenzylimine. 
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Figure 6.23 6 eq of Benzyl imine with iridium complex, + 3 eq p-Methylbenzylimine, 
Mixture of both imine bound complexes (6:1 ratio). 
After cooling to 253 K and the addition of hydrogen gas at an atmospheric 
pressure, it can be seen that both species are reduced at a similar rate, whilst 
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maintaining the ratio of bound benzyl imine to p-methylbenzyl imine complex 
(Figure 6.12). 
 
Figure 6.24 The scrambled benzyl imine/p-methyl benzyl imine complex from above with 
addition of H2 253K, Increase to 273K, then upto 298K.  
 A further experiment of reducing the temperature for the pre-formed benzyl 
imine iridium complex, prior to the addition of the p-methylbenzyl imine was run 
(Figure 6.13). This showed that at a low temperature of 253 K, conversion of just the 
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p-methyl benzyl imine occurred, with the low rate of conversion potentially being 
caused by the low pressure and temperature. Upon warming it was seen that 
scrambling occurred once more, such that both complexes were present. During 
scrambling the bound benzyl imine was not reduced but removed intact, indicating 
that an intermolecular hydrogenation is occurring, rather than an intramolecular 
hydrogenation. 
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Figure 6.25 Blue Benzyl imine iridium complex 253 K plus p-methyl imine with 
atmospheric pressure H2, 263 K, 273 K, 298 K scrambling of bound imine. 
6.5.4 Aniline Monitoring 
 To determine if this new iridium species was catalytically active for the 
aniline imine, 1 eq of the benzyl imine was stirred with the iridium complex in TFE 
for 30 min. The aniline imine was added and the reaction ran as previously stated 
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(Scheme 6.8). Complete conversion was obtained with an ee of 10% for the aniline 
product, compared to 0% ee during screening. This indicates that this complex is 
responsible for the chiral induction to the product; it was later shown that 30 min 
was insufficient time to completely form the new complex at 1 eq of imine to 
iridium complex, indicating a higher enantioselectivity may be observed if a longer 
pre-mixing time was used. 
 
Scheme 6.28 AH of aniline imine, utilising the benzyl imine bound complex. 
In an attempt to further understand the system, similar 1H NMR 
experiments were performed on the aniline imine. No new species was observed 
upon addition of the aniline imine to the iridium complex, as was seen with the 
benzyl imine. The conversion occurred at a faster rate initially, before slowing 
down, which may be due to a lack of H2. This suggested that the standard iridicycle 
was able to perform the reaction, the same TFE hydride was also formed initially     
(-10 ppm). Multiple hydrides were seen in the final spectra after the reaction was 
complete, indicating the standard complex is less stable and decomposes to a large 
number of iridium hydride species, with those around -15 ppm once more being 
observed (bottom spectra, Figure 6.14).  
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Figure 6.26 Iridium catalyst with 5 eq of aniline at 253 K, additions of atmospheric H2, 
heated to 298 K. 
 A pre-formed sample of the benzyl imine iridium complex was treated with 5 
eq of the aniline-based imine and subjected to the above conditions (Figure 6.15). 
This showed a much slower rate of reaction than previously observed for the aniline 
imine, indicating the benzyl imine bound complex is stable. After 24 hours complete 
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conversion of the aniline imine was observed, although some catalyst 
decomposition was observed. 
 
Figure 6.27 Preformed benzylimine iridium bound complex plus aniline cooled to 253K 
atmospheric pressure H2, warmed to 263 K, warmed to 298 K 24 hours later. 
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6.5.5 Solvent Test 
It was previously observed (Table 6.2) that the AH was inactive in common 
laboratory solvents, such as MeOH and CHCl3. These solvents were therefore 
investigated via 1H NMR for their varied effect upon the iridium complex. 
Chloroform was trialled initially; this showed no change in the complex upon 
addition of the benzyl imine (Figure 6.16). After treatment with atmospheric H2 gas, 
no change was observed in the complex or conversion of imine, even after being 
sealed at room temperature for 3 days. 
  
Figure 6.28 Ir cat in CDCl3, addition of imine, addition of atmospheric pressure H2 left for 3 
days. 
Methanol was also examined, this showed no alteration of the standard Ir 
11 complex, although it was rapidly seen that the key CH2 imine peak was lost 
(Figure 6.17). There was no formation of new peaks observed to specify product 
synthesis. This indicates the formation of the new complex is unique to the TFE 
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system, emphasising the formation of this new species in situ may be crucial for the 
AH to occur. 
 
Figure 6.29 Ir cat In MeOD, plus 1 eq of imine, addition of H2 (1 atm) 7.5 min apart. 
6.5.6 Proposed mechanism 
 Considering the output from the modelling and experimental observations 
an intermolecular mechanism appeared to be likely (Figure 6.18). The 
hydrogenation is only possible in TFE as no other solvent allows for removal of the 
chloride and is therefore shown to be inactive. It is clear that the major form of the 
iridium species is bound to the imine and that the bound imine is not hydrogenated, 
but maybe removed intact at room temperature. The presence of this imine bound 
species also offers an increase in the enantioselectivity observed, indicating this 
species is plays a key role in the reduction step. A second minor iridium species is 
present, which appears to be the hydride species, though this species was too weak 
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to be fully observed and characterised, from the high pressure NMR it was seen that 
hydride species of -15 ppm were formed, consistent with an iridicycle hydride 
species (such as Ir 11). For the minor hydride species observed to have resulted 
from the bound imine iridium complex, ligand dissociation would have to occur; 
either through the dissociation of the cyclometallated nitrogen, or through the 
slilppage of the cyclopentadienyl species, to allow a hydride to bind. An interaction 
between the two iridium species would account for the increased enantioselectivity 
observed for the aniline imine, as well as the reduction in ee at a 1:1 imine iridium 
ratio, although the nature of this coordination could not be observed. The 
decomposition of the complex has been observed after the reaction was complete 
via reductive elimination, to yield free ligand and multiple iridium hydride species. 
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Figure 6.30 Proposed mechanism. 
6.6 Conclusions 
 The results presented in this chapter demonstrate further utility for the 
bulky oxazoline containing complexes. Proving highly active under mild 
hydrogenation conditions for the asymmetric reduction of benzyl imines, yielding 
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the desired amines in both high conversions and moderate to high ees. The 
corresponding complex however, showed high conversion but racemic amines 
when utilised for the reduction of aryl imines. This observation initiated a 
mechanistic investigation, identifying the formation of a novel iridium species upon 
subjection to the catalytic conditions. The in-situ formed species was revealed to 
have formed via the co-ordination of the imine onto the existing iridium species. 
Further mechanistic and modelling investigation indicated the hydrogenation 
occurred via an intermolecular hydrogenation pathway in which the un-bound 
imine is hydrogenated in preference over the iridium bound imine species. 
6.7 Experimental 
IPA, toluene and DCM were dried on a MB-SPS 800 and methanol was dried 
over magnesium and iodine; all other chemicals were used as purchased. Standard 
NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer, with TMS as 
internal standard. High pressure mechanistic NMRs were run on a Bruker 200 MHz 
spectrometer in non-deuterated TFE. Low pressure mechanistic NMRs were run on 
a BrukerAvance 400 MHz spectrometer using d3-TFE. COSY and HSQC were run on a 
BrukerAvance 500 MHz. NOESY was run on a BrukerAvance 400 MHz spectrometer 
with mixing time of 0.5 s. Modelling studies were conducted on Spartan ’08 and 
presented using Chemcraft software. 
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6.7.1 Standard Procedures 
Imine synthesis 
Imines were synthesised by the literature procedure. Ketone (1 eq) and amine 
(1.1eq) were refluxed in toluene in the presence of a catalytic amount of PTSA. The 
imines were purified by recrystallisation or distillation. 
Imine hydrogenation 
A glass lined autoclave was charged with a stirrer bar, the imine (1 eq, 0.5 mmol) 
and iridicycle (1 mol%), followed by TFE (2.5 mL). The autoclave was sealed and 
flushed three times with hydrogen gas, then charged to 20 bar and allowed to stir at 
room temperature for 16 h. The resulting mixture was concentrated under vacuum. 
The residue was purified by column chromatography in 10% EtOAc in hexane, in 
quantative yields. 
High pressure NMR hydrogenation 
A Sapphire NMR tube was charged with catalyst (0.012 mmol, 10 mg), to which 2 
mL TFE was added. An NMR spectrum was obtained, to allow for solvent 
suppression to be conducted. The imine (0.06 mmol, 2.5 mg) in TFE (0.5 mL) was 
charged into the tube. Another spectrum was run. Hydrogen gas was bubbled 
through the solution until a pressure of 20 bar was achieved. The hydrogen flow 
was reduced and multiple spectra were run. 
Low pressure NMR hydrogenation 
A Schlenk NMR tube was charged with imine and catalyst (0.0097 mmol, 8.4 mg, 
ratios described above) and 0.5 mL d3-TFE was added. The tube was sealed and 
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cooled to 253 K. After a lock and shim was completed the NMR tube was removed 
from the machine and maintained at 253 K in a cardice/acetonitrile bath. Balloon 
pressure H2 was added via a long needle and bubbled through the solution. The 
tube was sealed once more and inserted into the NMR machine and multiple NMR 
spectra ran. The temperature was slowly raised by 5 to 10 K every hour, until room 
temperature was reached or the reaction was complete.  
6.7.2 Analytical data 
 
(E)-1-Phenyl-N-(1-phenylethylidene)methanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.88-7.85 (m, 2H), 7.44-7.32 (m, 8H), 
4.82 (s, 0.3H, minor isomer), 4.75 (s, 1.77H, major isomer), 2.38 (s, 0.4H, minor 
isomer), 2.34 (s, 2.6H, major isomer). 13C NMR (CDCl3, 100 MHz)  (ppm) 166.09, 
141.09, 140.53, 129.63, 128.41, 128.24, 127.71, 126.76, 126.57, 55.70, 15.90. HRMS 
(CI) [M+H]+ calculated 210.1277 [M+H]+ found 210.1286. CHN C15H15N calculated C, 
86.08; H, 7.22; N, 6.69; found C, 86.65; H, 7.03; N, 5.43.  
 
(E)-N-(1-Phenylethylidene)-1-(p-tolyl)methanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.87-7.83 (m, 2H), 7.39-7.37 (m, 
3H), 7.31 (d, J = 7.9 Hz, 2H), 7.16 (d, J = 7.9 Hz, 2H), 4.70 (s, 2H), 2.34 (s, 3H), 3.32 (s, 
3H).  13C NMR (CDCl3, 100 MHz)  (ppm) 165.87, 141.15, 137.49, 136.07, 129.58, 
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129.10, 128.23, 127.64, 126.77, 55.50, 21.15, 15.85. HRMS (CI) [M+H]+ calculated 
244.1434, [M+H]+ found 224.1439. 
 
1-Phenyl-N-(1-(m-tolyl)ethylidene)methanamine (mixture of E and Z) 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.87-7.84 (m, 2H), 7.40-7.36 (m, 
4H), 6.91-6.86 (m, 3H), 4.73 (s, 0.2H, minor isomer), 4.68 (s, 1.8H, major isomer), 
3.84 (s, 0.3H, minor isomer), 3.81 (s, 2.7H, major isomer), 2.36 (s, 0.3H, minor 
isomer), 2.33 (s, 2.7H, major isomer). 13C NMR (CDCl3, 100 MHz)  (ppm) 165.76, 
158.36, 141.14, 132.73, 129.58, 128.78, 128.22, 126.75, 113.83, 55.32, 45.93, 15.84. 
HRMS (CI) [M+H]+ calculated 240.1383 [M+H]+ found 240.1392. CHN C16H17NO 
calculated C, 80.30; H, 7.16; N, 5.85; found C, 79.15; H, 7.08; N, 5.65. 
  
Cream solid. 1H NMR (CDCl3, 400 MHz)  (ppm)7.86-7.84 (m, 2H), 7.40-7.37 (m, 3H), 
6.97 (d, J = 1.27 Hz, 1H), 6.88-6.76 (m, 2H), 5.94 (s, 2H), 4.68 (s, 0.2H minor isomer), 
4.63 (s, 1.8H, major isomer), 2.36 (s, 0.3H, minor isomer), 2.33 (s, 2.7H, major 
isomer). 13C NMR (CDCl3, 100 MHz)  (ppm)165.88, 147.71, 146.19, 141.01, 134.59, 
129.64, 128.23, 126.74, 120.55, 108.48, 108.12, 100.84, 55.44, 15.90. HRMS (CI) 
[M+H]+ calculated 254.1176, [M+H]+ found 254.1186. 
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(E)-1-(3,5-Bis(trifluoromethyl)phenyl)-N-(1-phenylethylidene)methanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm)7.97 (s, 2H), 7.89-7.87 (m, 2H), 7.79 
(s, 1H), 7.45-7.41 (m, 3H), 4.78 (s, 2H), 2.39 (s, 3H). 13C NMR (CDCl3, 100 MHz)  
(ppm)167.26, 143.43, 140.39, 131.68, 131.35, 130.10, 128.41, 128.00, 126.72, 
120.68, 54.67, 16.30. 
 
(E)-N-(1-Phenylethylidene)-1-(o-tolyl)methanamine 
Cream solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.88-7.86 (m, 2H), 7.40-7.38 (m, 
4H), 7.20-7.17 (m, 3H), 4.69 (s, 2H), 2.39 (s, 3H), 2.34 (s, 3H).  13C NMR (CDCl3, 100 
MHz)  (ppm) 165.98, 141.11, 138.49, 136.06, 130.08, 129.61, 128.24, 126.74, 
126.64, 125.98, 53.82, 19.43, 15.78. 
 
(E)-N-(1-Phenylethylidene)-1-(o-tolyl)methanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.90-7.87 (m, 2H), 7.66 (d, J = 6.4 
Hz, 1H), 7.42-7.37 (m, 4H), 7.28-7.17 (m, 2H), 4.77 (s, 2H), 2.36 (s, 3H). 13C NMR 
(CDCl3, 100 MHz)  (ppm)166.77, 140.97, 138.11, 133.15, 129.77, 129.33, 128.30, 
127.76, 126.86, 126.78, 53.04, 16.12. 
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(E)-1-(2-Bromophenyl)-N-(1-phenylethylidene)methanamine 
Orange solid. 1H NMR (CDCl3, 400 MHz)  (ppm)7.91-7.88 (m, 2H), 7.66 (d, J = 7.6 
Hz, 1H), 7.58  (dd, J = 7.9, 0.8 Hz, 1H), 7.43-7.41 (m, 3H), 7.33 (td, J = 7.61, 0.7 Hz, 
1H), 7.13 (td, J = 7.6, 1.3 Hz, 1H), 4.75 (s, 2H), 2.37 (s, 3H).  13C NMR (CDCl3, 100 
MHz)  (ppm)166.75, 140.94, 129.67, 132.40, 129.78, 129.54, 128.30, 128.09, 
127.47, 126.78, 123.48, 55.61, 16.19. HRMS (CI) [M+H]+ calculated 288.0382 [M+H]+ 
found 288.0375. 
  
(E)-1-(2-Methoxyphenyl)-N-(1-phenylethylidene)methanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.89-7.87 (m, 2H), 7.51 (d, J = 7.4 
Hz, 1H), 7.39 (dd, J = 4.0, 2.6 Hz, 3H), 6.99-6.85 (m, 3H), 4.83 (s, 0.2H, minor isomer), 
4.74 (s, 1.8H, major isomer), 3.86 (s, 3H), 2.39 (s, 0.3H, minor isomer), 2.33 (s, 2.7H, 
major isomer). 13C NMR (CDCl3, 100 MHz)  (ppm) 166.17, 156.88, 141.32, 129.52, 
128.79, 126.47, 128.22, 127.43, 126.78, 120.58, 109.94, 55.34, 50.05, 15.85. HRMS 
(CI) [M+H]+ calculated 240.1383 [M+H]+ found 240.1392. CHN C16H17NO calculated 
C, 80.30; H, 7.16; N, 5.85; found C, 79.04; H, 7.02; N, 5.59. 
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(E)-1-(2-Bromophenyl)-N-(1-phenylethylidene)methanamine 
Yellow solid. 1H NMR (400 MHz, CDCl3)  (ppm)7.78-7.75 (m, 2H), 7.37-7.35 (m, 
5H), 7.16 (t, J = 7.80 Hz, 1H), 4.88 (s, 2H), 2.43 (s, 3H). 13C NMR (CDCl3, 100 MHz)  
(ppm) 177.5, 140.8, 128.3, 128.2, 127.9, 127.4, 126.7, 126.3, 56.5, 39.2, 20.2. 
 
(E)-1-Phenyl-N-(1-(p-tolyl)ethylidene)methanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.86-7.84 (m, 2H), 7.38-7.36 (m, 
3H), 7.31 (d, J = 7.8 Hz, 2H), 7.15 (d, J=7.8 Hz, 2H),  4.76 (s, 0.2H, minor isomer), 4.70 
(s, 1.8H, major isomer), 2.36 (d, J = 0.8 Hz, 0.4H, minor isomer), 2.34 (s, 2.8H, major 
isomer), 2.31 (s, 2.8H, major isomer). 13C NMR (CDCl3, 100 MHz)  (ppm)165.86, 
141.16, 137.51, 136.07, 129.59, 129.11, 128.23, 127.65, 126.78, 55.51, 21.16, 15.84. 
HRMS (CI) [M+H]+ calculated 244.1434, [M+H]+ found 224.1437. CHN C16H17N 
calculated C, 86.05; H, 7.67; N, 6.27; found C, 85.23; H, 7.46; N, 5.85. 
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(E)-N-(1-(4-Chlorophenyl)ethylidene)-1-phenylmethanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.81 (d, J = 8.7 Hz, 2H), 7.43-7.39 
(m, 2H), 7.37-7.34 (m, 4H), 7.28-7.24 (m, 1H), 4.83 (s, 0.12H, minor isomer), 4.72 (s, 
1.88H major isomer), 2.36 (s, 0.15H minor isomer), 2.31 (s, 2.85H, major isomer). 
13C NMR (CDCl3, 100 MHz)  (ppm)164.75, 140.33, 139.34, 135.71, 128.46, 128.39, 
128.13, 127.79, 126.67, 55.76, 15.72. HRMS (CI) [M+H]+ calculated 244.0888, 
[M+H]+ found 244.0892. CHN C15H14ClN calculated C, 73.92; H, 5.79; N, 5.75; found 
C, 73.43; H, 5.61; N, 4.65. 
 
(E)-1-Phenyl-N-(1-(m-tolyl)ethylidene)methanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm)  7.70 (s, 1H), 7.63 (d, J = 7.7 Hz, 1H), 
7.43-7.29 (m, 5H), 7.25-7.20 (m, 2H), 4.83 (s, 0.1H, minor isomer), 4.74 (s, 1.9H 
major isomer), 2.41 (s, 0.2H minor isomer), 2.39 (s, 2.8H major isomer), 2.36 (s, 
0.2H, minor isomer), 2.32 (s, 2.8H major isomer). 13C NMR (CDCl3, 100 MHz)  (ppm) 
166.41, 141.12, 140.52, 137.87, 130.40, 128.41, 128.12, 127.72, 127.36, 123.96, 
55.71, 21.52, 16.01. HRMS (CI) [M+H]+ calculated 244.1434, [M+H]+ found 
224.1436. 
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(E)-1-Phenyl-N-(1-(m-tolyl)ethylidene)methanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 8.12 (s, 1H), 8.05 (d, J = 7.8 Hz, 1H), 
7.64 (d, J = 7.7 Hz, 1H), 7.50 (t, J = 7.8 Hz, 1H), 7.44-7.35 (m, 5H), 4.83 (s, 0.2H, 
minor isomer), 4.75 (s, 1.8H, major isomer), 2.39 (s, 0.3H, minor isomer), 2.36 (s, 
2.7H, major isomer). 13C NMR (100 MHz, CDCl3)  (ppm)161.51, 141.64, 140.12, 
128.75, 128.51, 128.30, 128.00, 127.72, 126.76, 126.26, 126.22, 126.18, 126.15, 
123.66, 123.62, 123.58, 123.54, 55.91, 15.83. HRMS (CI) [M+H]+ calculated 
278.1151, [M+H]+ found 278.1155. 
 
(E)-1-Phenyl-N-(1-phenylpropylidene)methanamine 
Yellow liquid. 1H NMR (CDCl3, 400 MHz) (ppm) 7.88-7.85 (m, 2H), 7.42-7.34 (m, 
7H), 7.14 (m, 1H), 4.81 (s, 2H), 2.82 (q, J = 7.5 Hz, 2H), 1.16 (t, J = 7.5 Hz, 3H). 13C 
NMR (CDCl3, 100 MHz)  (ppm) 129.56, 128.51, 128.39, 128.31, 127.99, 127.65, 
127.02, 126.54, 126.35, 54.81, 22.14, 11.63. HRMS (CI) [M+H]+ calculated 244.1434 
[M+H]+ found 244.1438. 
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N-Benzyl-1-phenylethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.36-7.21 (m, 10H), 3.81 (q, J = 6.5 Hz, 
1H), 3.62 (q, J = 13.1 Hz, 2H), 1.63 (bs, 1H), 1.37 (d, J = 6.5 Hz, 3H).  13C NMR (CDCl3, 
100 MHz) (ppm) 145.57, 140.64, 128.50, 128.40, 128.17, 126.97, 126.88, 126.74, 
57.51, 51.67, 24.55. HRMS (CI) [M+H]+ Calculated 212.1434, [M+H]+ found 
212.1444. CHN calculated C, 85.26; H, 8.11; N, 6.63; found C, 85.41; H, 8.17; N, 6.61. 
HPLC (Chiralpak IB-3, 99:1 Hex:IPA + 0.1% HNEt2, 1 mL/min, 25 
oC, 254 nm) 5.65 min 
(major) and 6.09 min. 
 
N-(4-Methylbenzyl)-1-phenylethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.35-7.34 (m, 4H), 7.6-7.26 (m, 1H), 
7.17-7.10 (m, 4H), 3.80 (q, J = 6.6 Hz, 1H), 3.58 (q, J = 13.0 Hz, 2H), 2.33 (s, 3H), 1.60 
(bs, 1H), 1.35 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 145.62, 137.57, 
136.44, 129.08, 128.49, 128.13, 126.94, 126.76, 57.41, 51.36, 24.53, 21.31. HRMS 
(CI) [M+H]+ calculated 226.1590, [M+H]+ found 226.1596. CHN C16H19N calculated C, 
85.28; H, 8.50; N, 6.22; found C, 86.21; H, 8.58; N, 6.41. HPLC (Chiralpak IB-3, 
99.8:0.2 Hex:IPA (+ 0.1% HNEt2), 0.5 mL/min, 25 
oC, 254 nm) 16.83 min (major) and 
17.72 min.  
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N-(4-Fluorobenzyl)-1-phenylethanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.35-7.33 (m, 4H), 7.25-7.22 (m, 2H), 
7.08 (dt, J = 28.5, 8.8 Hz, 1H), 6.98 (t, J = 8.8 Hz, 2H), 3.79 (q, J = 6.6 Hz, 1H), 3.58 (q, 
J = 12.4 Hz, 2H), 1.65 (bs, 1H), 1.37 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  
(ppm) 145.42, 129.70, 129.62, 128.53, 127.02, 126.68, 115.22, 115.01, 57.53, 50.91, 
24.48. MS (CI) [M+H]+ Calculated 230.3, [M+H]+ found 230.1. HPLC (Chiralpak IB-3, 
99.8:0.2 Hex:IPA (+ 0.1% HNEt2), 0.5 mL/min, 25 
oC, 254 nm) 15.12 min (major) and 
15.71 min. 
 
N-Benzyl-1-(4-nitrophenyl)ethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.35-7.33 (m, 4H), 7.26-7.25 (m, 1H), 
7.19 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 3.82-3.77 (m, 4H), 3.56 (q, J = 12.9 
Hz, 2H), 1.36 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz) (ppm)158.55, 145.65, 
132.80, 129.32, 128.48, 126.93, 126.74, 113.76, 57.40, 55.30, 51.05, 24.55. HRMS 
(CI) [M+H]+ Calculated 242.1539, [M+H]+ found 242.1545. CHN C16H21NO calculated 
C, 79.63; H, 7.94; N, 5.80; found C, 79.86; H, 8.04; N, 5.83. HPLC (Chiralpak IB-3, 
99.8:0.2 Hex:IPA (+ 0.1% HNEt2), 0.5 mL/min, 25 
oC, 254 nm) 25.69 min (major) and 
27.27 min. 
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Yellow oil. 1H NMR (CDCl3, 400 MHz) (ppm) 7.35-7.34 (m, 4H), 7.26-7.23 (m, 1H), 
6.8 (d, J = 1.3 Hz, 1H), 6.75-6.69 (m, 2H), 5.93 (s, 2H), 3.79 (q, J = 6.6 Hz, 1H), 3.52 (q, 
J = 13.0 Hz, 2H), 1.59 (bs, 1H), 1.36 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 100 MHz,)  
(ppm) 147.64, 146.41, 145.52, 134.62, 128.50, 126.97, 126.71, 121.18, 108.74, 
108.06, 100.87, 57.33, 51.41, 24.53. HRMS (CI) calculated [M+H]+ 256.1332, found 
[M+H]+ 256.1325. HPLC (Chiralpak IB-3, 99.8:0.2 Hex:IPA + 0.1% HNEt2, 0.5 mL/min, 
25 oC, 254 nm) 26.39 min (major) and 30.42 min.  
 
N-(3,5-Bis(trifluoromethyl)benzyl)-1-phenylethanamine 
Orange oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.76 (s, 2H), 7.74 (s, 1H), 7.38-7.29 (m, 
5H), 3.80 (q, J = 6.6 Hz, 1H), 3.75 (s, 2H), 1.42 (d, J = 6.6 Hz, 3H. 13C NMR (CDCl3, 100 
MHz)   (ppm) 144.84, 143.41, 131.59, 131.26, 128.64, 128.18, 127.26, 126.61, 
120.81, 58.00, 50.81, 24.47. HRMS (CI) calculated [M+H]+ 348.1181, found [M+H]+ 
348.1190. HPLC (Chiralpak IB-3, 99.8:0.2 Hex:IPA (+ 0.1% HNEt2), 0.5 mL/min 25 
oC, 
254 nm) 12.63 min (major) and 13.66 min. 
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N-Benzyl-1-phenylethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.40-7.33 (m, 4H), 7.28-7.24 (m, 2H + 
CDCl3), 7.17-7.13 (m, 3H), 3.84 (q, J = 6.6 Hz, 1H), 3.60 (s, 2H), 2.26 (s, 3H), 1.53 (bs, 
1H), 1.38 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 145.70, 138.56, 
136.45, 130.28, 158.58, 128.47, 126.97, 126.47, 125.90, 58.23, 49.67, 30.98, 24.60, 
18.96. HRMS (CI) calculated [M+H]+ 226.1590, found [M+H]+ 226.1591. HPLC 
(Chiralpak IB-3, 99.5:0.5 Hex:IPA (+ 0.1% HNEt2), 1 mL/min, 25 
oC, 254 nm) 7.70 min 
and 8.23 min (major). 
 
N-(2-Chlorobenzyl)-1-phenylethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz,)  (ppm) 7.39-7.30 (m, 6H), 7.26-7.23 (m, 1H), 
7.22-7.16 (m, 2H), 3.82-3.67 (m, 3H), 1.8 (bs, 1H), 1.37 (d, J = 6.5 Hz, 3H). 13C NMR 
(CDCl3, 100 MHz)  (ppm) 145.28, 137.80, 133.81, 130.45, 129.53, 128.50, 128.31, 
127.03, 126.76, 57.43, 49.34, 24.58. HRMS (CI) [M+H]+ Calculated 246.1044, [M+H]+ 
found 246.1055. CHN C16H19NO2 calculated C, 73.31; H, 6.56; N, 5.70; found C, 
74.27; H, 6.65; N, 5.78. HPLC (Chiralpak IB-3, 99.8:0.2 Hex:IPA (+ 0.1% HNEt2), 0.5 
mL/min, 25 oC, 254 nm) 17.63 min (major) and 18.77 min. 
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N-(2-Bromobenzyl)-1-phenylethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.53 (dd, J = 7.9, 0.9 Hz, 1H), 7.39-7.24 
(m, 7H + CDCl3), 7.11 (dt, J = 7.51, 1.56 Hz, 1H), 3.79 (q, J = 6.54 Hz, 1H), 3.71 (q, J = 
13.76 Hz, 2H), 1.75 (bs, 1H), 1.37 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  
(ppm) 145.29, 139.44, 132.82, 130.61, 128.58, 128.49, 127.38, 127.03, 126.82, 
124.04, 57.36, 51.72, 24.59. MS (CI) [M+H]+ calculated 289.05, [M+H]+ found 
290.10. HPLC (Chiralpak IB-3, 99.5:0.5 Hex:IPA (+ 0.1% HNEt2), 1 mL/min, 25 
oC, 254 
nm) 8.33 min (major) and 8.67 min. 
  
N-(2-Methoxybenzyl)-1-phenylethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.38-7.32 (m, 4H), 7.27-7.25 (m, 2H), 
7.15 (dd, J = 7.3, 1.6 Hz, 1H), 6.91-6.85 (m, 2H), 3.82 (s, 3H), 3.78 (q, 6.5 Hz, 1H), 
3.72-3.69 (m, 1H), 3.59-3.56 (m, 1H), 1.35 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 100 
MHz) (ppm) 157.72, 145.75, 129.99, 128.48, 128.38, 128.16, 126.84, 120.36, 
110.23, 57.16, 55.21, 47.26, 24.62. HPLC (Chiralpak IB-3, 99.8:0.2 Hex:IPA (+ 0.1% 
HNEt2), 0.5 mL/min, 25 
oC, 254 nm) min (major) and min. 
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N-(2,6-Dichlorobenzyl)-1-phenylethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.40-7.38 (m, 2H), 7.33 (t, J = 7.5 Hz, 
2H), 7.26-7.22 (m, 3H), 7.10 (t, J = 7.6 Hz, 1H), 3.89 (s, 2H), 3.84 (q, J = 6.5 Hz, 1H), 
1.37 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 145.27, 136.13, 135.97, 
132.49, 128.80, 128.36, 126.36, 126.98, 126.74, 58.13, 47.04, 26.69. HRMS (CI) 
calculated [M+H]+ 280.1654, found [M+H]+ 280.0644. HPLC (Chiralpak IB-3, 99:1 
Hex:IPA (+ 0.1% HNEt2), 0.3 mL/min, 25 
oC, 254 nm) 25.96 min and 27.64 min. 
 
N-Benzyl-1-(p-tolyl)ethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz) (ppm)  7.36-7.32 (m, 4H), 7.26-7.23 (m, 1H), 
7.18-7.11 (m, 4H), 3.80 (q, J = 6.6 Hz, 1H), 3.58 (q, J = 12.6 Hz, 2H), 2.33 (s, 3H), 1.58 
(bs, 1H), 1.36 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 100 MHz) (ppm) 145.62, 137.57, 
136.43, 129.07, 128.47, 128.12, 126.75, 57.39, 51.34, 24.54, 21.13. HRMS (CI) 
calculated [M+H]+ 226.1590, found [M+H]+ 226.1599. HPLC (Chiralpak IB-3, 99.8:0.2 
Hex:IPA (+ 0.1% HNEt2), 0.5 mL/min, 25 
oC, 254 nm) 14.62 min (major) and 15.25 
min. 
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N-Benzyl-1-(4-chlorophenyl)ethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.34-7.24 (m, 9H), 3.79 (q, J = 6.6 Hz, 
1H), 3.60 (q, J = 13.2 Hz, 2H), 1.33 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3, 100 MHz) 
(ppm) 144.08, 140.39, 132.45, 128.63, 128.44, 128.14, 128.12, 126.97, 56.90, 
51.63, 24.60. HRMS (CI) [M+H]+ calculated 246.1044, found 246.1045. HPLC 
(Chiralpak IB-3, 99:1 Hex:IPA (+ 0.1% HNEt2), 1 mL/min, 25 
oC, 254 nm) 6.3 min 
(major) and 7.2 min. 
 
N-Benzyl-1-(m-tolyl)ethanamine 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.33-7.22 (m, 6H), 7.17-7.14 (m, 2H), 
7.07 (d, J = 7.3 Hz, 1H), 3.78 (q, J = 6.5 Hz, 1H), 3.63 (q, J = 13.2 Hz, 2H), 2.37 (s, 3H), 
1.36 (d, J = 6.8 Hz, 3H). 13C NMR (CDCl3, 100 MHz) (ppm) 145.56, 140.71, 138.07, 
128.63, 128.40, 128.16, 127.72, 127.40, 126.86, 123.79, 57.49, 51.72, 24.52, 21.55. 
HPLC (Chiralpak IB-3, 99:1 Hex:IPA (+ 0.1% HNEt2), 1 mL/min, 25 
oC, 254 nm) 5.40 
min (major) and 5.71 min. 
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N-Benzyl-1-(3-(trifluoromethyl)phenyl)ethanamine 
Yellow solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.64 (s, 1H), 7.50-7.45 (m, 3H), 7.30-
7.23 (m, 5H), 3.88 (q, J = 6.5 Hz, 1H), 3.62 (q, J = 13.2 Hz, 2H), 1.37 (d, J = 6.5 Hz, 3H).  
13C NMR (CDCl3, 100 MHz) (ppm) 146.71, 140.29, 130.93, 130.62, 130.30, 128.93, 
128.47, 128.11, 127.03, 125.66, 123.86, 123.82, 123.60, 123.56, 57.28, 51.74, 24.63. 
HRMS (CI) calculated [M+H]+ 280.1308, found [M+H]+ 280.1320. HPLC (Chiralpak IB-
3, 99:1 Hex:IPA (+ 0.1% HNEt2), 1 mL/min, 25 
oC, 254 nm) 5.87 min (major) and 6.80 
min. 
  
N-Benzyl-1-phenylpropan-1-amine 
Yellow oil. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.37-7.24 (m, 10H), 3.67-3.63 (m, 1H), 
3.56-3.52 (m, 2H), 1.79-1.65 (m, 2H), 0.81 (td, J = 7.4, 2.4 Hz, 3H). 13C NMR (CDCl3, 
100 MHz) (ppm)144.09, 140.81, 128.36, 128.34, 128.17, 127.48, 126.95, 126.82, 
64.23, 51.59, 31.16, 10.82. HRMS (CI) calculated [M+H]+ 226.1590; found [M+H]+  
226.1595. CHN C16H19N calculated C, 85.28; H, 8.50; N, 6.22; found C, 85.88; H, 8.46; 
N, 6.51. HPLC (Chiralpak IB-3, 99.8:0.2 Hex:IPA (+ 0.1% HNEt2), 0.5 mL/min, 25 
oC, 
254 nm) 13.15 min (major) and 15.10 min.  
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4-Methoxy-N-(1-phenylethyl)aniline15 
White solid. 1H NMR (CDCl3, 400 MHz)  (ppm) 7.37-7.29 (m, 4H), 7.23-7.20 (m, 1H), 
6.79 (d, J = 8.4 Hz, 2H), 6.49 (d, J = 8.5 Hz, 2H), 4.21 (q, J = 6.6 Hz, 1H), 3.69 (s, 3H), 
1.51 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 100 MHz)  (ppm) 152.1, 145.2, 141.2, 
128.6, 126.9, 126.0, 114.9, 114.8, 55.7, 54.5, 25.0. HRMS (CI) [M+H]+ Calculated 
228.1383, [M+H]+ found 228.1386. CHN C15H17NO calculated C, 79.26; H, 7.54; N, 
6.16; found C, 79.42; H, 7.50; N, 5.95. HPLC (Chiralpak IB-3, 98:2 Hex:IPA + 0.1% 
HNEt2, 1 mL/min, 25 
oC, 254 nm) 7.14 min and 8.61 min. 
 
1H NMR (d3-TFE, 400 MHz)  (ppm) 7.98 (d, J = 7.3 Hz, 2H), 7.95 (d, J = 7.8 Hz, 1H), 
7.81 (s, 1H), 7.62 (t, J = 7.3 Hz, 1H), 7.49 (t, 7.8 Hz, 3H), 7.34-7.28 (m, 6H), 7.23-7.11 
(m, 7H), 6.94-6.92 (m, 2H),6.71 (d, J = 7 Hz, 2H), 6.60 (d, J = 8.7 Hz, 1H), 5.57 (d, J = 
8.9 Hz, 1H), 3.47 (d, J = 13.4 Hz, 1H), 3.26 (d, J = 13.4 Hz, 1H), 2.98 (dt, J = 13.8, 6.9 
Hz, 1H), 2.85 (dt, J = 13.6, 6.7 Hz, 1H), 2.69 (dt, J = 13.7, 6.9 Hz, 1H), 1.78 (s, 15H), 
1.32 (d, J = 7.0 Hz, 6H), 1.24 (d, J= 6.9 Hz, 3H), 1.17 (d, J = 6.7 Hz, 3H), 1.10 (d, J = 6.9 
Hz, 3H), 0.95 (d, J = 6.9 Hz, 3H).  13C NMR (CDCl3, 100 MHz) (ppm) 181.7, 162.3, 
148.7, 148.1, 146.4, 146.1, 137.6, 136.4, 136.3, 135.3, 133.7, 133.4, 128.9, 128.7, 
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128.6, 128.5, 128.3, 128.1, 127.9, 127.7, 126.7, 120.4, 120.3, 89.3, 89.2, 88.7, 70.9, 
52.6, 34.0, 30.4, 24.9, 23.1, 23.0, 22.7, 22.6, 7.8, 7.6.  
 
 
1D NMR
180 160 140 120 100 80 60 40 20
Chemical Shift (ppm)
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
0.11
0.12
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
13
C NMR of imine bound iridium 
complex 
1D NMR
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
1
H NMR of imine bound iridium 
complex 
- 254 - 
 
1H-1H COSY NMR of imine bound iridium complex 
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HSQC NMR of imine bound iridium complex 
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NOESY NMR of imine bound iridium complex 
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 During this project great progress was made in the areas of chiral iridicycle 
synthesis and asymmetric reduction. A large number of novel chiral ligands and 
their corresponding iridicycles were synthesised and characterised. These 
complexes all bore an iridium cyclopentadienyl chloride center, varying in the 
cyclometalated ligand bound to the metal center which could be split into two 
groups, oxazoline and imidazoline complexes. A number of bulky complexes were 
synthesised based on a terphenyl motif, to determine the effect of bulk on the 
observed enantioselectivites. For comparison smaller complexes were also 
synthesised, from these the electronic effects could also be investigated, with the 
presence of electron withdrawing and donanting groups in various substitution 
patterns. 
 These novel iridicycles were screened for a range of asymmetric reductions 
under mild transfer hydrogenation conditions. Reductive amination (the reduction 
of an imine formed in-situ) was investigated, the less bulky electron rich complexes 
proved highly successful, selectively reducing the imine in the presence of the 
ketone. The enantioselectivites achieved were moderate to high for the substrates 
screened, under mild conditions. These complexes also showed activity towards 
pyridinium salt reduction, yielding a number of asymmetric piperidines. Whilst high 
activity was observed for all substrates screened, not all enantioselectivites could 
be determined with the equipment available, however those determined showed 
great promise for this system. Several of the bulky oxazoline complexes synthesised 
showed great activity towards quinoline reductions, under aqueous transfer 
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hydrogenation conditions. Improved enantioselectivites and conversions could be 
obtained in the presence of a small amount of 2-methyl tetrahydrofuran. 
The same bulky complexes proved active under hydrogenation conditions. 
Benzyl imines could be successfully reduced under mild hydrogenation conditions, 
with complete conversion and moderate to high enantioselectivites. A mechanistic 
study of this system was undertaken, indicating a key intermediate is synthesised 
for the asymmetric reduction, by coordination of the substrate to the iridium 
center, which is stable at low temperatures. 
To further improve on the catalytic results obtained with these complexes 
modification of the ligands present could be undertaken. For example varying the 
steric and electronic properties of the cyclopentadienyl ligand, the 
enantioselectivites achieved in these catalytic transformations may show significant 
improvement. The addition of a solid support to either ligand may also allow for a 
heterogeneous complex to be synthesised. This may offer the opportunity for the 
iridicycle to be recycled, affording less waste and a greater atom economy. 
 A diverse range of reductive reactions were achieved in the presence of 
these complexes, affording moderate to high enantioselectivites. This included 
difficult transformations such as the DARA and the asymmetric reduction of 
pyridinium salts, both under transfer hydrogenation conditions. Further 
transformations may also be investigated utilising these conplexes, such as ketone 
reduction, N-alkylation of alcohols and amines, as well as other transformations the 
non-chiral iridicycles have shown activity for. 
